Orgenesis (ORGS) 10-K 13 Feb 19 2018 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Nov. 30, 2018	Feb. 13, 2019	May 31, 2018
Document Type	10-K
Amendment Flag	false
Document Period End Date	Nov. 30, 2018
Trading Symbol	orgs
Entity Registrant Name	Orgenesis Inc.
Entity Central Index Key	1,460,602
Current Fiscal Year End Date	--11-30
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		15,620,971
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well Known Seasoned Issuer	No
Entity Public Float			$ 92,456,008
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	FY
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Nov. 30, 2018	Nov. 30, 2017
CURRENT ASSETS:
Cash and cash equivalents	$ 16,064	$ 3,519
Restricted Cash	392	0
Accounts receivable, net	4,151	1,336
Prepaid expenses and other receivables	913	841
GPP receivable	6,600	0
Receivables from related party	0	691
Grants receivable	441	183
Inventory	1,736	725
Total current assets	30,297	7,295
Loan to related party	1,007	0
NON CURRENT ASSETS:
Bank deposits	85	0
Call option derivative	0	339
Investments in associates, net	0	1,321
Property and equipment, net	11,901	5,104
Intangible assets, net	16,700	15,051
Goodwill	15,165	10,684
Other assets	292	78
Total non-current assets	45,150	32,577
TOTAL ASSETS	75,447	39,872
CURRENT LIABILITIES:
Accounts payable	3,804	3,914
Accrued expenses and other payables	2,269	1,435
Employees and related payables	3,006	2,961
Related parties	0	116
Advance payments on account of grant	1,724	1,719
Short-term loans and current maturities of long term loans	647	378
Deferred income	5,317	3,611
Current maturities of convertible loans	378	2,780
TOTAL CURRENT LIABILITIES	17,145	16,914
LONG-TERM LIABILITIES:
Loans payable	1,662	2,118
Convertible loans	1,038	2,415
Retirement benefits obligation	265	6
Deferred taxes	1,702	690
Other long term liabilities	833	0
TOTAL LONG-TERM LIABILITIES	5,500	5,229
TOTAL LIABILITIES	22,645	22,143
COMMITMENTS	0	0
REDEEMABLE NON CONTROLLING INTEREST EQUITY:	24,153	3,606
EQUITY:
Common stock of $0.0001 par value, 145,833,334 shares authorized, 14,951,783 and 9,872,659 shares issued as of November 30, 2018 and November 30, 2017, respectively	1	1
Additional paid-in capital	88,082	55,334
Receipts on account of shares to be allotted	2,253	1,483
Accumulated other comprehensive income	425	1,425
Accumulated deficit	(62,411)	(44,120)
Equity attributable to Orgenesis Inc.	28,350	14,123
Non-controlling interests	299	0
TOTAL EQUITY	28,649	14,123
TOTAL LIABILITIES AND EQUITY	$ 75,447	$ 39,872

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Nov. 30, 2018	Nov. 30, 2017
Common Stock, par or stated value	$ 0.0001	$ 0.0001
Common Stock, shares authorized	145,833,334	145,833,334
Common Stock, shares issued	14,951,783	9,872,659
Common Stock, shares outstanding	14,951,783	9,872,659

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Nov. 30, 2018	Nov. 30, 2017
REVENUES	$ 18,655	$ 10,089
COST OF REVENUES	10,824	6,807
GROSS PROFIT	7,831	3,282
RESEARCH AND DEVELOPMENT EXPENSES, net	6,464	2,478
AMORTIZATION OF INTANGIBLE ASSETS	1,913	1,631
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES	16,303	9,189
OTHER INCOME, net	(2,930)	0
SHARE IN LOSSES OF ASSOCIATED COMPANY	731	1,214
OPERATING LOSS	14,650	11,230
FINANCIAL EXPENSES, net	3,117	2,447
LOSS BEFORE INCOME TAXES	17,767	13,677
TAX EXPENSES (INCOME)	1,337	(1,310)
NET LOSS	19,104	12,367
NET INCOME ATTRIBUTABLE TO NON- CONTROLLING INTERESTS (INCLUDING REDEEMABLE)	(813)	0
NET LOSS ATTRIBUTABLE TO THE COMPANY	$ 18,291	$ 12,367
NET LOSS ATTRIBUTABLE TO THE COMPANY LOSS PER SHARE:
Basic	$ 1.43	$ 1.28
Diluted	$ 1.43	$ 1.31
WEIGHTED AVERAGE NUMBER OF SHARES USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE:
Basic	13,374,103	9,679,964
Diluted	13,374,103	9,714,252
COMPREHENSIVE LOSS -
Net loss	$ 19,104	$ 12,367
Other Comprehensive (income) loss - Translation adjustment	1,000	(2,630)
Comprehensive loss	20,104	9,737
Comprehensive income attributed to non-controlling interests (including redeemable)	(813)	0
COMPREHENSIVE LOSS ATTRIBUTED TO ORGENESIS INC.	$ 19,291	$ 9,737

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Receipts on Account of Share to be Allotted [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]	Equity Attributable to Orgenesis Inc. [Member]	Non-Controlling Interest [Member]	Total
Beginning Balance at Nov. 30, 2016	$ 1	$ 45,454		$ (1,205)	$ (31,753)	$ 12,497		$ 12,497
Beginning Balance (Shares) at Nov. 30, 2016	9,508,068
Stock-based compensation to employees and directors		1,536				1,536		1,536
Stock-based compensation to service providers		1,828				1,828		1,828
Stock-based compensation to service providers (Shares)	79,167
Issuance of shares and receipts on account of shares and warrants to be allotted		3,702	$ 1,483			5,185		5,185
Issuance of shares and receipts on account of shares and warrants to be allotted (Shares)	285,424
Beneficial conversion feature of convertible loans and Warrants issued		2,814				2,814		2,814
Adjustment to redemption value of redeemable non-controlling interest								0
Comprehensive income (loss) for the period				2,630	(12,367)	(9,737)		(9,737)
Ending Balance at Nov. 30, 2017	$ 1	55,334	1,483	1,425	(44,120)	14,123		14,123
Ending Balance (Shares) at Nov. 30, 2017	9,872,659
Stock-based compensation to employees and directors		2,426				2,426		2,426
Stock-based compensation to service providers		1,938				1,938		1,938
Stock-based compensation to service providers (Shares)	315,198
Issuance of shares and warrant due to conversion of convertible loans		7,511				7,511		7,511
Issuance of shares and warrant due to conversion of convertible loans (Shares)	1,486,722
Issuance of warrants and beneficial conversion feature of convertible loans		438				438		438
Issuance of shares and receipts on account of shares to be allotted related to acquisition of Atvio and CureCell		2,452				2,452	$ 299	2,751
Issuance of shares and receipts on account of shares to be allotted related to acquisition of Atvio and CureCell (Shares)	286,811
Issuance of shares and receipts on account of shares and warrants to be allotted		18,021	770			18,791		18,791
Issuance of shares and receipts on account of shares and warrants to be allotted (Shares)	2,853,747
Issuance of Shares due to exercise of warrants		846				846		846
Issuance of Shares due to exercise of warrants (Shares)	136,646
Adjustment to redemption value of redeemable non-controlling interest		(884)				(884)		(884)
Comprehensive income (loss) for the period				(1,000)	(18,291)	(19,291)		(19,291)
Ending Balance at Nov. 30, 2018	$ 1	$ 88,082	$ 2,253	$ 425	$ (62,411)	$ 28,350	$ 299	$ 28,649
Ending Balance (Shares) at Nov. 30, 2018	14,951,783

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS $ in Thousands, ₪ in Millions	12 Months Ended
	Nov. 30, 2018USD ($)	Nov. 30, 2017USD ($)
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (19,104)	$ (12,367)
Adjustments required to reconcile net loss to net cash used in operating activities:
Stock-based compensation	4,364	3,364
Share in losses of associated company	731	1,214
Depreciation and amortization expenses	2,624	2,598
Net gain on remeasurement of previously equity interest in Atvio and CureCell to acquisition date at fair value	(4,509)	0
Change in fair value of warrants and embedded derivatives	26	(826)
Change in fair value of convertible bonds	0	(192)
Interest expense accrued on loans and convertible loans (including amortization of beneficial conversion feature)	2,564	1,110
Increase (decrease) in deferred taxes	982	(1,310)
Changes in operating assets and liabilities:
Decrease (increase) in accounts receivable, net	(2,901)	33
Increase in inventory	(931)	(265)
Increase in other assets	(19)	(3)
Decrease (increase) in prepaid expenses, other accounts receivable and GPP receivable	380	(107)
Decrease in related parties, net	(532)	(583)
Decrease in accounts payable	(796)	(933)
Increase in accrued expenses	428	92
Increase (decrease) in employee and related payables	(105)	1,142
Increase in deferred income	1,309	1,044
Increase (decrease) in advance payments and receivables on account of grant	(193)	2,156
Net cash used in operating activities	(15,682)	(3,833)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(5,556)	(975)
Investments in associates	0	(2,429)
Long-term bank deposits	(15)	0
Increase in loan to JV with a related party	(1,000)	0
Acquisition of CureCell, net of cash acquired	58	0
Acquisition of Atvio, net of cash acquired	245	0
Net cash used in investing activities	(6,268)	(3,404)
CASH FLOWS FROM FINANCING ACTIVITIES:
Short-term line of credit	0	(21)
Proceeds from issuance of shares and warrants (net of transaction costs)	17,392	5,297
Redeemable non-controlling interest	14,058	2,349
Proceeds from receipts on account of shares to be allotted	2,252	0
Repayment of short and long-term debt	(377)	(1,108)
Repayment of convertible loans and convertible bonds	(177)	(4,051)
Proceeds from issuance of convertible loans (net of transaction costs)	1,912	5,899
Net cash provided by financing activities	35,060	8,365
NET CHANGE IN CASH AND CASH EQUIVALENTS	13,110	1,128
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS	(173)	1,497
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR	3,519	891
CASH, CASH EQUIVALENTS AND RESTRCITED CASH AT END OF YEAR	16,456	3,519
SUPPLEMENTAL NON-CASH FINANCING ACTIVITY
Conversion of principal amount and accrued interest of convertible loans and bonds to common stock and warrants	7,511	1,277
Classification of loan receivable into services to be received from CureCell	836	0
Leases of Fixed assets	955	0
Receivable from GPP	6,600	0
SUPPLEMENTAL INFORMATION ON INTEREST PAID IN CASH	$ 0	$ 903

DESCRIPTION OF BUSINESS

DESCRIPTION OF BUSINESS	12 Months Ended
	Nov. 30, 2018
DESCRIPTION OF BUSINESS [Text Block]	NOTE 1 – DESCRIPTION OF BUSINESS a. General Orgenesis Inc., a Nevada corporation (the “Company”), is a biotechnology company specializing in the development, manufacturing and provision of services in the cell and gene therapy industry. The Company operates through two platforms:(i) a point-of-care (“POCare”) cell therapy (“PT”) platform and (ii) a Contract Development and Manufacturing Organization (“CDMO”) platform conducted through its subsidiary, Masthercell Global Inc., a Delaware corporation. Through the PT business, the Company’s aim is to further the development of Advanced Therapy Medicinal Products (“ATMPs”) through collaborations and in-licensing with other pre-clinical and clinical-stage biopharmaceutical companies and research and healthcare institutes to bring such ATMPs to patients. The Company out-license these ATMPs through regional partners to whom the Company also provide regulatory, pre-clinical and training services to support their activity in order to reach patients in a point-of-care hospital setting. Through the CDMO platform, the Company is focused on providing contract manufacturing and development services for biopharmaceutical companies. Activities in the PT business include a multitude of cell therapies, including autoimmune, oncologic, neurologic and metabolic diseases and other indications. The Company provides services for its joint venture (“JV”) partners, pharmaceutical and biotech companies as well as research institutions and hospitals that have cell therapies in clinical development. Each of these customers and collaborations represents a revenue and growth opportunity upon regulatory approval. Furthermore, the Company’s trans-differentiation technology demonstrates the capacity to induce a shift in the developmental fate of cells from the liver or other tissues and transdifferentiating them into “pancreatic beta cell-like” Autologous Insulin Producing (“AIP”) cells for patients with Type 1 Diabetes, acute pancreatitis and other insulin deficient diseases. This technology, which has yet to be proven in human clinical trials, has shown in pre-clinical animal models that the human derived AIP cells produce insulin in a glucose-sensitive manner. This trans-differentiation technology is licensed by the Orgenesis Ltd (the “Israeli Subsidiary) and is based on the work of Prof. Sarah Ferber, the Company’s Chief Science Officer and a researcher at Tel Hashomer Medical Research Infrastructure and Services Ltd. (“THM”) in Israel. The development plan calls for conducting additional pre-clinical safety and efficacy studies with respect to diabetes and other potential indications prior to initiating human clinical trials. The CDMO platform operates through Masthercell Global Inc. (“ Masthercell Global”), which currently consists of the following subsidiaries: MaSTherCell S.A (“MaSTherCell”) in Belgium, Atvio Biotech Ltd. (“Atvio”) in Israel, CureCell Co., Ltd. (“CureCell”) in South Korea and Masthercell U.S. LLC in the United States (collectively, the “ Masthercell Global Subsidiaries”), having unique know-how and expertise for manufacturing in a multitude of cell types. Masthercell Global strives to provide services that are all compliant with GMP requirements, ensuring identity, purity, stability, potency and robustness of cell therapy products for clinical phase I, II, III and through commercialization. (Masthercell U.S. LLC was incorporated in June 2018 and had no activity as of November 30, 2018). MaSTherCell Global, through the Masthercell Global Subsidiaries, is engaged in the business of providing manufacturing and development services to third parties related to cell therapy products, and the creation and development of technology, and optimizations in connection with such manufacturing and development services for third parties (the “CDMO Business”). The Company operates its CDMO and PT business as two separate business segments. These consolidated financial statements include the accounts of Orgenesis Inc. and its subsidiaries, including those of the Masthercell Global Subsidiaries; Orgenesis SPRL (the “Belgian Subsidiary”), a Belgian-based subsidiary which is engaged in development and manufacturing activities together with clinical development studies in Europe; Orgenesis Maryland Inc. (the “U.S. Subsidiary”), a Maryland corporation; and Orgenesis Ltd., an Israeli corporation, (the “Israeli Subsidiary”). As used in this report and unless otherwise indicated, the term “Company” refers to Orgenesis Inc. and its subsidiaries (“Subsidiaries”). Unless otherwise specified, all amounts are expressed in United States Dollars. Until March 13, 2018, the Company’s common shares were traded on OTC Market Group’s OTCQB, at which point the Company's common stock began to be listed and traded on the Nasdaq Capital Market under the symbol “ORGS”. b. Change in Fiscal Year End On October 22, 2018, the Board of Directors of the Company approved a change in the Company’s fiscal year end from November 30 to December 31 of each year. This change to the calendar year reporting cycle began January 1, 2019. As a result of the change, the Company will have a December 2018 fiscal month transition period, the results of which will be separately reported in the Company’s Quarterly Report on Form 10-Q for the calendar quarter ending March 31, 2019, June 30, 2019, September 30, 2019 and in the Company’s Annual Report on Form 10-K for the calendar year ending December 31, 2019. c. Liquidity As of November 30, 2018, the Company has accumulated losses of approximately $62.4 million. Although the Company is showing positive revenues and gross profit trends in the CDMO platform, the Company expects to incur further losses in the PT business. To date, the Company has been funding operations primarily from the proceeds from private placements of the Company’s equity securities and convertible debt and from revenues generated by Masthercell Global, mainly revenues generated from MaSTherCell S.A. in Belgium. From December 1, 2017 through November 30, 2018, the Company received, through MaSTherCell, proceeds of approximately $17.3 million in revenues and accounts receivable from customers, $12.6 million from SFPI and GPP (See also Note 3) and $21.5 million from the private placement to accredited investors of the Company's equity and convertible loans net of finders’ fees, convertible loans and exercise of warrants. In addition, from December 1, 2018 through February 13, 2019, the Company raised $0.25 million from the private placement referred to above of unsubscribed units under such investor’s subscription agreement, $6.6 million from GPP (See Note 3(b)) and proceeds of approximately $4.7 million in accounts receivable from customers of MaSTherCell. Based on its current cash resources and commitments, the Company believes it will be able to maintain its current planned development activity and corresponding level of expenditures for at least 12 months from the date of the issuance of the financial statements, although no assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases in general and administrative expenses or research and development expenses, or decreases in MaSTherCell's income, the Company will need to seek additional financing.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Nov. 30, 2018
SIGNIFICANT ACCOUNTING POLICIES [Text Block]	NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES The accounting policies adopted are generally consistent with those of the previous financial year. a. Use of Estimates in the Preparation of Financial Statements The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the financial statement date and the reported expenses during the reporting periods. Actual results could differ from those estimates. b. Business Combination The Company allocates the purchase price of an acquired business to the tangible and intangible assets acquired and liabilities assumed based upon their estimated fair values on the acquisition date. Any excess of the purchase price over the fair value of the net assets acquired is recorded as goodwill. Acquired in-process backlog, customer relations, brand name and know how are recognized at fair value. The purchase price allocation process requires management to make significant estimates and assumptions, especially at the acquisition date with respect to intangible assets. Direct transaction costs associated with the business combination are expensed as incurred. The allocation of the consideration transferred in certain cases may be subject to revision based on the final determination of fair values during the measurement period, which may be up to one year from the acquisition date. The Company includes the results of operations of the business that it has acquired in its consolidated results prospectively from the date of acquisition. If the business combination is achieved in stages, the acquisition date carrying value of the acquirer’s previously held equity interest in the acquire is re-measured to fair value at the acquisition date; any gains or losses arising from such re-measurement are recognized in profit or loss. c. Cash Equivalents The Company considers all short term, highly liquid investments, which include short term bank deposits with original maturities of three months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents. d. Bank Deposits Bank deposits with maturity of more than one year are considered long-term. The fair value of bank deposits approximates the carrying value since they bear interest at rates close to the prevailing market rates. e. Research and Development, net Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, stock-based compensation expenses, payroll taxes and other employees' benefits, lab expenses, consumable equipment and consulting fees. All costs associated with research and developments are expensed as incurred. Participation from government departments and from research foundations for development of approved projects is recognized as a reduction of expense as the related costs are incurred. f. Principles of Consolidation The consolidated financial statements include the accounts of the Company and its Subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. g. Non-Marketable Equity Investments The Company’s investments in certain non-marketable equity securities in which it has the ability to exercise significant influence, but does not control through variable interests or voting interests These are accounted for under the equity method of accounting and presented as Investment in associates, net, in the Company’s consolidated balance sheets. Under the equity method, the Company recognizes its proportionate share of the comprehensive income or loss of the investee. The Company’s share of income and losses from equity method investments is included in share in losses of associated company. The Company reviews its investments accounted for under the equity method for possible impairment, which generally involves an analysis of the facts and changes in circumstances influencing the investments. h. Functional Currency The currency of the primary economic environment in which the operations of the Company and part of its Subsidiaries are conducted is the U.S. dollar (“$” or “dollar”). The functional currency of the Belgian Subsidiaries is the Euro (“€” or “Euro”). The functional currency of CureCell is the Won (“KRW”). Most of the Company’s expenses are incurred in dollars, and the source of the Company’s financing has been provided in dollars. Thus, the functional currency of the Company and its other subsidiaries is the dollar. Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in foreign currencies are translated into dollars using historical and current exchange rates for nonmonetary and monetary balances, respectively. For foreign transactions and other items reflected in the statements of operations, the following exchange rates are used: (1) for transactions – exchange rates at transaction dates or average rates and (2) for other items (derived from nonmonetary balance sheet items such as depreciation) – historical exchange rates. The resulting transaction gains or losses are recorded as financial income or expenses. The financial statements of the Belgian Subsidiaries and CureCell are included in the consolidated financial statements, translated into U.S. dollars. Assets and liabilities are translated at year-end exchange rates, while revenues and expenses are translated at yearly average exchange rates during the year. Differences resulting from translation of assets and liabilities are presented as other comprehensive income. i. Inventory The Company’s inventory consists of raw material for use for the services provided. The Company periodically evaluates the quantities on year end. Cost of the raw materials is determined using the weighted average cost method. j. Property and Equipment Property and equipment are recorded at cost and depreciated by the straight-line method over the estimated useful lives of the related assets. Annual rates of depreciation are presented in the table below: Weighted Average Useful Life (Years) Production facility 5 - 20 Laboratory equipment 5 Office equipment and computers 3 - 5 Intangible assets and their useful lives are as follows: Weighted Average Amortization Recorded at Useful Life (Years) Comprehensive Loss Line Item Customer Relationships 2.5 - 10 Amortization of intangible assets Brand 9.75 Amortization of intangible assets Know-How 11.75 - 12 Amortization of intangible assets Backlog 1.5 Amortization of intangible assets Intangible assets are recorded at acquisition cost less accumulated amortization and impairment. Definite lived intangible assets are amortized over their estimated useful life using the straight-line method, which is determined by identifying the period over which the cash flows from the asset are expected to be generated. k. Goodwill Goodwill represents the excess of the purchase price of acquired business over the estimated fair value of the identifiable net assets acquired. Goodwill is not amortized but is tested for impairment at least annually (at November 30), at the reporting unit level or more frequently if events or changes in circumstances indicate that the asset might be impaired. The goodwill impairment test is applied by performing a qualitative assessment before calculating the fair value of the reporting unit. If, on the basis of qualitative factors, it is considered not more likely than not that the fair value of the reporting unit is less than the carrying amount, further testing of goodwill for impairment would not be required. Otherwise, goodwill impairment is tested using a two-step approach. The first step involves comparing the fair value of the reporting unit to its carrying amount. If the fair value of the reporting unit is determined to be greater than its carrying amount, there is no impairment. If the reporting unit's carrying amount is determined to be greater than the fair value, the second step must be completed to measure the amount of impairment, if any. The second step involves calculating the implied fair value of goodwill by deducting the fair value of all tangible and intangible assets, excluding goodwill, of the reporting unit from the fair value of the reporting unit as determined in step one. The implied fair value of the goodwill in this step is compared to the carrying value of goodwill. If the implied fair value of the goodwill is less than the carrying value of the goodwill, an impairment loss equivalent to the difference is recorded. There were no impairment charges in 2018 and 2017. l. Impairment of Long-lived Assets The Company reviews its property and equipment, intangible assets subject to amortization and other long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset class may not be recoverable. Indicators of potential impairment include: an adverse change in legal factors or in the business climate that could affect the value of the asset; an adverse change in the extent or manner in which the asset is used or is expected to be used, or in its physical condition; and current or forecasted operating or cash flow losses that demonstrate continuing losses associated with the use of the asset. If indicators of impairment are present, the asset is tested for recoverability by comparing the carrying value of the asset to the related estimated undiscounted future cash flows expected to be derived from the asset. If the expected cash flows are less than the carrying value of the asset, then the asset is considered to be impaired and its carrying value is written down to fair value, based on the related estimated discounted cash flows. There were no impairment charges in 2018 and 2017. m. Revenue Recognition The Company recognizes revenue for services linked to cell process development and cell manufacturing services based on individual contracts in accordance with Accounting Standards Codification (“ASC”) 605, Revenue Recognition, n. Financial Liabilities Measured at Fair Value 1) Fair Value Option Topic 815 provides entities with an option to report certain financial assets and liabilities at fair value with subsequent changes in fair value reported in earnings. The election can be applied on an instrument by instrument basis. The Company elected the fair value option to its convertible bonds. The liability is measured both initially and in subsequent periods at fair value, with changes in fair value charged to finance expenses, net (See Note 17). 2) Derivatives Embedded derivatives are separated from the host contract and carried at fair value when (1) the embedded derivative possesses economic characteristics that are not clearly and closely related to the economic characteristics of the host contract and (2) a separate, standalone instrument with the same terms would qualify as a derivative instrument. The derivative is measured both initially and in subsequent periods at fair value, with changes in fair value charged to finance expenses, net. As to embedded derivatives arising from the issuance of convertible debentures (See Note 17). o. Income Taxes 1) With respect to deferred taxes, income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is recognized to the extent that it is more likely than not that the deferred taxes will not be realized in the foreseeable future. 2) The Company follows a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the available evidence indicates that it is more likely than not that the position will be sustained on examination. If this threshold is met, the second step is to measure the tax position as the largest amount that is greater than 50% likely of being realized upon ultimate settlement. 3) Taxes that would apply in the event of disposal of investment in Subsidiaries have not been taken into account in computing the deferred income taxes, as it is the Company’s intention to hold these investments and not realize them. p. Stock-based Compensation The Company accounts for employee stock-based compensation in accordance with the guidance of ASC Topic 718, Compensation - Stock Compensation The Company follows ASC Topic 505-50, Equity-Based Payments to Non-Employees q. Redeemable Non-controlling Interest Non-controlling interests with embedded redemption features, whose settlement is not at the Company’s discretion, are considered redeemable non-controlling interest. Redeemable non-controlling interests are considered to be temporary equity and are therefore presented as a mezzanine section between liabilities and equity on the Company's consolidated balance sheets. Subsequent adjustment of the amount presented in temporary equity is required only if the Company's management estimates that it is probable that the instrument will become redeemable. Adjustments of redeemable non-controlling interest to its redemption value are recorded through additional paid-in capital. r. Loss per Share of Common Stock Basic net loss per share is computed by dividing the net loss for the period by the weighted average number of shares of common stock outstanding for each period. Diluted net loss per share is based upon the weighted average number of common shares and of common shares equivalents outstanding when dilutive. Common share equivalents include: (i) outstanding stock options warrants which are included under the treasury share method when dilutive, and (ii) common shares to be issued under the assumed conversion of the Company’s outstanding convertible loans, which are included under the if-converted method when dilutive (See Note 14). s. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist of principally cash and cash equivalents, bank deposits and certain receivables. The Company held these instruments with highly rated financial institutions and the Company has not experienced any significant credit losses in these accounts and does not believe the Company is exposed to any significant credit risk on these instruments apart of accounts receivable. The Company performs ongoing credit evaluations of its customers for the purpose of determining the appropriate allowance for doubtful accounts. An appropriate allowance for doubtful accounts is included in the accounts and netted against accounts receivable. In the year ended November 30, 2018 the Company has not experienced any material credit losses in these accounts and does not believe it is exposed to significant credit risk on these instruments. In the year ended November 30, 2017, the Company has recorded an allowance of $897 thousand. Bad debt allowance is created when objective evidence exists of inability to collect all sums owed it under the original terms of the debit balances. Material customer difficulties, the probability of their going bankrupt or undergoing economic reorganization and insolvency or material delays in payments are all considered indicative of reduced debtor balance value. t. Beneficial Conversion Feature (“BCF”) When the Company issues convertible debt, if the stock price is greater than the effective conversion price (after allocation of the total proceeds) on the measurement date, the conversion feature is considered "beneficial" to the holder. If there is no contingency, this difference is treated as issued equity and reduces the carrying value of the host debt; the discount is accreted as deemed interest on the debt (See Note 8). u. Other Comprehensive Loss Other comprehensive loss represents adjustments of foreign currency translation. v. Newly issued and recently adopted Accounting Pronouncements 1) In January 2016, the FASB issued guidance on recognition and measurement of financial assets and financial liabilities (ASU No. 2016-01) that will supersede most current guidance. Changes to the U.S. GAAP model primarily affect the accounting for equity investments, financial liabilities under the fair value option and the presentation and disclosure requirements for financial instruments. In addition, the FASB clarified guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The accounting for other financial instruments, such as loans, investments in debt securities, and financial liabilities, is largely unchanged. The classification and measurement guidance became effective as of December 1, 2018. The Company does not expect to have a material impact on its consolidated financial statements. 2) In May 2014, the FASB issued Accounting Standards Update (“ASU”) 2014-09 “Revenue from Contracts with Customers (Topic 606)” (“Topic 606”) that will supersede most current revenue recognition guidance, including industry specific guidance. Under the new standard, a good or service is transferred to the customer when (or as) the customer obtains control of the good or service, which differs from the risk and rewards approach under current guidance. The guidance provides a five-step analysis of transactions to determine when and how revenue is recognized. Other major provisions include capitalization of certain contract costs, consideration of the time value of money in the transaction price and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The guidance also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity’s contracts with customers. The guidance is effective in annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. The Company will implement the guidance for our annual period ending on December 31, 2019 and interim periods within such annual periods, using the modified retrospective method and will adjust the accumulated deficit and deferred revenue as of the adoption date. Under current GAAP, the Company recognizes revenue for services linked to cell process development based on both the input and output methods of measurement. The Company has evaluated the application of the requirements of ASC 606 to recognize revenue when or as the entity satisfies a performance obligation to its business. The Company has several types of revenue contracts: a) Cell process development services The Company has concluded that under the revised standard, contracts for cell process development services are in some cases a single performance obligation (where promises offered to customers are not distinct within the context of the contract), and in other cases have multiple performance obligations (where promises to the customers are distinct). In all cases the performance obligations are satisfied over time. Under the new standard, the Company will recognize revenue over time using either a cost-based input method or output method, whichever fairly depicts the transfer of control over the life of the performance obligation, as appropriate. b) Cell manufacturing services Regarding revenues from cell manufacturing services, the Company concluded that these comprised a single performance obligation. The progress towards completion will continue to be measured on an output measure based on direct measurement of the value transferred to the customer (units produced). c) Tech transfer The Company has concluded that under the revised standard contracts for Tech Transfer services are considered a single performance obligation and will be measured over time using a cost-based input method where progress on the performance obligation is measured by the proportion of actual costs incurred to the total costs expected to complete the contract. The cost-based and output methods of revenue recognition require the Company to make estimates of costs to complete its projects and the percentage of completion on an ongoing basis. Significant judgment is required to evaluate assumptions related to these estimates. The effect of revisions to estimates related to the transaction price (including variable consideration relating to reimbursement on a cost-plus basis on certain expenses) or costs to complete a project are recorded in the period in which the estimate is revised. The adoption of th enew standard is not expected to result in a material effect on the total stockholders' equity as of December 1, 2018. 3) In November 2016, the FASB issuedASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash (a Consensus of the FASB Emerging Issues Task Force) (“ASU 2016-18”), which requires entities to include amounts generally described as restricted cash and restricted cash equivalents in cash and cash equivalents when reconciling beginning-of-period and end-of-period total amounts shown on the statement of cash flows. ASU 2016-18 is effective for annual reporting periods (including interim periods within those annual reporting periods) beginning after December 15, 2017. The Company adopted this standard during the year ended November 30, 2018. 4) In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)” (“ASU 2016-02”), which supersedes the existing guidance for lease accounting, “Leases (Topic 840)”. ASU 2016-02 requires lessees to recognize leases on their balance sheets, and leaves lessor accounting largely unchanged. The amendments in ASU 2016-02 are effective for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years. Early application is permitted for all entities. ASU 2016-02 requires a modified retrospective approach for all leases existing at, or entered after, the date of initial application, with an option to elect to use certain transition relief. The Company expects to apply the ASU without adjusting the comparative periods and, if applicable, recognizing a cumulative effect adjustment to the opening balance of retained earnings in the period of adoption. The Company is currently evaluating the impact of this new standard on its consolidated financial statements. 5) In June 2016, the FASBissued ASU 2016-13, “Financial Instruments-Credit Losses (Topic 326)” (“ASU 2016-13”). ASU 2016-13 requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis. The income statement reflects the measurement of credit losses for newly recognized financial assets, as well as the expected credit losses during the period. The measurement of expected credit losses is based upon historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. Credit losses relating to available-for-sale debt securities will be recorded through an allowance for credit losses rather than as a direct write-down to the security. ASU 2016-13 is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted as of the fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company does not expect to have a material impact on its consolidated financial statements. 6) In May 2017, the FASB issued ASU 2017-09, “Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting” (“ASU 2017-09”), which gives direction on which changes to the terms or conditions of share-based payment awards require an entity to apply modification accounting in Accounting Standard Codification (“ASC”) Topic 718. In general, entities will apply the modification accounting guidance if the value, vesting conditions or classification of the award changes. ASU 2017-09 is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The Company does not expect the implementation of this new pronouncement to have a material impact on its consolidated financial statements. 7) In June 2018, the FASB issued ASU 2018-07, “Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-based Payment Accounting” that expands the scope of ASC Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of ASC Topic 718 to nonemployee awards except for certain exemptions specified in the amendment. The guidance is effective for fiscal years beginning after December 15, 2018, including interim reporting periods within that fiscal year. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606. The Company don’t expect to have a material impact on its consolidated financial statements. 8) In January 2017, FASB issued Accounting Standards Update (ASU) 2017-04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment, which eliminated the calculation of implied goodwill fair value. Instead, companies will record an impairment charge based on the excess of a reporting unit’s carrying amount of goodwill over its fair value. This guidance simplifies the accounting as compared to prior GAAP. The guidance is effective for fiscal years beginning after December 15, 2019. The Company does not expect the implementation of this new pronouncement to have a material impact on its consolidated financial statements.

REDEEMABLE NON CONTROLLING INTE

REDEEMABLE NON CONTROLLING INTEREST	12 Months Ended
	Nov. 30, 2018
REDEEMABLE NON CONTROLLING INTEREST [Text Block]	NOTE 3 – REDEEMABLE NON CONTROLLING INTEREST a. Subscription and Shareholders Agreement with Belgian Sovereign Funds Société Fédérale de Participations et d'Investissement ("SFPI"). On November 15, 2017, the Company, MaSTherCell and SFPI entered into a Subscription and Shareholders Agreement (“SFPI Agreement” ) pursuant to which SFPI made an equity investment in MaSTherCell in the aggregate amount of Euro 5 million (approximately $5.9 million), for approximately 16.7% of MaSTherCell (SFPI received B-shares of MaSTherCell which have the same voting, dividend and other rights as the existing shares of MaSTherCell). The equity investment commitment included the conversion of the outstanding loan and accrued interest of Euro 1.07 million (approximately $1.18 million), previously made by SFPI to MaSTherCell. In November 2017, the initial subscription amount of Euro 2 million ($2.3 million) was paid by SFPI to MaSTherCell. The proceeds from the investment are to be used in accordance with the long-term business plan that was appended to the SFPI Agreement which includes, without limitation, expanding MaSTherCell’s facilities in Belgium with the addition of five new cGMP manufacturing cleanrooms. The agreement contains customary representations, warranties and covenants by MaSTherCell and the Company, in respect of which the Company has undertaken to indemnify SFPI for the consequences of any breach thereof by MaSTherCell or the Company. Under the Agreement, SFPI has the right to appoint one member to the board of directors of MaSTherCell’s five-person board. In addition, the holders of the B-Shares have a right to, along with the Company, appoint an independent director who will serve as the chairman of the board of MaSTherCell for a renewable three-year term. The agreement provides that, under certain specified circumstances, SFPI is entitled to transfer its equity interest in MaSTherCell to the Company at a price equal to the total investment amount, plus a specified annual premium ranging from 10% to 25%, depending on the year following the subscription in which the put is exercised. Under the terms of the agreement since the Company listed to Nasdaq, SFPI is entitled to convert its MaSTherCell’ s equity interest (using an exchange rate of approximately $0.85), into shares of Common Stock of the Company based upon a conversion price of $6.24, the exercise period of the option is 3 years from the closing date of the SFPI Agreement. The $6.24 conversion price represents the price after the previous stock split of the Company. Furthermore, under the agreement, the Company had the right to spin-off the CDMO business into a Subsidiary provided that the Subsidiary adhered to the terms of the agreement. In June 2018, the Company effectuated such a spin-off and consolidated the CDMO business into Masthercell Global and Masthercell Global adhered to the terms of this agreement. Also, the Company possesses a drag along right under the Agreement whereby if the Company transfers all or the majority of its shares in MaSTherCell, it can force SFPI to do the same. (See also Note 3(b)). On June 13, 2018, SFPI has paid into MaSTherCell the remaining amount of Euro 1.9 million (approximately $2.3 million) to complete its subscription obligations under the agreement. Due to the embedded redemption feature whose settlement is not at the Company discretion, the Company accounted for the investment made by SFPI as a redeemable non-controlling interest. As of November 30, 2018, and 2017 SFPI investment was presented as redeemable non-controlling interest in the balance sheet, in the amount of $5.8 million and $3.6, respectively. b. Stock Purchase Agreement and Stockholders’ Agreement with Great Point Partners, LLC (“GPP”) On June 28, 2018, the Company, Masthercell Global GPP, and certain of GPP’s affiliates, entered into a series of definitive strategic agreements intended to finance, strengthen and expand Orgenesis’ CDMO business. In connection therewith, the Company, Masthercell Global and GPP-II Masthercell, LLC, a Delaware limited liability company (“GPP-II”) and an affiliate of GPP entered into Stock Purchase Agreement (the “SPA”) pursuant to which GPP-II purchased 378,000 shares of newly designated Series A Preferred Stock of Masthercell Global (the “Masthercell Global Preferred Stock”), representing 37.8% of the issued and outstanding share capital of Masthercell Global, for a cash consideration to be paid into Masthercell Global of up to $25 million, of which $13.2 million was subject to certain contingencies described below (the “Consideration”). Orgenesis holds 622,000 shares of Masthercell Global’s Common Stock, representing 62.2% of the issued and outstanding equity share capital of Masthercell Global. An initial cash payment of $11.8 million of the Consideration was remitted at closing by GPP-II. $1.5 Million of the initial capital contributed to Masthercell Global was used to reimburse the investors for their fees and expenses incurred in conjunction with this transaction (net payment of $10.3 million). Under the terms of the SPA the follow up payments will be in the amount of $6.6 million to be made in each of years 2018 and 2019 (the “Future Payments”), if (a) Masthercell Global achieves specified EBITDA and revenues targets during each of these years, and (b) the Orgenesis’ shareholders approve certain provisions of the SPA entered into by these parties. Such shareholder approval was obtained on October 23, 2018. None of the future Consideration amounts, if any, will result in an increase in GPP-II’s equity holdings in MaSTherCell. In connection with the entry into the SPA as described above, each of the Company, Masthercell Global and GPP-II entered into the Masthercell Global Inc. Stockholders’ Agreement (the “Stockholders’ Agreement”) providing for certain restrictions on the disposition of Masthercell Global securities, the provisions of certain options and rights with respect to the management and operations of Masthercell Global, certain rights to GPP-II (including, without limitation, a tag along right, drag along right and certain protective provisions). After the earlier of the second anniversary of the closing or certain enumerated circumstances, GPP-II is entitled to effectuate a spinoff of Masthercell Global and the Masthercell Global Subsidiaries (the “Spinoff”). The Spinoff is required to reflect a market value, provided that under certain conditions, such market valuation shall reflect a valuation of Masthercell Global and its Subsidiaries of at least $50 million. In addition, upon certain enumerated events described below, GPP-II is entitled, at its option, to put to the Company (or, at Company’s discretion, to Masthercell Global if Masthercell Global shall then have the funds available to consummate the transaction) its shares in Masthercell Global or, alternatively, purchase from the Company its share capital in Masthercell Global at a purchase price equal to the fair market value provided that the purchase price shall not be greater than three times the price per share of Masthercell Global Preferred Stock paid by GPP-II and shall not be less than the price per share of Masthercell Global Preferred Stock paid by GPP-II. GPP-II may exercise its put or call option upon the occurrence of any of the following: (i) there is an Activist Shareholder of the Company; (ii) the Chief Executive Officer and/or Chairman of the board of directors of the Company resigns or is replaced, removed, or terminated for any reason prior to June 28, 2023; (iii) there is a change of control event of the Company as defined in the Stockholders’ Agreement; or (iv) the industry expert director appointed to the board of directors of Masthercell Global is removed or replaced (or a new such director is appointed) without the prior written consent of GPP-II. Activist Shareholder shall mean any Person who acquires shares of capital stock of the Company who either: (x) acquires more than a majority of the voting power of the Company, (y) actively takes over and controls a majority of the board of directors of the Company, or (z) is required to file a Schedule 13D with respect to such Person’s ownership of the Company and has described a plan, proposal or intent to take action with respect to exerting significant pressure on the management of or directors of, the Company. The Stockholders’ Agreement further provides that GPP-II is entitled, at any time, to convert its share capital in Masthercell Global for the Company’s common stock in an amount equal to the lesser of (a)(i) the fair market value of GPP-II’s shares of Masthercell Global Preferred Stock to be exchanged, divided by (ii) the average closing price per share of the Company’s Common Stock during the thirty day period ending on the date that GPP-II provides the exchange notice (the “Exchange Price”) and (b)(i) the fair market value of GPP-II’s shares of Masthercell Global Preferred Stock to be exchanged assuming a value of Masthercell Global equal to three and a half (3.5) times the revenue of Masthercell Global during the last twelve (12) complete calendar months immediately prior to the exchange divided by (ii) the Exchange Price; provided, that in no event will (A) the Exchange Price be less than a price per share that would result in Orgenesis Inc. having an enterprise value of less than $250 million and (B) the maximum number of shares of the Company’s Common Stock to be issued shall not exceed 2,704,247 shares, unless the Company obtains shareholder approval for the issuance of such greater amount of shares of the Company in accordance with the rules and regulations of the Nasdaq Stock Market. Great Point and Masthercell Global entered into an advisory services agreement pursuant to which Great Point is to provide management services to Masthercell Global for which Great Point will be compensated at an annual base compensation equal to the greater of (i) $250 thousand per each 12 month period or (ii) 5% of the EBITDA for such 12 month period, payable in arrears in quarterly installments; provided, that these payments will (A) begin to accrue immediately, but shall not be paid in cash to Great Point until such time as Masthercell Global generates EBITDA of at least $2 million for any 12 month period or the sale of or change in control of Masthercell Global, and (B) shall not exceed an aggregate annual amount of $0.5 million. Such compensation accrues but is not owed to Great Point until the earlier of (i) Masthercell Global generating EBITDA of at least $2 million for any 12 -month period following the date of the agreement or (ii) a Sale of the Company or Change of Control of the Company (as both terms are defined therein). GPP and Masthercell Global entered into a transaction services agreement pursuant to which GPP is to provide certain brokerage services to Masthercell Global for which GPP will be entitled to a certain exit fee and transaction fee (as both terms are defined in the agreement), such fees not to be less than 2 percent of the applicable transaction value. Due to the embedded redemption feature whose settlement is not at the Company discretion, the Company accounted for the investment made by GPP as a redeemable non-controlling interest in the amount of $18.4. On November 30, 2018 Masthercell Global achieved the specified EBITDA and revenues targets for 2018 as described in the SPA. The Company reflected the $6.6 million in the balance sheet as GPP receivable. On January 16, 2019, GPP-II remitted to Masthercell Global the $6.6 million.

CORPORATE REORGANIZATION AND EX

CORPORATE REORGANIZATION AND EXERCISE OF CALL OPTIONS OF CURECELL AND ATVIO	12 Months Ended
	Nov. 30, 2018
CORPORATE REORGANIZATION AND EXERCISE OF CALL OPTIONS OF CURECELL AND ATVIO [Text Block]	NOTE 4- CORPORATE REORGANIZATION AND EXERCISE OF CALL OPTIONS OF CURECELL AND ATVIO Description of the Transaction Contemporaneous with the execution of the SPA and the Stockholders’ Agreement (see Note 3), the Company and Masthercell Global entered into a Contribution, Assignment and Assumption Agreement pursuant to which the Company contributed to Masthercell Global assets relating to the CDMO platform including: (i) all of the Company’s holdings in Masthercell Global Subsidiaries (ii) the debt in the total amount of $2.3 million owed to the Company by Atvio and CureCell (iii) the license agreement between the Company and MaSTherCell dated December 30, 2016; (v) the Joint Venture Agreement with Atvio dated May 10, 2016 (as amended on May 30, 2016); (vi) the SFPI Agreement (vii) the Joint Venture Agreement between Orgenesis and CureCell dated March 14, 2016 (the “Corporate Reorganization”). See Note 12(b). In furtherance thereof, Masthercell Global, as the Company assignee, acquired all of the issued and outstanding share capital of Atvio and 94.12% of the share capital of CureCell. The Company exercised the "call option" to which it was entitled under the joint venture agreements with each of these entities to purchase from the former shareholders their equity holding. The consideration for the outstanding share equity in each of Atvio and CureCell consisted solely of the Company Common Stock. In respect of the acquisition of Atvio, the Company issued to the former Atvio shareholders an aggregate of 83,965 shares of Company’s Common Stock. In respect of the acquisition of CureCell, the Company issued the former CureCell shareholders an aggregate of 202,846 shares of the Company Common Stock. The exercise of the call options of CureCell and Atvio, pursuant to which the Company obtained effective control over such entities, was accounted for as a business combination. The results of operations of CureCell and Atvio have been included in the Company’s condensed consolidated statements of operations starting from June 28, 2018, the date on which the Company obtained effective control of CureCell and Atvio. Before the closing date Atvio and CureCell were associated companies, see Note 12. The net gain on remeasurement of the previously held equity interest in Atvio and CureCell to acquisition date fair value was $4.5 million. CureCell The following table summarizes the allocation of purchase price to the fair values of the assets acquired and liabilities assumed as of the transaction date: Total assets acquired: Cash and cash equivalents $ 58 Property and equipment, net 1,104 Inventory 148 Other assets 300 Other Intangible assets (a) 3,933 Goodwill (b) 3,950 Total assets 9,493 Total liabilities assumed: Deferred income from the Company and others 1,945 Deferred taxes 80 Fair value of convertible loan from the Company 892 Non-controlling interests 299 Other liabilities 1,487 Total liabilities 4,703 Total consideration transferred $ 4,790 Fair value of 36.4% of shared issued 1,853 Acquisition date fair value of previously held equity interest 2,937 Total consideration transferred $ 4,790 * Fair value of the consideration is based on the company’s market share price. a. The allocation of the purchase price to the net assets acquired and liabilities assumed resulted in the recognition of other intangible assets which comprised of: Customer Relationships of $859 and “Know How” of $3,074. These other intangible assets have a useful life of 10 and 12 years, respectively. The useful life of the other intangible assets for amortization purposes was determined considering the period of expected cash flows generated by the assets used to measure the fair value of the intangible assets adjusted as appropriate for the entity-specific factors, including legal, regulatory, contractual, competitive, economic or other factors that may limit the useful life of intangible assets. The fair value of the Know How was estimated using a relief of royalties’ approach. Under this method, the fair value of the Know How is equal to the royalty fee that the owner of the Know How could profit from if he was to license the Know How out. Customer Relationships were estimated using a discounted cash flow method with the application of the multi-period excess earnings method. Under this method, an intangible asset’s fair value is equal to the present value of the incremental after-tax cash flows attributable only to the subject intangible asset after deducting contributory asset charges. An income and expenses forecast were built based upon revenue and expense estimates. b. The primary items that generate goodwill include the value of the synergies between the acquired company and the Company and the acquired assembled workforce, neither of which qualifies for recognition as an intangible asset. The Goodwill is not deductible for tax purposes. Atvio The total consideration of Atvio of $890 thousand was attributed mainly to goodwill. Pro forma Impact of Business Combination The unaudited pro forma financial results have been prepared using the acquisition method of accounting and are based on the historical financial information of the Company, Atvio and CureCell. The unaudited pro forma condensed financial results have been prepared for illustrative purposes only and do not purport to be indicative of the results of operations that would have resulted had the acquisition of Atvio and CureCell occurred at the beginning of the fiscal year, or of future results of the combined entities. The unaudited pro forma condensed financial information does not reflect any operating efficiencies and expected realization of cost savings or synergies associated with the acquisition. The acquired business contributed revenues of $1.1 million and for the period of June 28, 2018 to November 30, 2018. The following unaudited pro forma summary presents consolidation information of the Company as if the business combination had occurred on December 1, 2017: Year Ended November 30, 2018 2017 (in thousands) Revenue $ 18,794 $ 10,216 Net loss $ 20,919 $ 14,520

SEGMENT INFORMATION

SEGMENT INFORMATION	12 Months Ended
	Nov. 30, 2018
SEGMENT INFORMATION [Text Block]	NOTE 5 - SEGMENT INFORMATION The Chief Executive Officer ("CEO") is the Company’s chief operating decision-maker ("CODM"). Management has determined that there are two operating segments, based on the Company's organizational structure, its business activities and information reviewed by the CODM for the purposes of allocating resources and assessing performance. CDMO The CDMO platform is comprised of a specialization in cell therapy development and comprised of two types of services to its customers: (i) manufacturing and development services and (ii) cGMP contract manufacturing services. The CDMO platform operates through Masthercell Global, which currently consists of MaSTherCell in Belgium, Atvio in Israel and CureCell in South Korea, having unique know-how and expertise for manufacturing in a multitude of cell types. The CDMO activities include the operations of Masthercell Global, Atvio and CureCell from the date of the Corporate Reorganization. PT Business Through the PT business, the Company is focused on the development of proprietary cell and gene therapies, including the autologous trans-differentiation technology, and therapeutic collaborations and licensing with other pre-clinical and clinical-stage biopharmaceutical companies and research and healthcare institutes. The CODM does not review assets by segment, therefore the measure of assets has not been disclosed for each segment. Segment data for the year ended November 30, 2018 is as follows: Corporate PT and CDMO Business Eliminations Consolidated (in thousands) Revenues from external customers $ 22,582 $ - $ (3,927 ) $ 18,655 Cost of revenues (11,541 ) 1,235 (10,306 ) Segment gross profit (loss) 11,041 - (2,692 8,349 Research and development expenses, net (39 ) (7,931 ) 2,485 (5,485 ) Operating expenses (6,889 ) (6,224 ) 207 (12,906 ) Other expenses (77 ) - (77 ) Segment operating profit (loss) 4,036 (14,155 ) - (10,119 ) Adjustments to presentation of segment Adjusted EBIT Depreciation and amortization (2,613 ) (11 ) (2,624 ) Segment performance 1,423 (14,166 ) (12,743 ) Reconciliation of segment performance to loss for the year: Year ended November 30, 2018 in thousands Segment subtotal performance (12,743 ) Stock-based compensation (4,364 ) Financial expenses, net (2,938 ) Net gain on remeasurement of previously equity interest in Atvio and CureCell to acquisition date fair value 4,509 Transaction expenses related to GPP agreement (1,500 ) Share in losses of associated companies (731 ) Loss before income tax (17,767 ) Segment data for the year ended November 30, 2017 is as follows: Corporate CT and CDMO Business Eliminations Consolidated (in thousands) Revenues from external customers $ 11,484 $ - $ (1,395 ) $ 10,089 Cost of revenues (6,356 ) 638 (5,718 ) Gross profit 5,128 - (757 ) 4,371 Research and development expenses, net (2,517 ) 757 (1,760 ) Operating expenses (4,699 ) (3,335 ) (8,034 ) Operating profit 429 (5,852 ) - (5,423 ) Adjustments to presentation of segment Adjusted EBIT Depreciation and amortization (2,720 ) (6 ) Segment performance (2,291 ) (5,858 ) Reconciliation of segment performance to loss for the year: Year ended November 30, 2017 in thousands Segment performance (8,149 ) Stock-based compensation (3,364 ) Financial income (expenses), net (950 ) Share in losses of associated company (1,214 ) Loss before income tax $ (13,677 ) Geographic, Product and Customer Information Substantially all the Company's revenues and long-lived assets are located in Belgium through its subsidiary, MaSTherCell. Net revenues from single customers from the CDMO segment that exceed 10% of total net revenues are: Year Ended Year Ended November 30, November 30, 2018 2017 (in thousands) Customer A $ 2,338 $ 4,115 Customer B $ 4,374 $ 2,837 Customer C $ - $ 2,055 Customer D $ 5,236 $ - Customer E $ 2,242 $ - The CDMO business has substantially diversified revenues by source signing contracts with biotech companies in their respective cell-based therapy field.

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
	Nov. 30, 2018
PROPERTY AND EQUIPMENT [Text Block]	NOTE 6 – PROPERTY AND EQUIPMENT The following table represents the components of property and equipment: November 30, 2018 2017 (in thousands) Cost: Production facility $ 11,413 $ 6,246 Office furniture and computers 1,875 353 Lab equipment 3,292 2,039 16,580 8,638 Less – accumulated depreciation (4,679 ) (3,534 ) Total $ 11,901 $ 5,104 Depreciation expense for the years ended November 30, 2018 and 2017 was $711 thousand and $1,096 thousand, respectively.

INTANGIBLE ASSETS AND GOODWILL

INTANGIBLE ASSETS AND GOODWILL	12 Months Ended
	Nov. 30, 2018
INTANGIBLE ASSETS AND GOODWILL [Text Block]	NOTE 7 – INTANGIBLE ASSETS AND GOODWILL Changes in the carrying amount of the Company’s goodwill in our CDMO platform for the years ended November 30, 2018 and 2017 are as follows: (in thousands) Goodwill as of November 30, 2016 $ 9,584 Translation differences 1,100 Goodwill as of November 30, 2017 10,684 Goodwill as acquired 4,918 Translation differences (437 ) Goodwill as of November 30, 2018 $ 15,165 Goodwill Impairment The Company reviews goodwill for impairment annually and whenever events or changes in circumstances indicate the carrying amount of goodwill may not be recoverable. The Company performed a quantitative two-step assessment for goodwill impairment for each reporting unit. Reporting Unit of MaSTherCell’ s Goodwill As part of the first step of the two-step impairment test, the Company compared the fair value of the reporting unit to her carrying value and determined that the carrying amount of the unit do not exceed her fair value. The Company estimated the fair value of the unit by using an income approach based on discounted cash flows. The assumptions used to estimate the fair value of the Company’s reporting unit were based on expected future cash flows and an estimated terminal value using a terminal year growth rate based on the growth prospects for each reporting unit. The Company used an applicable discount rate which reflected the associated specific risks for the reporting unit future cash flows. Key assumptions used to determine the estimated fair value include: (a) expected cash flow for the five-year period following the testing date (including market share, sales volumes and prices, costs to produce and estimated capital needs); (b) an estimated terminal value using a terminal year growth rate of 2% determined based on the growth prospects; and (c) a discount rate of 15%. Based on the Company’s assessment as of November 30, 2018 and 2017, respectively, the carrying amount of its reporting unit does not exceed its fair value. A decrease in the terminal year growth rate of 1% or an increase of 1% to the discount rate would reduce the fair value of the reporting unit by approximately $1,126 thousand and $1,961 thousand, respectively. These changes would not result in an impairment. A decrease in the terminal year growth rate and an increase in the discount rate of 1% would reduce the fair value of the reporting unit by approximately $2,899 thousand. These changes would not result in an impairment. Reporting Unit of Atvio’s Goodwill and Reporting Unit of CureCell’s Goodwill As of the year ended November 30, 2018 the Company elected to preform qualitative assessment. Due to the fair value measurement that was performed on June 28, 2018 as part of the business combination. Based on the Company’s assessment as of November 30, 2018, the carrying amount of its reporting unit does not exceeds its fair value. Other Intangible Assets Other intangible assets consisted of the following: November 30, November 30, 2018 2017 (In thousands) Gross Carrying Amount: Know How $ 20,344 $ 17,998 Backlog 117 - Customer relationships 1,274 369 Brand name 1,359 1,418 23,094 19,785 Accumulated amortization 6,394 4,734 Net carrying amount of other intangible assets $ 16,700 $ 15,051 Intangible asset amortization expenses were approximately $1.9 and $1.8 and million for the years ended November 30, 2018 and 2017, respectively. Estimated aggregate amortization expenses for the five succeeding years ending November 30 th 2019 2020 to 2023 (in thousands) Amortization expenses $ 2,086 $ 7,929

CONVERTIBLE LOANS

CONVERTIBLE LOANS	12 Months Ended
	Nov. 30, 2018
CONVERTIBLE LOANS [Text Block]	NOTE 8– CONVERTIBLE LOANS a. Long term convertible loans outstanding as of November 30, 2018 and 2017 are as follows: Shares and Warrants Issued Upon Conversion Accumulated Shares Warrant Interest Up to s Principal Issuance Interest Maturity Exercise BCF Conversion (5) Amount Year Rate Period Price Date (in (in thousands) thousands) (Years) Convertible Loans Outstanding as of November 30, 2018 $1,250 2018 2% 3 $ 7 (1) 114 $ - - - Convertible Loans converted during the year ended November 30, 2018 220 2018 6% 2 $ 6.24 87 $ 2 35,543 35,543 500 (2) 2018 6% 0.5 $ 6.24 106 4 80,756 80,756 5,050 2017 6% 2 $ 6.24 2,311 235 846,961 846,961 798 (3) 2017 6% 0.5 - 1.7 $ 6.24 81 40 134,372 34,269 1,388 2016 6% 2 $ 6.24 251 132 243,443 243,443 100 2014 6%/24% (4) 0.5 $ 4.8 85 81 37,662 - 8,056 $ 494 1,378,737 1,240,972 Convertible Loans repaid during the year ended November 30, 2017 $400 (6) 2017 6% 0.25 $ 6.24 - - - (1) The holders, at their option, may convert the outstanding principal amount and accrued interest under this note into a total of 178,570 shares and 178,570 three-year warrants to purchase up to an additional 178,570 shares of the Company’s common stock at a per share exercise price of $7. In the initial two years, the holders have the right to convert the outstanding principal amount and accrued interest into shares of capital stock of Hemogenyx-Cell or Immugenyx, LLC according under the relevant note agreement, subsidiaries of Hemogenyx Pharmaceuticals Plc, at a price per share based on a pre-money valuation of Hemogenyx-Cell or Immugenyx, LLC of $12 million and $8 million, respectively, pursuant to the collaboration agreement with Hemogenyx Pharmaceuticals Plc and Immugenyx, LLC. As of November 30, 2018, the loans are presented in long term convertible notes in the balance sheet. See Note 11(f) and 11(g). (2) On the issuance date of the note the Company issued to certain investors 40,064 three-year warrants to purchase up to an additional one share of the Company’s common stock at a per share exercise price of $6.24. (3) On the issuance date of the note the Company issued to certain investors 145,509 three-year warrants to purchase up to an additional one share of the Company’s common stock at a per share exercise price of $6.24. (4) The Company failed to reimburse the loan by the maturity date, therefore the interest expenses increase to loan had a default interest of 24% under the terms of the agreement. (5) The warrant, exercisable for a period of three years from the date of conversion, for an additional share of Common Stock, at a per share exercise price of $6.24. (6) The principal amount and accrued interest were repaid by the Company on March 7, 2017. The fair value of the shares as of March 7, 2017, was $494 thousand and was recorded as financial expenses. b. On February 27, 2017, the Company and Admiral Ventures Inc. (“Admiral”) entered into an agreement resolving the payment of convertible loan received in prior years and owed to Admiral. Under the terms of the settlement agreement, Admiral extended the maturity date to June 30, 2018. The Company agreed to pay to Admiral, on or before March 1, 2017, between $0.3 million and $1.5 million. Further, beginning April 2017, the Company agreed to make a monthly payment of $125 thousand on account of remaining unpaid balance, and also agreed to remit additional payments under the term of the agreement. The Company accounted for the above changes as a modification of the old debt. During the year ended November 30, 2017, the Company repaid $1,875 thousand on account of the principal amount and accrued interest. In January 2018, the Company repaid the remaining of accrued interest in total amount of $179 thousand. In 2018 and 2017 the Company was in arrears in its payment obligations under such agreement therefore, the Company issued to Admiral 120,193 units as forbearance fees according to the terms of the agreement. Each unit consisting of one share of the Company’s common Stock and one three-year warrant exercisable into an additional share of common stock at a per share exercise price of $6.24. The fair value of the units was recorded as financial expenses during the year ended November 30, 2018 and 2017 in total amount of $179 and 983 thousand, respectively, out of which $434 thousand reflect the fair value of the warrants using the Black-Scholes valuation model. c. On November 2, 2016, the Company entered into unsecured convertible note agreements with accredited or offshore investors for an aggregate amount of NIS 1 million ($280 thousand). The loan bears a monthly interest rate of 2% and mature on May 1, 2017, unless converted earlier. On April 27, 2017 and November 2, 2017, the Company entered into extension agreements through November 2, 2017 and May 2, 2018, respectively In March 2018, the investor submitted a notice of its intention to convert into shares of the Company's common stock the principal amount and accrued interest of approximately $383 thousand outstanding. A related party of such investor at the same time, exercised warrants issued in November 2016 to purchase shares of the Company's Common Stock. The exercise price of the warrants and conversion price were fixed at $0.52 per share (pre-reverse stock split implemented by the Company in November 2017). There is a significant disagreement between the Company and these two entities as to the number of shares of Common Stock issuable to these entities, and they contend that the number of shares of Common Stock issuable to them should not consider the reverse stock split. The Company rejects these contentions in their entirety and, based on the advice of specially retained counsel, believes that these claims are without legal merit and not made in good faith. The Company intends to vigorously defend its interests and pursue other avenues of legal address. Through its counsel, the Company has advised these entities that unless they withdraw their request within a specified period, the Company will cancel the above referenced agreements and these parties’ right to receive any shares of the Company’s Common Stock. In April 2018, the Company withdrew the agreements and deposited the shares in total amount of 107,985 issued under those agreements and the principal amount and accrued interest of the loan in escrow account. The deposit of the principal amount and accrued interest presented as restricted cash in the balance sheet as of November 30, 2018. d. In January 2017, MaSTherCell repaid all but one of its bondholders (originally issued on September 14, 2014), and the aggregate payment amounted to $1.7 million (€ 1.5 million). On January 17, 2017, the remaining bondholder agreed to extend the duration of his Convertible bond until March 21, 2017. In consideration for the extension, the Company issued to the bondholder warrants to purchase 8,569 shares of the Company’s Common Stock, exercisable over a three-year period at a per share exercise price of $6.24. The fair value of those warrants as of the date of grant was $20 thousand using the Black-Scholes valuation model. On March 20, 2017, the remaining bondholder converted his convertible bonds into 40,682 shares of the Company’s Common Stock (See also note 13(c)).

LOANS

LOANS	12 Months Ended
	Nov. 30, 2018
LOANS [Text Block]	NOTE 9 – LOANS a. Terms of Long-term Loans Principal Year of November 30, Amount Grant Year Interest Rate Maturity 2018 2017 (in thousands) (in thousands) Long-term loan (*) € 1,400 2012 4.05% 2022 $ 700 $ 899 Long-term loan € 1,000 2013 6%- 7.5% 2023 869 977 Long-term loan € 790 2012-2016 5.5%- 6% 2021-2024 461 620 $ 2,030 $ 2,496 Current portion of loans payable (368 ) (378 ) $ 1,662 $ 2,118 (*) The loan has a business pledge on the Company’s assets at the same value. b. Terms of Short-term Loans and Current Portion of Long-Term Loans November 30, Currency Interest Rate 2018 2017 (in thousands) Current portion of loans payable Euro 4.05% $ 168 $ 169 Current portion of loans payable Euro 6%- 7.5% 67 70 Current portion of loans payable Euro 5.5%- 6% 133 139 Short term loans KRW 3.02%, 4.15% 279 - $ 647 $ 378

COMMITMENTS

COMMITMENTS	12 Months Ended
	Nov. 30, 2018
COMMITMENTS [Text Block]	NOTE 10 - COMMITMENTS a. Maryland Technology Development Corporation On June 30, 2014, the Company’s U.S. Subsidiary entered into a grant agreement with Maryland Technology Development Corporation (“TEDCO”). TEDCO was created by the Maryland State Legislature in 1998 to facilitate the transfer and commercialization of technology from Maryland’s research universities and federal labs into the marketplace and to assist in the creation and growth of technology-based businesses in all regions of the State. Under the agreement, TEDCO paid to the U.S Subsidiary an amount of $406 thousand (the “Grant”). On June 21, 2016 TEDCO has approved an extension until June 30, 2017. Through November 30, 2018, the Company utilized $356 thousand from the grant and recorded it as a deduction of research and development expenses in the statement of comprehensive loss. b. Department De La Gestion Financiere Direction De L’analyse Financiere (“DGO6”) (1) On March 20, 2012, MaSTherCell was awarded an investment grant from the DGO6 of Euro 1.2 million. This grant is related to the investment in the production facility with a coverage of 32% of the investment planned. As of November 30, 2018, the DGO6 transferred the entire amount to MaSTherCell. (2) On November 17, 2014, the Belgian Subsidiary, received the formal approval from the DGO6 for a Euro 2 million ($2.4 million) support program for the research and development of a potential cure for Type 1 Diabetes. The financial support was composed of Euro 1,085 thousand ( 70% of budgeted costs) grant for the industrial research part of the research program and a further recoverable advance of Euro 930 thousand ( 60% of budgeted costs) of the experimental development part of the research program. In December 2014, the Belgian Subsidiary received advance payment of Euro 1,209 thousand under the grant. The grants are subject to certain conditions with respect to the Belgian Subsidiary’s work in the Walloon Region. In addition, the DGO6 is also entitled to a royalty upon revenue being generated from any commercial application of the technology. In 2017 the Company received by the DGO6 final approval for Euro 1.8 million costs invested in the project out of which Euro 1.2 million founded by the DGO6. As of November 30, 2018, the Company repaid to the DGO6 a total amount of $34 thousand (Euro 30 thousand) and amount of $152 thousand was recorded in other payables. (3) ln April 2016, the Company's Belgian Subsidiary received the formal approval from DGO6 for a Euro 1.3 million ($1.5 million) support program for the development of a potential cure for Type 1 Diabetes. The financial support was awarded to the Belgium Subsidiary as a recoverable advance payment at 55% of budgeted costs, or for a total of Euro 717 thousand ($800 thousand). The grant will be paid over the project period. On December 19, 2016, the Belgian Subsidiary received advance payment of Euro 359 thousand ($374 thousand). Up through November 30, 2018, an amount of Euro 303 thousand was recorded as deduction of research and development expenses and an amount of $64 thousand was recorded as advance payments on account of grant. (4) On October 8, 2016, the Belgian Subsidiary received the formal approval from the DGO6 for a Euro 12.3 million ($12.8 million) support program for the GMP production of AIP cells for two clinical trials that will be performed in Germany and Belgium. The project will be held during a period of three years commencing January 1, 2017. The financial support is awarded to the Belgium subsidiary at 55% of budgeted costs, a total of Euro 6.8 million ($7 million). The grant will be paid over the project period. On December 19, 2016, the Belgian Subsidiary received a first payment of Euro 1.7 million ($1.8 million). Up through November 30, 2018, an amount of $1.1 million was recorded as deduction of research and development expenses and an amount of $847 thousand was recorded as advance payments on account of grant. c. Israel-U.S. Binational Industrial Research and Development Foundation (“BIRD”) On September 9, 2015, the Israeli Subsidiary entered into a pharma Cooperation and Project Funding Agreement (CPFA) with BIRD and Pall Corporation, a U.S. company. BIRD will give a conditional grant of $400 thousand each (according to terms defined in the agreement), for a joint research and development project for the use Autologous Insulin Producing (AIP) Cells for the Treatment of Diabetes (the “Project”). The Project started on March 1, 2015. Upon the conclusion of product development, the grant shall be repaid at the rate of 5% of gross sales. The grant will be used solely to finance the costs to conduct the research of the project during a period of 18 months starting on March 1, 2015. To date the Israeli Subsidiary received $200 thousand under the grant. On July 28, 2016 BIRD approved an extension till May 31, 2017 and final report was submitted to BIRD. Up through November 30, 2018, an amount of $359 thousand was recorded as deduction of research and development expenses and $159 thousand as a receivable on account of grant. d. Korea-Israel Industrial Research and Development Foundation (“KORIL”) On March 14, 2016, the Israel subsidiary, entered into a collaboration agreement with CureCell, initially for the purpose of applying a grant from KORIL for pre-clinical and clinical activities related to the commercialization of the Israel subsidiary AIP cell therapy product in Korea. The Parties agreed to carry out at their own expenses and their respective commitments under the work plan approved by KORIL and any additional work plan to be agreed between the Israeli Subsidiary and CureCell. The Israeli Subsidiary will own sole rights to any intellectual property developed from the collaboration which is derived under the Israeli Subsidiary’s AIP cell therapy product, information licensed from THM. Subject to obtaining the requisite approval needed to commence commercialization in Korea, the Israel subsidiary has agreed to grant to CureCell, or a fully owned subsidiary thereof, under a separate sub-license agreement an exclusive sub-license to the intellectual property underlying the Company’s API product solely for commercialization of the Israel subsidiary products in Korea. As part of any such license, CureCell has agreed to pay annual license fees, ongoing royalties based on net sales generated by CureCell and its sublicensees, milestone payments and sublicense fees. Under the agreement, CureCell is entitled to share in the net profits derived by the Israeli Subsidiary from world - On May 26, 2016, the Israeli Subsidiary and CureCell entered into a pharma Cooperation and Project Funding Agreement (CPFA) with KORIL. KORIL will give a conditional grant of up to $400 thousand each (according to terms defined in the agreement), for a joint research and development project for the use of AIP Cells for the Treatment of Diabetes (the “Project”). The Project started on June 1, 2016. Upon the conclusion of product development, the grant shall be repaid at the yearly rate of 2.5% of gross sales. The grant will be used solely to finance the costs to conduct the research of the project during a period of 18 months starting. On July 26, 2018 KORIL approved extension for the project period till May 31, 2019. As of November 30, 2018, The Israeli Subsidiary and CureCell received total amount of $440 thousand under the grant. Up through November 30, 2018, The Isreali Subsidiary recorded an amount of $279 thousand as a deduction of research and development expenses and $119 thousand as a receivable on account of grant, and CureCell recorded $134 thousand as advance payments on account of grant. e. BIRD Secant On July 30, 2018, Orgenesis Inc and Atvio Biotech, entered into a collaboration agreement with Secant Group LLC ("Secant"). Under the agreement, Secant will engineer and prototype 3D scaffolds based on novel biomaterials and technologies involving bioresorbable polymer microparticles, while Atvio will provide expertise in cell coatings, cell production, process development and support services. Under the agreement, Orgenesis is authorized to utilize the jointly developed technology for its autologous cell therapy platform, including its Autologous Insulin Producing (“AIP”) cell technology for patients with Type 1 Diabetes, acute pancreatitis and other insulin deficient diseases. In the beginning of 2018, Atvio entered into a Cooperation and Project Funding Agreement (CPFA) with BIRD and Secant. BIRD will give a conditional grant up to $450 thousand each to support the join project (according to terms defined in the agreement). As of November 30, 2018, Atvio received a total amount of $125 thousand under the grant. Up through November 30, 2018, an amount of $275 thousand was recorded as deduction of research and development expenses and $163 thousand as a receivable on account of grant. f. Lease Agreement The Company leases office space for its CDMO facilities and research and development facilities in Belgium, Korea, Israel and the United States of America under several lease agreements. The expiration dates of the lease agreements for the facilities in each country are as follow: Country Expire Date Belgium February 29, 2020 and March 31, 2030 Israel July 31, 2023 Korea July 14, 2020 United States * *The company signed a new lease agreement during January 2019, see Note 21(f) Future minimum lease commitments under non-cancelable operating lease agreements are as follows: 2019 $ 783 2020 626 2021 and thereafter 3,504 Total $ 4,913

COLLABORATION AND LICENSE AGREE

COLLABORATION AND LICENSE AGREEMENTS	12 Months Ended
	Nov. 30, 2018
COLLABORATION AND LICENSE AGREEMENTS [Text Block]	NOTE 11 – COLLABORATION AND LICENSE AGREEMENTS a. Adva Biotechnology Ltd. On January 28, 2018, the Company and Adva Biotechnology Ltd. (“Adva”), entered into a Master Services Agreement (“MSA”), under which the Company and/or its affiliates are to provide certain services relating to development of products to Adva, as may be agreed between the parties from time to time. Under the MSA, the Company undertook to provide Adva with in kind funding in the form of materials and services having an aggregate value of $750 thousand at the Company’s own cost in accordance with a project schedule and related mutually acceptable project budget. The Company entered into agreement with Atvio, to fulfill its obligations pursuant this MSA. As of November 30, 2018, the Company incurred a total expense of $361 thousand. In consideration for and subject to the fulfillment by the Company of such in-kind funding commitment, Adva agreed that upon completion of the development of the products, the Company and/or its affiliates and Adva shall enter into a supply agreement pursuant to which for a period of eight (8) years following execution of such supply agreement, the Company and/or its affiliates (as applicable) is entitled (on a non-exclusive basis) to purchase the products from Adva at a specified discount pricing from their then standard pricing. The Company and/or its affiliates were also granted a non-exclusive worldwide right to distribute such products, directly or through any of their respective contract development and manufacturing organization (CDMO) service centers during such term. The MSA shall remain in effect for 10 years unless earlier terminated in accordance with its terms. b. Tel Hashomer Medical Research, Infrastructure and Services Ltd (“THM”). On February 2, 2012, the Company’s Israeli Subsidiary entered into a licensing agreement with THM. According to the agreement, the Israeli Subsidiary was granted a worldwide, royalty bearing, exclusive license to trans-differentiation of cells to insulin producing cells, including the population of insulin producing cells, methods of making this population, and methods of using this population of cells for cell therapy or diabetes treatment developed by Dr. Sarah Ferber of THM. As consideration for the license, the Israeli Subsidiary will pay the following to THM: 1) A royalty of 3.5% of net sales; 2) 16% of all sublicensing fees received; 3) An annual license fee of $15 thousand, which commenced on January 1, 2012 and shall be paid once every year thereafter. The annual fee is non-refundable, but it shall be paid each year against the royalty noted above, to the extent that such are payable, during that year; and 4) Milestone payments as follows: a. $50 thousand on the date of initiation of phase I clinical trials in human subjects; b. $50 thousand on the date of initiation of phase II clinical trials in human subjects; c. $150 thousand on the date of initiation of phase III clinical trials in human subjects; d. $750 thousand on the date of initiation of issuance of an approval for marketing of the first product by the FDA; and e. $2 million when worldwide net sales of Products (as defined in the agreement) have reached the amount of $150 million for the first time, (the “Sales Milestone”). As of November 30, 2018, the Israeli Subsidiary had not reached any of these milestones. In the event of closing of an acquisition of all of the issued and outstanding share capital of the Israeli Subsidiary and/or consolidation of the Israeli Subsidiary or the Company into or with another corporation (“Exit”), the THM shall be entitled to choose whether to receive from the Israeli Subsidiary a one-time payment based, as applicable, on the value of either 463,651 shares of common stock of the Company at the time of the Exit or the value of 1,000 shares of common stock of the Israeli Subsidiary at the time of the Exit. c. Mircod Limited On June 18, 2018, the Company and Mircod Limited, a company formed under the laws of Cyprus (“Mircod”) entered into a Collaboration and License Agreement (the “Mircod Collaboration Agreement”) for the research, development and commercialization of potential key technologies related to biological sensing for the Company's clinical development and manufacturing projects (the “Development Project”). Under the Mircod Collaboration Agreement, all results of such collaboration (“Project Results”) shall be jointly owned by Mircod and the Company. The Company was granted an exclusive, worldwide sub licensable license under Mircod’s right in such Project Results to use and commercialize Project Results in consideration for a royalty of 5% of net sales (as defined in the Collaboration Agreement) of products incorporating Project Results. Subject to completion of the Development Project, Mircod and the Company are to negotiate and enter into a manufacturing and supply agreement under which Mircod is to manufacture and supply products incorporating the Project Results and, at the Company’s request, to provide support and maintenance service for such products. If for whatever reason the parties fail to enter into such manufacturing and supply agreement within 90 days of the completion of the Development Project or if Mircod is unable to perform such services, the Company is entitled to manufacture the products, in which event Mircod will be entitled to a payment of $80,000 and royalties on Net Sales are to increase to 8% of Net Sales. As of November 30, 2018, the Developments Project has not completed. d. HekaBio K.K On July 10, 2018, the Company and HekaBio K.K. (“HB”), a corporation organized under the laws of Japan entered into a Joint Venture Agreement (the “HB JVA”) pursuant to which the parties will collaborate in the clinical development and commercialization of regeneration and cell and gene therapeutic products (hereinafter the “Products”) in Japan (the “Project”). The parties intend to pursue the joint venture through a newly established Japanese company (hereinafter the “JV Company”) which the Company by itself, or together with a designee, will hold a 49% participating interest therein, with the remaining 51% participating interest being held by HB. HB will fund, at its sole expense, all costs associated with obtaining the requisite regulatory approvals for conducting clinical trials, as well as performing all clinical and other testing required for market authorization of the Products in Japan. Under the JVA, each party may invest up to $10 million, which may take the form of a loan, if required, as determined by the steering committee. The terms of such investment, if any, will be on terms mutually agreeable to the parties, provided that the minimum pre-money valuation for any such investment shall not be less than $10 million. Additionally, HB was granted an option to affect an equity investment in the Company of up to $15 million within the next 12 months on mutually agreeable terms. If such investment is in fact consummated, the Company agreed to invest in the JV Company by way of a convertible loan an amount equal to HB’s pro-rata participating interest in the JV Company, which initially will be at 51%. Such loan may then be converted by the Company into share capital of the JV company at an agreed upon formula for determining JV Company valuation which in no event shall be less than $10 million. Under the JVA, the Company can require HB to sell to the Company its participating (including equity) interest in the JV Company in consideration for the issuance of the Company’s common stock based on an agreed upon formula for determining JV Company valuation which in no event shall be less than $10 million. In addition, under the JVA, the Company shall grant the JV Company an exclusive license to certain intellectual property of the Company as may be required for the JV Company to develop and commercialize the Products in Japan. In consideration of such license, the JV Company shall pay the Company, in addition to other payments, royalties at the rate of 10% of the JV Company’s net sales of Products. It was further agreed that the JV Company shall grant the Company (and its affiliates) a non-exclusive, worldwide (other than Japan), royalty-free and fully paid-up license to use and practice, for any purpose, new inventions, discoveries and intellectual property rights that are generated by and/or on behalf of HB and/or the JV Company in connection with the Project. On October 3, 2018, the Company entered into a License Agreement with the JV Company pursuant to the JVA pertaining to the licenses described above. Apart from the above, as of November 30, 2018, no activity had begun in the said JV and no investments were made therein. e. Image Securities Ltd. On July 11, 2018, the Company and Image Securities Ltd., a corporation with its registered office in Grand Cayman, Grand Cayman Islands (“India Partner”) entered into a Joint Venture Agreement (the “India JVA”) pursuant to which the parties will collaborate in the development and/or marketing, clinical development and commercialization of cell therapy products in India (the “Cell Therapy Products”). The India Partner will collaborate with a network of healthcare facilities and a healthcare infrastructure as well as financial partners to advance the development and commercialization of the cell therapy products. The India JVA becomes effective upon the consummation of an equity investment by the India Partner in the Company of $5 million within 15 days of the execution of the India JVA through the purchase of units of the Company securities at a per unit purchase price payable into the Company of $6.24, with each unit comprised of one share of the Company and three-year warrant for the acquisition of an additional common share at a per share exercise price of $6.24. Following the consummation of such equity investment in the Company, on October 18, 2018, the Company entered into a convertible loan agreement with the India Joint Venture company (“India JV”) pursuant to which the Company agreed to invest $5 million into the India JV. The loan is convertible into equity capital of the India JV at an agreed upon formula for determining India JV valuation. The investment in the Company by the India Partner was the consummation of the previously disclosed private placement subscription agreement entered into in December 2016 between the Company and an affiliate of the India Partner pursuant to which the closing of such subscription agreement was by the terms thereof delayed until terms comprising the India JV were mutually agreed to. As of November 30, 2018, the Company has advanced $1 million to the JV Company under the convertible loan agreement, the loan will bear interest of 6% per annum and the outstanding amount (principal and interest) will be payable after two years. The loan was presented in the balance sheet as loan to related party. Under the India JVA, the India Partner agreed to invest in the JV $10 million within 12 months of the incorporation of the India JV. If for whatever reason such investment is not made by the India Partner within such time, then the Company is authorized to convert its above-referenced loan into 50% of the equity capital of the India JV on a fully diluted basis, provided that if the pre-money valuation of the India JV is then independently determined to be less than $5 million, then such conversion to be effected in the basis of such valuation. Apart from the above, as of November 30, 2018, no activity had begun. As part of the agreement, the Indian joint venture will procure consulting services from the Company in the amount of $1 million per month – See also Note 21(c). f. Hemogenyx Pharmaceuticals PLC. On October 18, 2018, the Company and Hemogenyx Pharmaceuticals PLC., a corporation with its registered office in the United Kingdom and Hemogenyx-Cell (“H-Cell"), a corporation with its registered office in Belgium (together “Hemo”) which are engaged in the development of cell replacement bone marrow therapy technology entered into a Collaboration Agreement (the “Hemo agreement”) pursuant to which the parties will collaborate in the funding of the continued development of, and commercialization of the Hemo technology via the Hemo group companies. Pursuant to the Hemo agreement the Company and Hemogenyx LLC (“Hemo-LLC”) (a wholly owned USA subsidiary of Hemo) entered into a loan agreement on November 7, 2018 according to which the Company agreed to loan Hemo-LLC not less than $1 million by way of a convertible loan. On November 25, 2018 the Company and Hemo entered into a License and Distribution agreement according to which Company received the worldwide rights to market the products under the agreement in consideration for the payment of a 12% royalty all subject to the terms of the agreement. On November 25, 2018, the Company and H-Cell signed an Exclusive Manufacturing agreement according to which the Company will receive the right to manufacture certain of H-Cell products. As of November 30, 2018, the Company advanced $0.5 million as a convertible loan, and an additional $0.25 million was advanced in December 2018 (see Note 21(b)). The entire loan as of November 30, 2018, in the amount of $0.5 million, was charged to expense under ASC 730-10-50 and 20-50 and presented as research and development costs. See Note 8 (a). g. Immugenyx LLC. On October 16, 2018, the Company and Immugenyx LLC., a corporation with its registered office in the USA (“Immu”) which is engaged in the development of technology related to the production and use of humanized mice entered into a Collaboration Agreement (the “Immu agreement”) pursuant to which the parties will collaborate in the funding of the continued development of, and commercialization of the Immu technology. Pursuant to the agreement, the Company received the worldwide rights to market the products under the agreement in consideration for the payment of a 12% royalty all subject to the terms of the agreement. Pursuant to the Immu agreement the Company and Immu entered into a loan agreement on November 7, 2018 according to which the Company agreed to loan Immu not less than US$1 Million by way of a convertible loan. As of November 30, 2018, the Company advanced $0.5 million as convertible loan, and an additional $0.25 million was advanced in December 2018 (see Note 21(b)). The entire loan as of November 30, 2018, in the amount of $0.5 million, was charged to expense under ASC 730-10-50 and 20-50 and presented as research and development costs. See also Note 8 (a). h. BG Negev Technologies and Applications (“BGN”). On August 2, 2018, the Company’s USA Subsidiary entered into a licensing agreement with BGN. According to the agreement, the USA Subsidiary was granted a worldwide, royalty bearing, exclusive license to develop and commercialize a novel alginate scaffold technology for cell transplantation focused on autoimmune diseases. On November 25, 2018, the Company’s USA Subsidiary entered into a further licensing agreement with BGN. According to the agreement, the USA Subsidiary was granted a worldwide, royalty bearing, exclusive license to develop and commercialize technology directed to RAFT modification of polysaccharides and use of a bioreactor for supporting cell constructs. As consideration for the licenses, the USA Subsidiary will pay royalties of between 2% and 4% of net sales of the licensed product, sub-license fees of between 15% and 20% of sub-license income received, license fees of $10,000 per year per license, and milestone and budget payments according to agree upon work plans to BGN. i. Collaboration agreement During 2018, the Company and Cure Therapeutics entered into a collaboration agreement for the development of therapies based on liver and NK cells. The agreement will be governed by a joint steering committee and carried out in accordance with the projects' work plans. Under the plan, each party will generally bear its own share of expenses. As of November 30, 2018, the Company has incurred $1.2 million of research and development expenses in relation to the project. As part of the agreement, Cure Therapeutics has subcontracted development and contract manufacturing activates to CureCell, for which service revenue of $1 million has been recognized.

INVESTMENTS IN ASSOCIATE, NET

INVESTMENTS IN ASSOCIATE, NET	12 Months Ended
	Nov. 30, 2018
INVESTMENTS IN ASSOCIATE, NET [Text Block]	NOTE 12 – INVESTMENTS IN ASSOCIATES, NET a. On May 10, 2016, the Company and Atvio entered into joint venture agreement, pursuant to which the parties agreed to collaborate in the field of the CDMO in Israel (the “Atvio JVA”). The parties pursued the joint venture through Atvio, the Company had 50% participating interest therein in any and all rights and obligations and in any and all profits and losses. Atvio's operations commenced in September 2016. The Company remitted to Atvio $1 million under the terms of the Atvio JVA to defray the costs associated with the setting up and the maintenance of the GMP facility. The Company’s funding was made by way of a convertible loan to Atvio, which could have been convertible at the Company’s option at any time. The Company concluded that, based on the terms of the agreement, it had the ability to exercise significant influence in Atvio, but had no control. Therefore, the investment was accounted for under the equity method. In addition, at any time following the first anniversary year of the Effective Date the Company had the option to require the Atvio’s shareholders to transfer to the Company the entirety of their interest in Atvio for the consideration specified in the agreement. Within three years from the Effective Date, the Atvio’s shareholders had the option to require the Company to purchase from Atvio's shareholders their entire interest in Atvio for the consideration based on Atvio's valuation mechanism as specified in the agreement. The above-mentioned options were accounted as derivatives and measured at fair value and was presented in the balance sheet in " put option derivative " line item (See Note 17). On June 28, 2018 the Company exercised its call options in Atvio, see also Note 4. b. On March 14, 2016, Orgenesis Inc. and CureCell entered into a joint venture agreement (the “CureCell JVA”), pursuant to which the parties are collaborating in the field of the CDMO in Korea. Under the CureCell JVA, CureCell had procured, at its sole expense, a GMP facility and appropriate staff in Korea for the manufacture of the cell therapy products. The Company had to share with CureCell the Company’s know-how in the field of cell therapy manufacturing All obligations were fulfilled by the parties and each party had 50% from the participating interest and in any and all profits and losses of the joint venture. The Company remitted to CureCell $2.1 million under the terms of the CureCell JVA. On June 28, 2018 the Company exercised its call options in CureCell, see also Note 4 . c. The table below sets forth a summary of the changes in the investments for the years ended November 30, 2018 and 2017: November 30, 2018 2017 (In thousands) Opening balance $ 1,321 $ (12 ) Reclass with short-term receivables (795 ) 118 Investments during the period - 2,429 Share in losses (731 ) (1,214 ) Reductions due to the acquisition of CureCell and Atvio – see also Note 4 205 - $ - $ 1,321

EQUITY

EQUITY	12 Months Ended
	Nov. 30, 2018
EQUITY [Text Block]	NOTE 13 – EQUITY a. Share Capital The Company’s common shares were traded on the OTCQB Venture Market under OTC Market Group’s OTCQB tier under the symbol “ORGS”. On March 13, 2018, the Company's common stock began to be listed and traded on the Nasdaq Capital Market under the symbol “ORGS.”. b. Financings (1) In January 2017, the Company entered into definitive agreements with an institutional investor for the private placement of 2,564,115 units of the Company’s securities for aggregate subscription proceeds to the Company of $16 million at $6.24 price per unit. Each unit is comprised of one share of the Company’s Common Stock and a one warrant, exercisable over a three-years period from the date of issuance, to purchase one additional share of Common Stock at a per share exercise price of $6.24 (“Unit”). The subscription proceeds have been paid to the Company on a periodic basis through October 2018. In July 2018, the Company entered into definitive agreements with assignees of the aforementioned institutional investor whereby these assignees remitted $4.6 million in respect of the units available under the original subscription agreement that have not been subscribed for, entitling such investors to 702,307 units, with each unit being comprised of (i) one share of the Company's common stock and (ii) one three-year warrant to purchase up to an additional one share of the Company’s common stock at a per share exercise price of $6.24. During the year ended November 30, 2018 and 2017 the investor and the assignees remitted to the Company $11.5 and $4.5 million, and the Company issued 1,813,687 and 721,160 Units, respectively. As of November 30, 2018, 550,481 shares have not been issued and therefore the Company has recorded $2.3 million in receipts on account of shares to be allotted in the statement of equity. In connection therewith, during the year ended November 30, 2018 and 2017, the Company had transaction costs of approximately $328 and $225 thousand, respectively, out of which $121 and $253 thousand are stock-based compensation expenses due to issuance of warrants and shares. See also Note 15(d). (2) During the year ended November 30, 2018, the Company entered into definitive agreements with accredited and other qualified investors relating to a private placement of 1,237,642 units. Each unit is comprised of (i) one share of the Company’s common stock and (ii) three-year warrant to purchase up to an additional one share of the Company’s Common Stock at a per share exercise price of $6.24, for aggregate proceeds to the Company of approximately $7.7 million. The transaction costs were approximately $349 thousand, out of which $125 thousand are stock-based compensation due to issuance of warrants. See also 15(d). (3) During the year ended November 30, 2018, investors exercised 136,646 warrants into 136,646 shares of the Company’s Common Stock, for aggregate proceeds of $853 thousand. c. Contingent Shares According to the share exchange agreement signed during 2015, the former shareholders of MaSTherCell received a “consideration of shares” of Orgenesis Inc. in exchange of their shares in MaSTherCell. At the time of MaSTherCell’s acquisition by the Company, there was outstanding convertible bonds issued by MaSTherCell in an amount of $1.8 million (Euro 1.6 million). Under the share exchange agreement in case MaSTherCell is repaying the principal amount and the accrued interest of the convertible bonds, the former shareholders will give back to the Company a portion of the consideration shares. To that effect, the number of consideration shares to be released back to the Company, shall be determined by dividing the subscription amount of the outstanding convertible bonds plus interest owed thereunder (converted into USD according to the currency exchange rate applicable on the day of conversion) by the consideration and by applying the resulting quotient to actual total number of consideration shares received by former shareholder of MaSTherCell. During January 2017 MaSTherCell repaid all but one of its bondholders and the aggregate payment amounted to $1.7 million (Euro 1.5 million). According to the terms of the release back pursuant the share exchange agreement, the Company returned to treasury a total of 263,148 shares. These shares have been retired and cancelled. See also Note 8(d). d. Warrants A summary of the Company's warrants granted to investors and as finder's fees as of November 30, 2018 and 2017 and changes for the years then ended is presented below: 2018 2017 Weighted Weighted Average Average Exercise Exercise Number of Price Number of Price Warrants $ Warrants $ Warrants 2,609,864 6.26 1,620,993 6.25 Changes during the year: Issued 4,488,854 6.27 1,144,647 6.32 Exercised (136,646 ) 6.24 - Expired (382,414 ) 6.10 (155,776 ) 6.24 Cancelled** (66,667 ) 6.24 - Warrants 6,512,991 6.27 2,609,864 6.26 * As of November 30, 2018, and 2017, 769,411 and 1,066,691 warrants respectively, are subject to exercise price adjustments **

LOSS PER SHARE

LOSS PER SHARE	12 Months Ended
	Nov. 30, 2018
LOSS PER SHARE [Text Block]	NOTE 14 – LOSS PER SHARE The following table sets forth the calculation of basic and diluted loss per share for the periods indicated: Year Ended November 30, 2018 2017 (in thousands, except per share data) Basic: Net loss attributable to Orgenesis Inc $ 18,291 $ 12,367 Adjustment of redeemable non-controlling interest to redemption amount 884 - Net loss attributable to Orgenesis Inc. for loss per share $ 19,175 $ 12,367 Weighted average number of common shares outstanding 13,374,103 9,679,964 Basic loss per common share $ 1.43 $ 1.28 Diluted Net loss attributable to Orgenesis Inc. for loss per share $ 19,175 12,367 Changes in fair value of embedded derivative and interest expenses on convertible note - 392 Loss for the year $ 19,175 $ 12,759 Weighted average number of shares used in the computation of basic loss per share 13,374,103 9,679,964 Number of dilutive shares related to convertible note - 34,288 Weighted average number of common shares outstanding 13,374,103 9,714,252 Diluted loss per common share $ 1.43 $ 1.31 For the year ended November 30, 2018, all outstanding convertible notes, options and warrants have been excluded from the calculation of the diluted net loss per share since their effect was anti-dilutive. For the year ended November 30, 2017, all outstanding options and warrants and 1,057,785 shares upon conversion of convertible notes have been excluded from the calculation of the diluted net loss per share since their effect was anti-dilutive.

STOCK BASED COMPENSATION

STOCK BASED COMPENSATION	12 Months Ended
	Nov. 30, 2018
STOCK BASED COMPENSATION [Text Block]	NOTE 15– STOCK-BASED COMPENSATION a. Global Share Incentive Plan On May 11, 2017, the annual meeting of the Company’s stockholders approved the 2017 Equity Incentive Plan (the “2017 Plan”) under which, the Company had reserved a pool of 1,750,000 shares of the Company’s common stock, which may be issued at the discretion of the Company's board of directors from time to time. Under this Plan, each option is exercisable into one share of common stock of the Company. The options may be exercised after vesting and in accordance with the vesting schedule that will be determined by the Company's board of directors for each grant. The maximum contractual life term of the options is 10 years. As of November 30, 2018, total options granted under this plan are 1,040,942 709,058 On May 23, 2012, the Company's board of directors adopted the Global Share Incentive Plan 2012 (the “2012 Plan") under which, the Company had reserved a pool of 1,000,000 shares of the Company’s common stock, which may be issued at the discretion of the Company's board of directors from time to time. Under this plan, each option is exercisable into one share of common stock of the Company. The options may be exercised after vesting and in accordance with the vesting schedule that will be determined by the Company's board of directors for each grant. The maximum contractual life term of the options is 10 years. As of November 30, 2018, total options granted under this plan are 699,991 300,009 b. Options Granted to Employees and Directors Below is a table summarizing all of the options grants to employees and made during the years ended November 30, 2018, and 2017: Year of No. of options Exercise price Vesting period Fair value at grant Expiration grant granted (in thousands) period Employees 2018 762,400 $4.42 -$8.91 vest immediately- 4 years $4,233 10 years Directors 2018 113,800 $5.99 1 year $507 10 years Directors 2017 166,668 $4.80 2 years $558 10 years Employees 2017 525,005 $4.8,$7.2 vest immediately- 4 years $1,915 10 years The fair value of each stock option grant is estimated at the date of grant using a Black Scholes option pricing model. The volatility is based on historical volatility of the Company, by statistical analysis of the weekly share price for past periods based on expected term. The expected option term is calculated using the simplified method , Year Ended November 30, 2018 2017 Value of one common share $4.42 -$8.7 $4.68,$7.2 Dividend yield 0% 0% Expected stock price volatility 88%- 98% 93.8%- 95.4% Risk free interest rate 2.33%- 3.2% 1.89%- 1.76% Expected term (years) 4.13 - 10 5 A summary of the Company's stock options granted to employees and directors as of November 30, 2018 and 2017 and changes for the years then ended is presented below: 2018 2017 Weighted Weighted Average Average Exercise Exercise Number of Price Number of Price Options $ Options $ Options outstanding at the beginning of the year 1,605,055 3.11 978,853 1.92 Changes during the year: Granted 876,200 7.13 691,673 5.28 Expired (61,463 ) 5.26 (38,106 ) 7.58 Forfeited (43,365 ) 4.68 (27,365 ) 4.8 Options outstanding at end of the year 2,376,427 4.51 1,605,055 3.11 Options exercisable at end of the year 1,504,542 2.91 1,135,107 2.57 The following table presents summary information concerning the options granted and exercisable to employees and directors outstanding as of November 30, 2018: Weighted Average Aggregate Aggregate Exercise Number of Remaining Intrinsic Number of Exercisable Price Outstanding Contractual Value Exercisable Options $ Options Life $ Options Value $ (in thousands) (in thousands) 0.0012 462,015 4.78 2,776 462,015 1 0.012 278,191 3.18 1,669 278,191 3 4.42 50,000 9.02 79 37,500 166 4.8 524,999 8.03 635 440,104 2,112 5.99 384,050 9.35 8 32,750 196 6 33,334 5.67 - 33,334 200 7.2 83,334 8.51 - 83,334 600 8.36 250,000 9.58 - - 8.43 160,994 9.46 - 14,492 156 8.91 30,500 9.55 - 3,813 34 9 20,834 4.63 - 20,834 188 9.48 58,908 3.61 - 58,908 558 10.2 39,268 3.51 - 39,267 401 2,376,427 7.15 5,167 1,504,542 4,598 Costs incurred with respect to stock-based compensation for employees and directors for the years ended November 30, 2018 and 2017 were $2,426 thousand and $1,536 thousand, respectively. As of November 30, 2018, there was $3,783 thousand of unrecognized compensation costs related to non-vested employees and directors stock options, to be recorded over the next 3.89 years. c. Options Granted to Consultants and service providers Below is a table summarizing all the compensation granted to consultants and service providers during the years ended November 30, 2018 and 2017: Fair value at Year of No. of options Exercise grant Expiration grant granted price Vesting period ( in thousands ) period Non-employees 2018 102,763 $4.42 -$8.34 vest immediately- 4 years $444 10 years Non-employees 2017 16,668 $4.8 Quarterly over a period of one year $68 10 years The fair value of options granted during 2018 and 2017 to consultants and service providers, was computed using the Black-Scholes model. The fair value of each stock option grant is estimated at the date of grant using a Black Scholes option pricing model. The volatility is based on historical volatility of the Company, by statistical analysis of the weekly share price for past periods based on the expected term period, the expected term is the contractual term of each grant. The expenses are subsequently adjusted to fair value at the end of each reporting period until such options vest, and the fair value of such instruments, as adjusted, is expensed over the related vesting period. The underlying data used for computing the fair value of the options are as follows: Year Ended November 30, 2018 2017 Value of one common share $ 4.42 -$8.34 $ 3.6 -$7.44 Dividend yield 0% 0% Expected stock price volatility 91%- 95% 87%- 95% Risk free interest rate 2.33%- 3.20% 1.19%- 1.89% Expected term (years) 9.79 - 10 4 - 5 A summary of the status of the stock options granted to consultants and service providers as of November 30, 2018, and 2017 and changes for the years then ended is presented below: 2018 2017 Weighted Weighted Average Average Exercise Exercise Number of Price Number of Price Options $ Options $ Options outstanding at the beginning of the year 399,380 7.47 441,621 6.24 Changes during the year: Granted 102,763 4.92 16,668 4.80 Expired - - (58,909 ) 8.28 Forfeited (15,500 ) - - - Cancelled (16,669 ) 7.02 Options outstanding at end of the year 469,974 5.75 399,380 7.47 Options exercisable at end of the year 436,640 5.75 379,712 5.76 The following table presents summary information concerning the options granted and exercisable to consultants and service providers outstanding as of November 30, 2018 (in thousands, except per share data): Weighted Average Aggregate Number of Aggregate Exercise Number of Remaining Intrinsic Exercisable Exercisable Price Outstanding Contractual Value* Options Options $ Options Life $ Value $ (in thousands) (in thousands) 3.36 136,775 7.41 362 136,775 460 3.6 83,334 7.25 201 83,334 300 4.42 10,325 9.02 16 10,325 46 4.8 16,667 8.03 20 16,667 80 5.3 35,000 9.79 25 20,000 106 5.99 25,005 9.9 13,337 80 6 90,000 5.67 90,000 540 6.4 8,333 9.13 1,667 11 7.32 8,334 3.98 8,334 61 8.34 8,600 9.61 8,600 72 11.52 8,334 4.35 8,334 96 16.8 39,267 3.37 39,267 660 469,974 6.83 624 436,640 2,512 Costs incurred with respect to options granted to consultants and service providers for the year ended November 30, 2018 and 2017 was $331 thousand and $322 thousand, respectively. As of November 30, 2018, there was $157 thousand of unrecognized compensation costs related to non-vested consultants and service providers, to be recorded over the next 3.13 years. d. Warrants and Shares Issued to Non-Employees 1) During the year ended November 30, 2018, the Company granted to several consultants 78,782 warrants each exercisable between $6.24 and $15.41 per share for three years. The fair value of those warrants as of the date of grant using the Black-Scholes valuation model was $350 thousand. The warrants granted as a success fee with respect to private placement and the issuance of convertible loans. 2) In December 2017, the Company entered into investor relations services, marketing and related services agreements. Under the terms of the agreement, the Company agreed to grant the consultants a total of 195,000 shares of restricted common stock, out of which the first 50,000 shares will vest after 30 days from the signing date, and 145,000 shares are to vest monthly over 15 months commencing February 2018. As of November 30, 2018, 140,000 shares were vested. The fair value of the shares as of the date of grant was $1,439 thousand. 3) In January 2018, the Company entered into a consulting agreement with a financial advisor for a period of one year. Under the terms of the agreement, the consultant was entitled to receive $60 thousand and 19,000 units of the Company securities. Each unit is comprised of (i) one share of the Company’s common stock and (ii) a three-year warrant to purchase up to an additional one share of the Company’s Common Stock at a per share exercise price of $6.24. The fair value of the units as of the date of grant was $171 thousand, out of which $62 thousand reflect the fair value of the warrants using the Black-Scholes valuation model. In July 2018, the board approved an additional issuance of 6,629 shares and three-year warrants to purchase up to 6,629 shares of the Company’s Common Stock at a per share exercise price of $6.24. The fair value of the units as of the date of grant was $88 thousand. 4) During the year ended November 30, 2017, the Company granted to several consultants 53,148 warrants each exercisable at $6.24 or $10.20 per share for three years. The fair value of those options as of the date of grant using the Black-Scholes valuation model was $211 thousand, out of which $169 thousand is related to 38,001 warrants granted as a success fee with respect to the issuance of the convertible notes.

TAXES

TAXES	12 Months Ended
	Nov. 30, 2018
TAXES [Text Block]	NOTE 16 – TAXES a. Corporate taxation in the U.S. The applicable corporate tax rate for the Company and the U.S. subsidiaries is 21% following the U.S. Tax Cuts and Jobs Act (the “TCJA”), excluding state tax and local tax. On December 22, 2017, the TCJA was signed into law, which among other changes reduced the federal corporate income tax rate from 35% to 21%, effective January 1, 2018. As of November 30, 2018, the Company has an accumulated tax loss carryforward of approximately $18.1 million (as of November 30, 2017, approximately $12.8 million). Under U.S. tax laws, subject to certain limitations, carryforward tax losses expire 20 years after the year in which incurred. Utilization of the U.S. net operating losses may be subject to substantial annual limitation due to the "change in ownership" provisions of the Internal Revenue Code of 1986 and similar state provisions. The annual limitation may result in the expiration of net operating losses before utilization. b. Corporate taxation in Israel The Israeli Subsidiaries are taxed in accordance with Israeli tax laws. The corporate tax rates applicable to 2018 and 2017 are 23% and 24% respectively. As of November 30, 2018, the Israeli Subsidiaries has an accumulated tax loss carryforward of approximately $7.23 million (as of November 30, 2017, approximately $5.8 million). Under the Israeli tax laws, carryforward tax losses have no expiration date. c. Corporate taxation in Belgian The Belgian Subsidiaries are taxed according to Belgian tax laws. The corporate tax rate applicable to 2020, 2019- 2018 and 2017 are 25%, 29.58% and 34%. As of November 30, 2018, the Belgian Subsidiaries has an accumulated tax loss carryforward of approximately $5.9 million (€ 5.2 million), (as of November 30, 2017 $15.8 million). Under the Belgian tax laws there are limitation on accumulated tax loss carryforward deductions of Euro 1 million per year. d. Corporate taxation in Korea The basic Korean corporate tax rates are currently: 10% on the first KRW 200 million of the tax base, 20% up to KRW 20 billion , 22% up to KRW 300 billion and 25% for tax base above KRW 300 billion. As of November 30, 2018, CureCell has an accumulated tax loss carryforward of approximately $3.2 million (KRW 3,421 million). e. Deferred Taxes The following table presents summary of information concerning the Company’s deferred taxes as of the periods ending November 30, 2018 and 2017 (in thousands): November 30, 2018 2017 (U.S dollars in thousands) Net operating loss carry forwards $ 8,868 $ 11,893 Research and development expenses 2,915 1,065 Employee benefits 181 180 Property and equipment (47 ) (61 ) Loans (125 ) - Deferred income (117 ) (292 ) Intangible assets (4,142 ) (5,117 ) Less: Valuation allowance (9,235 ) (8,358 ) Net deferred tax liabilities $ (1,702 ) $ (690 ) Realization of deferred tax assets is contingent upon sufficient future taxable income during the period that deductible temporary differences and carry forwards losses are expected to be available to reduce taxable income. As the achievement of required future taxable income is not considered more likely than not achievable, the Company and all its subsidiaries except MaSTherCell, Atvio and CureCell have recorded full valuation allowance. The changes in valuation allowance are comprised as follows: Year Ended November 30, 2018 2017 (U.S dollars in thousands) Balance at the beginning of year $ (8,358 ) $ (5,151 ) Additions during the year (877 ) (3,207 ) Balance at end of year $ (9,235 ) $ (8,358 ) f. Reconciliation of the Theoretical Tax Expense to Actual Tax Expense The main reconciling item between the statutory tax rate of the Company and the effective rate is the provision for full valuation allowance with respect to tax benefits from carry forward tax losses and changes in cooperate tax rate in the U.S. and Belgium. g. Uncertain Tax Provisions ASC Topic 740, “Income Taxes” requires significant judgment in determining what constitutes an individual tax position as well as assessing the outcome of each tax position. Changes in judgment as to recognition or measurement of tax positions can materially affect the estimate of the effective tax rate and consequently, affect the operating results of the Company. As of November 30, 2018, the Company has not accrued a provision for uncertain tax positions.

FAIR VALUE PRESENTATION

FAIR VALUE PRESENTATION	12 Months Ended
	Nov. 30, 2018
FAIR VALUE PRESENTATION [Text Block]	NOTE 17 - FAIR VALUE PRESENTATION The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2: Observable inputs that are based on inputs not quoted on active markets but corroborated by market data. Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs, to the extent possible, and considers credit risk in its assessment of fair value. As of November 30, 2017, the Company’s liabilities that are measured at fair value and classified as level 3 fair value are as follows (in thousands): November 30, 2017 Level 3 Embedded derivatives convertible loans * (37 ) CALL/PUT option derivative (339 ) * The embedded derivative is presented in the Company's balance sheets on a combined basis with the related host contract (the convertible loans). The fair value is determined by using a Black-Scholes Model. The following table presents the assumptions that were used for the models as of November 30, 2017 Embedded Put Option Derivative Derivative Fair value of shares of common stock $4.38 Expected volatility 77% 54% Discount on lack of marketability - 12% Risk free interest rate 1.21%- 1.39% 1.44% Expected term (years) 0.17 - 0.42 0.5 Expected dividend yield 0% The table below sets forth a summary of the changes in the fair value of the Company’s financial liabilities classified as Level 3 for the year ended November 30, 2018: Embedded Put Option Derivatives Derivative Balance at beginning of the period $ 37 $ (339 ) Repayment (14 ) - Changes in fair value during the period (23 ) 49 Option disposal - 290 Balance at end of the period $ - $ - (*) There were no transfers to Level 3 during the twelve months ended November 30, 2018. The table below sets forth a summary of the changes in the fair value of the Company’s financial liabilities classified as Level 3 for the year ended November 30, 2017: Embedded Convertible Put Option Derivatives Bonds Derivative Balance at beginning of the year $ 240 $ 1,818 $ 273 Repayment (876 ) (1,827 ) - Changes in fair value during the period 662 22 (612 ) Translation adjustments 11 (13 ) - Balance at end of the year $ 37 $ - $ (339 ) (*) There were no transfers to Level 3 during the twelve months ended November 30, 2017. The Company has performed a sensitivity analysis of the results for the Put Option Derivative fair value as of November 30, 2017 with the following parameters: Base - 50% Base Base+ 50% (in thousands) Sensitivity analysis due to changes in the assumptions expected volatility $ 335 $ 339 $ 379 Sensitivity analysis due to changes in Atvio's FV 252 339 440

RESEARCH AND DEVELOPMENT EXPENS

RESEARCH AND DEVELOPMENT EXPENSES, NET	12 Months Ended
	Nov. 30, 2018
RESEARCH AND DEVELOPMENT EXPENSES, NET [Text Block]	NOTE 18 – RESEARCH AND DEVELOPMENT EXPENSES, NET Year Ended November 30, 2018 2017 (in thousands) Total expenses $ 7,386 $ 3,326 Less grants (922 ) (848 ) Total $ 6,464 $ 2,478

FINANCIAL EXPENSES (INCOMES), N

FINANCIAL EXPENSES (INCOMES), NET	12 Months Ended
	Nov. 30, 2018
FINANCIAL EXPENSES (INCOMES), NET [Text Block]	NOTE 19– FINANCIAL EXPENSES, NET Year ended November 30, 2018 2017 (in thousands) Decrease in fair value of warrants and financial liabilities measured at fair value $ 48 $ (902 ) Stock-based compensation related to warrants granted due to issuance of credit facility 180 1,497 Interest expense on convertible loans 2,753 1,233 Foreign exchange loss, net 129 562 Other income 7 57 Total $ 3,117 $ 2,447

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Nov. 30, 2018
RELATED PARTY TRANSACTIONS [Text Block]	NOTE 20- RELATED PARTIES TRANSACTIONS a. Related Parties presented in the consolidated statements of comprehensive loss For the year ended November 30, 2018 2017 (in thousands) Management and consulting fees to Board Members $ 52 $ 25 Stock Based Compensation expenses to Board Members 304 393 Compensation of executive officers 1,119 419 Stock Based Compensation expenses to executive officers 1,479 821 Interest Expenses on convertible loan from director $ 13 $ 55 b. Related Parties presented in the consolidated balance sheets Year ended November 30, 2018 2017 (in thousands) Convertible Loan from director $ - $ 167 Executive officers' payables 1,164 358 Loan to Related Party. See Note 11(e) 1,007 - Non-executive directors payable $ 41 $ 316

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Nov. 30, 2018
SUBSEQUENT EVENTS [Text Block]	NOTE 21 - SUBSEQUENT EVENTS a. In December 2018, the Company entered into unsecured convertible loan agreements with accredited or offshore investors for an aggregate amount of $250 thousand. The loans bear an annual interest rate of 2% and mature in three years unless converted earlier under the same terms as the convertible loans presented in Note 8(a). b. During December 2018, the Company advanced a total of $0.5 million to Hemogenyx Pharmaceuticals PLC and Immugenyx PLC. See Notes 11(f), and 11(g). c. On February 4, 2019, the Indian Joint Venture transferred the first payment of $1 million for services under the India JVA. See also Note 11(e). d. In December 2018, the Company entered into a Controlled Equity Offering Sales Agreement (“Sales Agreement”) with Cantor Fitzgerald & Co.(“Cantor”) pursuant to which the Company may offer and sell, from time to time through Cantor, shares of the Company’s common stock having an aggregate offering price of up to $25.0 million. The Company will pay Cantor a commission rate equal to 3.0% of the aggregate gross proceeds from each sale. The Company has not yet sold any shares pursuant to the Sales Agreement. e. During December 2018, the Company received authorization from the Direction des Programmes de recherche in Belgium that based on a program and budget of $1.5 million in the field of gene-therapy research for diabetes 1 treatment, the Company could receive up to $350 thousand by June 2021. f. During January 2019, Masthercell Global executed a lease agreement for production facilities in the United States. Under the terms of the agreement, Masthercell Global leased approximately 32,000 square feet for 180 months. Masthercell Global advanced $1.6 million on account of a security deposit, tenant improvement allowance and prepaid base rent. The annual rental increases over the lease period from approximately $726 thousand to $962 thousand. g. In December 2018 and January 2019, the Board of Directors of Masthercell Global approved option grants for the purchase of 61,111 options in Masthercell Global under the Masthercell Global option plan to Masthercell Global executives, at an exercise price of $13.52.

Summary of Significant Accounti

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Nov. 30, 2018
Use of Estimates in the Preparation of Financial Statements [Policy Text Block]	a. Use of Estimates in the Preparation of Financial Statements The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the financial statement date and the reported expenses during the reporting periods. Actual results could differ from those estimates.
Business Combination [Policy Text Block]	b. Business Combination The Company allocates the purchase price of an acquired business to the tangible and intangible assets acquired and liabilities assumed based upon their estimated fair values on the acquisition date. Any excess of the purchase price over the fair value of the net assets acquired is recorded as goodwill. Acquired in-process backlog, customer relations, brand name and know how are recognized at fair value. The purchase price allocation process requires management to make significant estimates and assumptions, especially at the acquisition date with respect to intangible assets. Direct transaction costs associated with the business combination are expensed as incurred. The allocation of the consideration transferred in certain cases may be subject to revision based on the final determination of fair values during the measurement period, which may be up to one year from the acquisition date. The Company includes the results of operations of the business that it has acquired in its consolidated results prospectively from the date of acquisition. If the business combination is achieved in stages, the acquisition date carrying value of the acquirer’s previously held equity interest in the acquire is re-measured to fair value at the acquisition date; any gains or losses arising from such re-measurement are recognized in profit or loss.
Cash Equivalents [Policy Text Block]	c. Cash Equivalents The Company considers all short term, highly liquid investments, which include short term bank deposits with original maturities of three months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents.
Bank Deposits [Policy Text Block]	d. Bank Deposits Bank deposits with maturity of more than one year are considered long-term. The fair value of bank deposits approximates the carrying value since they bear interest at rates close to the prevailing market rates.
Research and Development, net [Policy Text Block]	e. Research and Development, net Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, stock-based compensation expenses, payroll taxes and other employees' benefits, lab expenses, consumable equipment and consulting fees. All costs associated with research and developments are expensed as incurred. Participation from government departments and from research foundations for development of approved projects is recognized as a reduction of expense as the related costs are incurred.
Principles of Consolidation [Policy Text Block]	f. Principles of Consolidation The consolidated financial statements include the accounts of the Company and its Subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.
Non-Marketable Equity Investments [Policy Text Block]	g. Non-Marketable Equity Investments The Company’s investments in certain non-marketable equity securities in which it has the ability to exercise significant influence, but does not control through variable interests or voting interests These are accounted for under the equity method of accounting and presented as Investment in associates, net, in the Company’s consolidated balance sheets. Under the equity method, the Company recognizes its proportionate share of the comprehensive income or loss of the investee. The Company’s share of income and losses from equity method investments is included in share in losses of associated company. The Company reviews its investments accounted for under the equity method for possible impairment, which generally involves an analysis of the facts and changes in circumstances influencing the investments.
Functional Currency [Policy Text Block]	h. Functional Currency The currency of the primary economic environment in which the operations of the Company and part of its Subsidiaries are conducted is the U.S. dollar (“$” or “dollar”). The functional currency of the Belgian Subsidiaries is the Euro (“€” or “Euro”). The functional currency of CureCell is the Won (“KRW”). Most of the Company’s expenses are incurred in dollars, and the source of the Company’s financing has been provided in dollars. Thus, the functional currency of the Company and its other subsidiaries is the dollar. Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in foreign currencies are translated into dollars using historical and current exchange rates for nonmonetary and monetary balances, respectively. For foreign transactions and other items reflected in the statements of operations, the following exchange rates are used: (1) for transactions – exchange rates at transaction dates or average rates and (2) for other items (derived from nonmonetary balance sheet items such as depreciation) – historical exchange rates. The resulting transaction gains or losses are recorded as financial income or expenses. The financial statements of the Belgian Subsidiaries and CureCell are included in the consolidated financial statements, translated into U.S. dollars. Assets and liabilities are translated at year-end exchange rates, while revenues and expenses are translated at yearly average exchange rates during the year. Differences resulting from translation of assets and liabilities are presented as other comprehensive income.
Inventory [Policy Text Block]	i. Inventory The Company’s inventory consists of raw material for use for the services provided. The Company periodically evaluates the quantities on year end. Cost of the raw materials is determined using the weighted average cost method.
Property and Equipment [Policy Text Block]	j. Property and Equipment Property and equipment are recorded at cost and depreciated by the straight-line method over the estimated useful lives of the related assets. Annual rates of depreciation are presented in the table below: Weighted Average Useful Life (Years) Production facility 5 - 20 Laboratory equipment 5 Office equipment and computers 3 - 5 Intangible assets and their useful lives are as follows: Weighted Average Amortization Recorded at Useful Life (Years) Comprehensive Loss Line Item Customer Relationships 2.5 - 10 Amortization of intangible assets Brand 9.75 Amortization of intangible assets Know-How 11.75 - 12 Amortization of intangible assets Backlog 1.5 Amortization of intangible assets Intangible assets are recorded at acquisition cost less accumulated amortization and impairment. Definite lived intangible assets are amortized over their estimated useful life using the straight-line method, which is determined by identifying the period over which the cash flows from the asset are expected to be generated.
Goodwill [Policy Text Block]	k. Goodwill Goodwill represents the excess of the purchase price of acquired business over the estimated fair value of the identifiable net assets acquired. Goodwill is not amortized but is tested for impairment at least annually (at November 30), at the reporting unit level or more frequently if events or changes in circumstances indicate that the asset might be impaired. The goodwill impairment test is applied by performing a qualitative assessment before calculating the fair value of the reporting unit. If, on the basis of qualitative factors, it is considered not more likely than not that the fair value of the reporting unit is less than the carrying amount, further testing of goodwill for impairment would not be required. Otherwise, goodwill impairment is tested using a two-step approach. The first step involves comparing the fair value of the reporting unit to its carrying amount. If the fair value of the reporting unit is determined to be greater than its carrying amount, there is no impairment. If the reporting unit's carrying amount is determined to be greater than the fair value, the second step must be completed to measure the amount of impairment, if any. The second step involves calculating the implied fair value of goodwill by deducting the fair value of all tangible and intangible assets, excluding goodwill, of the reporting unit from the fair value of the reporting unit as determined in step one. The implied fair value of the goodwill in this step is compared to the carrying value of goodwill. If the implied fair value of the goodwill is less than the carrying value of the goodwill, an impairment loss equivalent to the difference is recorded. There were no impairment charges in 2018 and 2017.
Impairment of Long-lived Assets [Policy Text Block]	l. Impairment of Long-lived Assets The Company reviews its property and equipment, intangible assets subject to amortization and other long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset class may not be recoverable. Indicators of potential impairment include: an adverse change in legal factors or in the business climate that could affect the value of the asset; an adverse change in the extent or manner in which the asset is used or is expected to be used, or in its physical condition; and current or forecasted operating or cash flow losses that demonstrate continuing losses associated with the use of the asset. If indicators of impairment are present, the asset is tested for recoverability by comparing the carrying value of the asset to the related estimated undiscounted future cash flows expected to be derived from the asset. If the expected cash flows are less than the carrying value of the asset, then the asset is considered to be impaired and its carrying value is written down to fair value, based on the related estimated discounted cash flows. There were no impairment charges in 2018 and 2017.
Revenue Recognition [Policy Text Block]	m. Revenue Recognition The Company recognizes revenue for services linked to cell process development and cell manufacturing services based on individual contracts in accordance with Accounting Standards Codification (“ASC”) 605, Revenue Recognition,
Financial Liabilities Measured at Fair Value [Policy Text Block]	n. Financial Liabilities Measured at Fair Value 1) Fair Value Option Topic 815 provides entities with an option to report certain financial assets and liabilities at fair value with subsequent changes in fair value reported in earnings. The election can be applied on an instrument by instrument basis. The Company elected the fair value option to its convertible bonds. The liability is measured both initially and in subsequent periods at fair value, with changes in fair value charged to finance expenses, net (See Note 17). 2) Derivatives Embedded derivatives are separated from the host contract and carried at fair value when (1) the embedded derivative possesses economic characteristics that are not clearly and closely related to the economic characteristics of the host contract and (2) a separate, standalone instrument with the same terms would qualify as a derivative instrument. The derivative is measured both initially and in subsequent periods at fair value, with changes in fair value charged to finance expenses, net. As to embedded derivatives arising from the issuance of convertible debentures (See Note 17).
Income Taxes [Policy Text Block]	o. Income Taxes 1) With respect to deferred taxes, income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is recognized to the extent that it is more likely than not that the deferred taxes will not be realized in the foreseeable future. 2) The Company follows a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the available evidence indicates that it is more likely than not that the position will be sustained on examination. If this threshold is met, the second step is to measure the tax position as the largest amount that is greater than 50% likely of being realized upon ultimate settlement. 3) Taxes that would apply in the event of disposal of investment in Subsidiaries have not been taken into account in computing the deferred income taxes, as it is the Company’s intention to hold these investments and not realize them.
Stock-Based Compensation [Policy Text Block]	p. Stock-based Compensation The Company accounts for employee stock-based compensation in accordance with the guidance of ASC Topic 718, Compensation - Stock Compensation The Company follows ASC Topic 505-50, Equity-Based Payments to Non-Employees
Redeemable Non-controlling Interest [Policy Text Block]	q. Redeemable Non-controlling Interest Non-controlling interests with embedded redemption features, whose settlement is not at the Company’s discretion, are considered redeemable non-controlling interest. Redeemable non-controlling interests are considered to be temporary equity and are therefore presented as a mezzanine section between liabilities and equity on the Company's consolidated balance sheets. Subsequent adjustment of the amount presented in temporary equity is required only if the Company's management estimates that it is probable that the instrument will become redeemable. Adjustments of redeemable non-controlling interest to its redemption value are recorded through additional paid-in capital.
Loss per Share of Common Stock [Policy Text Block]	r. Loss per Share of Common Stock Basic net loss per share is computed by dividing the net loss for the period by the weighted average number of shares of common stock outstanding for each period. Diluted net loss per share is based upon the weighted average number of common shares and of common shares equivalents outstanding when dilutive. Common share equivalents include: (i) outstanding stock options warrants which are included under the treasury share method when dilutive, and (ii) common shares to be issued under the assumed conversion of the Company’s outstanding convertible loans, which are included under the if-converted method when dilutive (See Note 14).
Concentration of Credit Risk [Policy Text Block]	s. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist of principally cash and cash equivalents, bank deposits and certain receivables. The Company held these instruments with highly rated financial institutions and the Company has not experienced any significant credit losses in these accounts and does not believe the Company is exposed to any significant credit risk on these instruments apart of accounts receivable. The Company performs ongoing credit evaluations of its customers for the purpose of determining the appropriate allowance for doubtful accounts. An appropriate allowance for doubtful accounts is included in the accounts and netted against accounts receivable. In the year ended November 30, 2018 the Company has not experienced any material credit losses in these accounts and does not believe it is exposed to significant credit risk on these instruments. In the year ended November 30, 2017, the Company has recorded an allowance of $897 thousand. Bad debt allowance is created when objective evidence exists of inability to collect all sums owed it under the original terms of the debit balances. Material customer difficulties, the probability of their going bankrupt or undergoing economic reorganization and insolvency or material delays in payments are all considered indicative of reduced debtor balance value.
Beneficial Conversion Feature (BCF) [Policy Text Block]	t. Beneficial Conversion Feature (“BCF”) When the Company issues convertible debt, if the stock price is greater than the effective conversion price (after allocation of the total proceeds) on the measurement date, the conversion feature is considered "beneficial" to the holder. If there is no contingency, this difference is treated as issued equity and reduces the carrying value of the host debt; the discount is accreted as deemed interest on the debt (See Note 8).
Other Comprehensive Loss [Policy Text Block]	u. Other Comprehensive Loss Other comprehensive loss represents adjustments of foreign currency translation.
Newly issued and recently adopted Accounting Pronouncements [Policy Text Block]	v. Newly issued and recently adopted Accounting Pronouncements 1) In January 2016, the FASB issued guidance on recognition and measurement of financial assets and financial liabilities (ASU No. 2016-01) that will supersede most current guidance. Changes to the U.S. GAAP model primarily affect the accounting for equity investments, financial liabilities under the fair value option and the presentation and disclosure requirements for financial instruments. In addition, the FASB clarified guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The accounting for other financial instruments, such as loans, investments in debt securities, and financial liabilities, is largely unchanged. The classification and measurement guidance became effective as of December 1, 2018. The Company does not expect to have a material impact on its consolidated financial statements. 2) In May 2014, the FASB issued Accounting Standards Update (“ASU”) 2014-09 “Revenue from Contracts with Customers (Topic 606)” (“Topic 606”) that will supersede most current revenue recognition guidance, including industry specific guidance. Under the new standard, a good or service is transferred to the customer when (or as) the customer obtains control of the good or service, which differs from the risk and rewards approach under current guidance. The guidance provides a five-step analysis of transactions to determine when and how revenue is recognized. Other major provisions include capitalization of certain contract costs, consideration of the time value of money in the transaction price and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The guidance also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity’s contracts with customers. The guidance is effective in annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. The Company will implement the guidance for our annual period ending on December 31, 2019 and interim periods within such annual periods, using the modified retrospective method and will adjust the accumulated deficit and deferred revenue as of the adoption date. Under current GAAP, the Company recognizes revenue for services linked to cell process development based on both the input and output methods of measurement. The Company has evaluated the application of the requirements of ASC 606 to recognize revenue when or as the entity satisfies a performance obligation to its business. The Company has several types of revenue contracts: a) Cell process development services The Company has concluded that under the revised standard, contracts for cell process development services are in some cases a single performance obligation (where promises offered to customers are not distinct within the context of the contract), and in other cases have multiple performance obligations (where promises to the customers are distinct). In all cases the performance obligations are satisfied over time. Under the new standard, the Company will recognize revenue over time using either a cost-based input method or output method, whichever fairly depicts the transfer of control over the life of the performance obligation, as appropriate. b) Cell manufacturing services Regarding revenues from cell manufacturing services, the Company concluded that these comprised a single performance obligation. The progress towards completion will continue to be measured on an output measure based on direct measurement of the value transferred to the customer (units produced). c) Tech transfer The Company has concluded that under the revised standard contracts for Tech Transfer services are considered a single performance obligation and will be measured over time using a cost-based input method where progress on the performance obligation is measured by the proportion of actual costs incurred to the total costs expected to complete the contract. The cost-based and output methods of revenue recognition require the Company to make estimates of costs to complete its projects and the percentage of completion on an ongoing basis. Significant judgment is required to evaluate assumptions related to these estimates. The effect of revisions to estimates related to the transaction price (including variable consideration relating to reimbursement on a cost-plus basis on certain expenses) or costs to complete a project are recorded in the period in which the estimate is revised. The adoption of th enew standard is not expected to result in a material effect on the total stockholders' equity as of December 1, 2018. 3) In November 2016, the FASB issuedASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash (a Consensus of the FASB Emerging Issues Task Force) (“ASU 2016-18”), which requires entities to include amounts generally described as restricted cash and restricted cash equivalents in cash and cash equivalents when reconciling beginning-of-period and end-of-period total amounts shown on the statement of cash flows. ASU 2016-18 is effective for annual reporting periods (including interim periods within those annual reporting periods) beginning after December 15, 2017. The Company adopted this standard during the year ended November 30, 2018. 4) In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)” (“ASU 2016-02”), which supersedes the existing guidance for lease accounting, “Leases (Topic 840)”. ASU 2016-02 requires lessees to recognize leases on their balance sheets, and leaves lessor accounting largely unchanged. The amendments in ASU 2016-02 are effective for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years. Early application is permitted for all entities. ASU 2016-02 requires a modified retrospective approach for all leases existing at, or entered after, the date of initial application, with an option to elect to use certain transition relief. The Company expects to apply the ASU without adjusting the comparative periods and, if applicable, recognizing a cumulative effect adjustment to the opening balance of retained earnings in the period of adoption. The Company is currently evaluating the impact of this new standard on its consolidated financial statements. 5) In June 2016, the FASBissued ASU 2016-13, “Financial Instruments-Credit Losses (Topic 326)” (“ASU 2016-13”). ASU 2016-13 requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis. The income statement reflects the measurement of credit losses for newly recognized financial assets, as well as the expected credit losses during the period. The measurement of expected credit losses is based upon historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. Credit losses relating to available-for-sale debt securities will be recorded through an allowance for credit losses rather than as a direct write-down to the security. ASU 2016-13 is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted as of the fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company does not expect to have a material impact on its consolidated financial statements. 6) In May 2017, the FASB issued ASU 2017-09, “Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting” (“ASU 2017-09”), which gives direction on which changes to the terms or conditions of share-based payment awards require an entity to apply modification accounting in Accounting Standard Codification (“ASC”) Topic 718. In general, entities will apply the modification accounting guidance if the value, vesting conditions or classification of the award changes. ASU 2017-09 is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The Company does not expect the implementation of this new pronouncement to have a material impact on its consolidated financial statements. 7) In June 2018, the FASB issued ASU 2018-07, “Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-based Payment Accounting” that expands the scope of ASC Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of ASC Topic 718 to nonemployee awards except for certain exemptions specified in the amendment. The guidance is effective for fiscal years beginning after December 15, 2018, including interim reporting periods within that fiscal year. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606. The Company don’t expect to have a material impact on its consolidated financial statements. 8) In January 2017, FASB issued Accounting Standards Update (ASU) 2017-04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment, which eliminated the calculation of implied goodwill fair value. Instead, companies will record an impairment charge based on the excess of a reporting unit’s carrying amount of goodwill over its fair value. This guidance simplifies the accounting as compared to prior GAAP. The guidance is effective for fiscal years beginning after December 15, 2019. The Company does not expect the implementation of this new pronouncement to have a material impact on its consolidated financial statements.

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Nov. 30, 2018
Schedule of Annual Depreciation Rates, Property and Equipment [Table Text Block]	Weighted Average Useful Life (Years) Production facility 5 - 20 Laboratory equipment 5 Office equipment and computers 3 - 5
Schedule of Intangible Assets, Useful Lives [Table Text Block]	Weighted Average Amortization Recorded at Useful Life (Years) Comprehensive Loss Line Item Customer Relationships 2.5 - 10 Amortization of intangible assets Brand 9.75 Amortization of intangible assets Know-How 11.75 - 12 Amortization of intangible assets Backlog 1.5 Amortization of intangible assets

CORPORATE REORGANIZATION AND _2

CORPORATE REORGANIZATION AND EXERCISE OF CALL OPTIONS OF CURECELL AND ATVIO (Tables)	12 Months Ended
	Nov. 30, 2018
Business Combination, Segment Allocation [Table Text Block]	Total assets acquired: Cash and cash equivalents $ 58 Property and equipment, net 1,104 Inventory 148 Other assets 300 Other Intangible assets (a) 3,933 Goodwill (b) 3,950 Total assets 9,493 Total liabilities assumed: Deferred income from the Company and others 1,945 Deferred taxes 80 Fair value of convertible loan from the Company 892 Non-controlling interests 299 Other liabilities 1,487 Total liabilities 4,703 Total consideration transferred $ 4,790 Fair value of 36.4% of shared issued 1,853 Acquisition date fair value of previously held equity interest 2,937 Total consideration transferred $ 4,790
Business Acquisition, Pro Forma Information [Table Text Block]	Year Ended November 30, 2018 2017 (in thousands) Revenue $ 18,794 $ 10,216 Net loss $ 20,919 $ 14,520

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	12 Months Ended
	Nov. 30, 2018	Nov. 30, 2017
Schedule of Segment Information [Table Text Block]	Corporate PT and CDMO Business Eliminations Consolidated (in thousands) Revenues from external customers $ 22,582 $ - $ (3,927 ) $ 18,655 Cost of revenues (11,541 ) 1,235 (10,306 ) Segment gross profit (loss) 11,041 - (2,692 8,349 Research and development expenses, net (39 ) (7,931 ) 2,485 (5,485 ) Operating expenses (6,889 ) (6,224 ) 207 (12,906 ) Other expenses (77 ) - (77 ) Segment operating profit (loss) 4,036 (14,155 ) - (10,119 ) Adjustments to presentation of segment Adjusted EBIT Depreciation and amortization (2,613 ) (11 ) (2,624 ) Segment performance 1,423 (14,166 ) (12,743 )	Corporate CT and CDMO Business Eliminations Consolidated (in thousands) Revenues from external customers $ 11,484 $ - $ (1,395 ) $ 10,089 Cost of revenues (6,356 ) 638 (5,718 ) Gross profit 5,128 - (757 ) 4,371 Research and development expenses, net (2,517 ) 757 (1,760 ) Operating expenses (4,699 ) (3,335 ) (8,034 ) Operating profit 429 (5,852 ) - (5,423 ) Adjustments to presentation of segment Adjusted EBIT Depreciation and amortization (2,720 ) (6 ) Segment performance (2,291 ) (5,858 )
Schedule of Reconciliation of Segment Performance [Table Text Block]	Year ended November 30, 2018 in thousands Segment subtotal performance (12,743 ) Stock-based compensation (4,364 ) Financial expenses, net (2,938 ) Net gain on remeasurement of previously equity interest in Atvio and CureCell to acquisition date fair value 4,509 Transaction expenses related to GPP agreement (1,500 ) Share in losses of associated companies (731 ) Loss before income tax (17,767 )	Reconciliation of segment performance to loss for the year: Year ended November 30, 2017 in thousands Segment performance (8,149 ) Stock-based compensation (3,364 ) Financial income (expenses), net (950 ) Share in losses of associated company (1,214 ) Loss before income tax $ (13,677 )
Schedule of Revenues from Major Customers [Table Text Block]	Year Ended Year Ended November 30, November 30, 2018 2017 (in thousands) Customer A $ 2,338 $ 4,115 Customer B $ 4,374 $ 2,837 Customer C $ - $ 2,055 Customer D $ 5,236 $ - Customer E $ 2,242 $ -

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Nov. 30, 2018
Schedule of Property, Plant and Equipment [Table Text Block]	November 30, 2018 2017 (in thousands) Cost: Production facility $ 11,413 $ 6,246 Office furniture and computers 1,875 353 Lab equipment 3,292 2,039 16,580 8,638 Less – accumulated depreciation (4,679 ) (3,534 ) Total $ 11,901 $ 5,104

INTANGIBLE ASSETS AND GOODWILL

INTANGIBLE ASSETS AND GOODWILL (Tables)	12 Months Ended
	Nov. 30, 2018
Schedule of Goodwill [Table Text Block]	(in thousands) Goodwill as of November 30, 2016 $ 9,584 Translation differences 1,100 Goodwill as of November 30, 2017 10,684 Goodwill as acquired 4,918 Translation differences (437 ) Goodwill as of November 30, 2018 $ 15,165
Schedule of Intangible Assets [Table Text Block]	November 30, November 30, 2018 2017 (In thousands) Gross Carrying Amount: Know How $ 20,344 $ 17,998 Backlog 117 - Customer relationships 1,274 369 Brand name 1,359 1,418 23,094 19,785 Accumulated amortization 6,394 4,734 Net carrying amount of other intangible assets $ 16,700 $ 15,051
Schedule of Intangible Assets, Future Amortization Expense [Table Text Block]	2019 2020 to 2023 (in thousands) Amortization expenses $ 2,086 $ 7,929

CONVERTIBLE LOANS (Tables)

CONVERTIBLE LOANS (Tables)	12 Months Ended
	Nov. 30, 2018
Schedule of Convertible Debt [Table Text Block]	Shares and Warrants Issued Upon Conversion Accumulated Shares Warrant Interest Up to s Principal Issuance Interest Maturity Exercise BCF Conversion (5) Amount Year Rate Period Price Date (in (in thousands) thousands) (Years) Convertible Loans Outstanding as of November 30, 2018 $1,250 2018 2% 3 $ 7 (1) 114 $ - - - Convertible Loans converted during the year ended November 30, 2018 220 2018 6% 2 $ 6.24 87 $ 2 35,543 35,543 500 (2) 2018 6% 0.5 $ 6.24 106 4 80,756 80,756 5,050 2017 6% 2 $ 6.24 2,311 235 846,961 846,961 798 (3) 2017 6% 0.5 - 1.7 $ 6.24 81 40 134,372 34,269 1,388 2016 6% 2 $ 6.24 251 132 243,443 243,443 100 2014 6%/24% (4) 0.5 $ 4.8 85 81 37,662 - 8,056 $ 494 1,378,737 1,240,972 Convertible Loans repaid during the year ended November 30, 2017 $400 (6) 2017 6% 0.25 $ 6.24 - - -

LOANS (Tables)

LOANS (Tables)	12 Months Ended
	Nov. 30, 2018
Schedule of Long-term Debt Instruments [Table Text Block]	Principal Year of November 30, Amount Grant Year Interest Rate Maturity 2018 2017 (in thousands) (in thousands) Long-term loan (*) € 1,400 2012 4.05% 2022 $ 700 $ 899 Long-term loan € 1,000 2013 6%- 7.5% 2023 869 977 Long-term loan € 790 2012-2016 5.5%- 6% 2021-2024 461 620 $ 2,030 $ 2,496 Current portion of loans payable (368 ) (378 ) $ 1,662 $ 2,118
Schedule of Short-term Debt [Table Text Block]	November 30, Currency Interest Rate 2018 2017 (in thousands) Current portion of loans payable Euro 4.05% $ 168 $ 169 Current portion of loans payable Euro 6%- 7.5% 67 70 Current portion of loans payable Euro 5.5%- 6% 133 139 Short term loans KRW 3.02%, 4.15% 279 - $ 647 $ 378

COMMITMENTS (Tables)

COMMITMENTS (Tables)	12 Months Ended
	Nov. 30, 2018
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	2019 $ 783 2020 626 2021 and thereafter 3,504 Total $ 4,913

INVESTMENTS IN ASSOCIATE, NET (

INVESTMENTS IN ASSOCIATE, NET (Tables)	12 Months Ended
	Nov. 30, 2018
Schedule of Investments [Table Text Block]	November 30, 2018 2017 (In thousands) Opening balance $ 1,321 $ (12 ) Reclass with short-term receivables (795 ) 118 Investments during the period - 2,429 Share in losses (731 ) (1,214 ) Reductions due to the acquisition of CureCell and Atvio – see also Note 4 205 - $ - $ 1,321

EQUITY (Tables)

EQUITY (Tables)	12 Months Ended
	Nov. 30, 2018
Schedule of Stockholders' Equity Note, Warrants or Rights, Activity [Table Text Block]	2018 2017 Weighted Weighted Average Average Exercise Exercise Number of Price Number of Price Warrants $ Warrants $ Warrants 2,609,864 6.26 1,620,993 6.25 Changes during the year: Issued 4,488,854 6.27 1,144,647 6.32 Exercised (136,646 ) 6.24 - Expired (382,414 ) 6.10 (155,776 ) 6.24 Cancelled** (66,667 ) 6.24 - Warrants 6,512,991 6.27 2,609,864 6.26

LOSS PER SHARE (Tables)

LOSS PER SHARE (Tables)	12 Months Ended
	Nov. 30, 2018
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Year Ended November 30, 2018 2017 (in thousands, except per share data) Basic: Net loss attributable to Orgenesis Inc $ 18,291 $ 12,367 Adjustment of redeemable non-controlling interest to redemption amount 884 - Net loss attributable to Orgenesis Inc. for loss per share $ 19,175 $ 12,367 Weighted average number of common shares outstanding 13,374,103 9,679,964 Basic loss per common share $ 1.43 $ 1.28 Diluted Net loss attributable to Orgenesis Inc. for loss per share $ 19,175 12,367 Changes in fair value of embedded derivative and interest expenses on convertible note - 392 Loss for the year $ 19,175 $ 12,759 Weighted average number of shares used in the computation of basic loss per share 13,374,103 9,679,964 Number of dilutive shares related to convertible note - 34,288 Weighted average number of common shares outstanding 13,374,103 9,714,252 Diluted loss per common share $ 1.43 $ 1.31

STOCK BASED COMPENSATION (Table

STOCK BASED COMPENSATION (Tables)	12 Months Ended
	Nov. 30, 2018
Employee Stock Ownership Plan (ESOP) Disclosures [Table Text Block]	Year of No. of options Exercise price Vesting period Fair value at grant Expiration grant granted (in thousands) period Employees 2018 762,400 $4.42 -$8.91 vest immediately- 4 years $4,233 10 years Directors 2018 113,800 $5.99 1 year $507 10 years Directors 2017 166,668 $4.80 2 years $558 10 years Employees 2017 525,005 $4.8,$7.2 vest immediately- 4 years $1,915 10 years
Schedule of Share-based Compensation, Stock Options Granted to Consultants [Table Text Block]	Fair value at Year of No. of options Exercise grant Expiration grant granted price Vesting period ( in thousands ) period Non-employees 2018 102,763 $4.42 -$8.34 vest immediately- 4 years $444 10 years Non-employees 2017 16,668 $4.8 Quarterly over a period of one year $68 10 years
Options Granted to Employees [Member]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Year Ended November 30, 2018 2017 Value of one common share $4.42 -$8.7 $4.68,$7.2 Dividend yield 0% 0% Expected stock price volatility 88%- 98% 93.8%- 95.4% Risk free interest rate 2.33%- 3.2% 1.89%- 1.76% Expected term (years) 4.13 - 10 5
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	2018 2017 Weighted Weighted Average Average Exercise Exercise Number of Price Number of Price Options $ Options $ Options outstanding at the beginning of the year 1,605,055 3.11 978,853 1.92 Changes during the year: Granted 876,200 7.13 691,673 5.28 Expired (61,463 ) 5.26 (38,106 ) 7.58 Forfeited (43,365 ) 4.68 (27,365 ) 4.8 Options outstanding at end of the year 2,376,427 4.51 1,605,055 3.11 Options exercisable at end of the year 1,504,542 2.91 1,135,107 2.57
Disclosure of Share-based Compensation Stock Options Exercisable [Table Text Block]	Weighted Average Aggregate Aggregate Exercise Number of Remaining Intrinsic Number of Exercisable Price Outstanding Contractual Value Exercisable Options $ Options Life $ Options Value $ (in thousands) (in thousands) 0.0012 462,015 4.78 2,776 462,015 1 0.012 278,191 3.18 1,669 278,191 3 4.42 50,000 9.02 79 37,500 166 4.8 524,999 8.03 635 440,104 2,112 5.99 384,050 9.35 8 32,750 196 6 33,334 5.67 - 33,334 200 7.2 83,334 8.51 - 83,334 600 8.36 250,000 9.58 - - 8.43 160,994 9.46 - 14,492 156 8.91 30,500 9.55 - 3,813 34 9 20,834 4.63 - 20,834 188 9.48 58,908 3.61 - 58,908 558 10.2 39,268 3.51 - 39,267 401 2,376,427 7.15 5,167 1,504,542 4,598
Options Granted to Non- Employees [Member]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Year Ended November 30, 2018 2017 Value of one common share $ 4.42 -$8.34 $ 3.6 -$7.44 Dividend yield 0% 0% Expected stock price volatility 91%- 95% 87%- 95% Risk free interest rate 2.33%- 3.20% 1.19%- 1.89% Expected term (years) 9.79 - 10 4 - 5
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	2018 2017 Weighted Weighted Average Average Exercise Exercise Number of Price Number of Price Options $ Options $ Options outstanding at the beginning of the year 399,380 7.47 441,621 6.24 Changes during the year: Granted 102,763 4.92 16,668 4.80 Expired - - (58,909 ) 8.28 Forfeited (15,500 ) - - - Cancelled (16,669 ) 7.02 Options outstanding at end of the year 469,974 5.75 399,380 7.47 Options exercisable at end of the year 436,640 5.75 379,712 5.76
Disclosure of Share-based Compensation Stock Options Exercisable [Table Text Block]	Weighted Average Aggregate Number of Aggregate Exercise Number of Remaining Intrinsic Exercisable Exercisable Price Outstanding Contractual Value* Options Options $ Options Life $ Value $ (in thousands) (in thousands) 3.36 136,775 7.41 362 136,775 460 3.6 83,334 7.25 201 83,334 300 4.42 10,325 9.02 16 10,325 46 4.8 16,667 8.03 20 16,667 80 5.3 35,000 9.79 25 20,000 106 5.99 25,005 9.9 13,337 80 6 90,000 5.67 90,000 540 6.4 8,333 9.13 1,667 11 7.32 8,334 3.98 8,334 61 8.34 8,600 9.61 8,600 72 11.52 8,334 4.35 8,334 96 16.8 39,267 3.37 39,267 660 469,974 6.83 624 436,640 2,512

TAXES (Tables)

TAXES (Tables)	12 Months Ended
	Nov. 30, 2018
Schedule of Deferred Tax Assets [Table Text Block]	November 30, 2018 2017 (U.S dollars in thousands) Net operating loss carry forwards $ 8,868 $ 11,893 Research and development expenses 2,915 1,065 Employee benefits 181 180 Property and equipment (47 ) (61 ) Loans (125 ) - Deferred income (117 ) (292 ) Intangible assets (4,142 ) (5,117 ) Less: Valuation allowance (9,235 ) (8,358 ) Net deferred tax liabilities $ (1,702 ) $ (690 )
Schedule of Valuation Allowance, Activity [Table Text Block]	Year Ended November 30, 2018 2017 (U.S dollars in thousands) Balance at the beginning of year $ (8,358 ) $ (5,151 ) Additions during the year (877 ) (3,207 ) Balance at end of year $ (9,235 ) $ (8,358 )

FAIR VALUE PRESENTATION (Tables

FAIR VALUE PRESENTATION (Tables)	12 Months Ended
	Nov. 30, 2018	Nov. 30, 2017
Schedule of Assets and Liabilities at Fair Value [Table Text Block]		November 30, 2017 Level 3 Embedded derivatives convertible loans * (37 ) CALL/PUT option derivative (339 )
Schedule of Fair Value, Assumptions Used [Table Text Block]		Embedded Put Option Derivative Derivative Fair value of shares of common stock $4.38 Expected volatility 77% 54% Discount on lack of marketability - 12% Risk free interest rate 1.21%- 1.39% 1.44% Expected term (years) 0.17 - 0.42 0.5 Expected dividend yield 0%
Schedule of Fair Value of Financial Liabilities, Activity [Table Text Block]	Embedded Put Option Derivatives Derivative Balance at beginning of the period $ 37 $ (339 ) Repayment (14 ) - Changes in fair value during the period (23 ) 49 Option disposal - 290 Balance at end of the period $ - $ -	Embedded Convertible Put Option Derivatives Bonds Derivative Balance at beginning of the year $ 240 $ 1,818 $ 273 Repayment (876 ) (1,827 ) - Changes in fair value during the period 662 22 (612 ) Translation adjustments 11 (13 ) - Balance at end of the year $ 37 $ - $ (339 )
Schedule of Sensitivity Analysis of Changes in Fair Value [Table Text Block]		Base - 50% Base Base+ 50% (in thousands) Sensitivity analysis due to changes in the assumptions expected volatility $ 335 $ 339 $ 379 Sensitivity analysis due to changes in Atvio's FV 252 339 440

RESEARCH AND DEVELOPMENT EXPE_2

RESEARCH AND DEVELOPMENT EXPENSES, NET (Tables)	12 Months Ended
	Nov. 30, 2018
Schedule of Research and Development Expenses [Table Text Block]	Year Ended November 30, 2018 2017 (in thousands) Total expenses $ 7,386 $ 3,326 Less grants (922 ) (848 ) Total $ 6,464 $ 2,478

FINANCIAL EXPENSES (INCOMES),_2

FINANCIAL EXPENSES (INCOMES), NET (Tables)	12 Months Ended
	Nov. 30, 2018
Schedule of Financial Expenses [Table Text Block]	Year ended November 30, 2018 2017 (in thousands) Decrease in fair value of warrants and financial liabilities measured at fair value $ 48 $ (902 ) Stock-based compensation related to warrants granted due to issuance of credit facility 180 1,497 Interest expense on convertible loans 2,753 1,233 Foreign exchange loss, net 129 562 Other income 7 57 Total $ 3,117 $ 2,447

RELATED PARTY TRANSACTIONS (Tab

RELATED PARTY TRANSACTIONS (Tables)	12 Months Ended
	Nov. 30, 2018
Schedule of Related Party Transactions [Table Text Block]	For the year ended November 30, 2018 2017 (in thousands) Management and consulting fees to Board Members $ 52 $ 25 Stock Based Compensation expenses to Board Members 304 393 Compensation of executive officers 1,119 419 Stock Based Compensation expenses to executive officers 1,479 821 Interest Expenses on convertible loan from director $ 13 $ 55
Schedule of Related Parties presented in the Consolidated Balance Sheets [Table Text Block]	Year ended November 30, 2018 2017 (in thousands) Convertible Loan from director $ - $ 167 Executive officers' payables 1,164 358 Loan to Related Party. See Note 11(e) 1,007 - Non-executive directors payable $ 41 $ 316

DESCRIPTION OF BUSINESS (Narrat

DESCRIPTION OF BUSINESS (Narrative) (Details) - USD ($) $ in Thousands	2 Months Ended	12 Months Ended
	Feb. 08, 2019	Nov. 30, 2018	Nov. 30, 2017
Accumulated deficit		$ 62,411	$ 44,120
Revenues		18,655	$ 10,089
Approximations [Member]
Accumulated deficit		62,400
MaSTherCell [Member]
Revenues	$ 4,700	17,300
Proceeds from Issuance of Private Placement	250	21,500
SFPI and GPP [Member]
Revenues		$ 12,600
GPP [Member]
Revenues	$ 6,600

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) $ in Thousands	12 Months Ended
	Nov. 30, 2017USD ($)
Provision for Doubtful Accounts	$ 897

REDEEMABLE NON CONTROLLING IN_2

REDEEMABLE NON CONTROLLING INTEREST (Narrative) (Details) € in Thousands	Jun. 13, 2018USD ($)	Jun. 13, 2018EUR (€)	Jan. 16, 2019USD ($)	Jun. 28, 2018USD ($)	Nov. 15, 2017USD ($)	Nov. 15, 2017EUR (€)	Nov. 30, 2018USD ($)shares	Nov. 30, 2017USD ($)
Debt Conversion, Converted Instrument, Amount							$ 8,056,000
Due to Related Parties, Current							0	$ 116,000
Non-controlling interests							299,000	0
GPP receivable							$ 6,600,000	0
SFPI [Member]
Noncontrolling Interest, Increase from Sale of Parent Equity Interest					$ 5,900,000	€ 5,000
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners					16.70%
Debt Conversion, Converted Instrument, Amount					$ 1,180,000	1,070
Payments for subscription amounts	$ 2,300,000	€ 1,900			2,300,000	€ 2,000
Debt Conversion, Converted Instrument, Rate							0.85%
Equity interest, convertible, conversion price					$ 6.24
Non-controlling interests							$ 5,800,000	$ 3,600,000
GPP [Member]
Noncontrolling Interest, Amount Represented by Preferred Stock				$ 378,000
Noncontrolling Interest, Increase from Sale of Parent Equity Interest				$ 25,000,000
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners				37.80%
Non-controlling interests							18,400
Noncontrolling Interest, Increase from Sale of Parent Equity Interest, subject to certain contingencies				$ 13,200,000
Proceeds from Divestiture of Interest in Subsidiaries and Affiliates				11,800,000
Proceeds used to reimburse the investors for their fees and expenses				1,500,000
Net Proceeds from Divestiture of Interest in Subsidiaries and Affiliates				10,300,000
Follow-up payments				6,600,000
Spinoff threshold				$ 50,000,000
Description of Stockholders Agreement				The Stockholders’ Agreement further provides that GPP-II is entitled, at any time, to convert its share capital in Masthercell Global for the Company’s common stock in an amount equal to the lesser of (a)(i) the fair market value of GPP-II’s shares of Masthercell Global Preferred Stock to be exchanged, divided by (ii) the average closing price per share of the Company’s Common Stock during the thirty day period ending on the date that GPP-II provides the exchange notice (the “Exchange Price”) and (b)(i) the fair market value of GPP-II’s shares of Masthercell Global Preferred Stock to be exchanged assuming a value of Masthercell Global equal to three and a half (3.5) times the revenue of Masthercell Global during the last twelve (12) complete calendar months immediately prior to the exchange divided by (ii) the Exchange Price; provided, that in no event will (A) the Exchange Price be less than a price per share that would result in Orgenesis Inc having an enterprise value of less than $250 million and (B) the maximum number of shares of the Company’s Common Stock to be issued shall not exceed 2,704,247 shares, unless the Company obtains shareholder approval for the issuance of such greater amount of shares of the Company in accordance with the rules and regulations of the Nasdaq Stock Market.
Description of advisory services agreement				Great Point and Masthercell Global entered into an advisory services agreement pursuant to which Great Point is to provide management services to Masthercell Global for which Great Point will be compensated at an annual base compensation equal to the greater of (i) $250 thousand per each 12 month period or (ii) 5% of the EBITDA for such 12 month period, payable in arrears in quarterly installments; provided, that these payments will (A) begin to accrue immediately, but shall not be paid in cash to Great Point until such time as Masthercell Global generates EBITDA of at least $2 million for any 12 month period or the sale of or change in control of Masthercell Global, and (B) shall not exceed an aggregate annual amount of $0.5 million. Such compensation accrues but is not owed to Great Point until the earlier of (i) Masthercell Global generating EBITDA of at least $2 million for any 12 months period following the date of the agreement or (ii) a Sale of the Company or Change of Control of the Company (as both terms are defined therein).
GPP receivable							$ 6,600,000
Proceeds from collection of receivables			$ 6,600,000
MaSTherCell [Member]
Shares of subsidiary held | shares							622,000
Equity Method Investment, Ownership Percentage							62.20%

CORPORATE REORGANIZATION AND _3

CORPORATE REORGANIZATION AND EXERCISE OF CALL OPTIONS OF CURECELL AND ATVIO (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Nov. 30, 2018	Nov. 30, 2017
Revenues	$ 18,655	$ 10,089
Atvio and CureCell [Member]
Debt contributed	2,300
Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain	4,500
Revenues	$ 1,100
CureCell [Member]
Equity Method Investment, Ownership Percentage	94.12%
Stock Issued During Period, Shares, Acquisitions	202,846
Other intangible assets	$ 3,933
Total consideration transferred	4,790
CureCell [Member] | Customer Relationships [Member]
Other intangible assets	$ 859
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	10 years
CureCell [Member] | Know-How [Member]
Other intangible assets	$ 3,074
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	12 years
Atvio [Member]
Stock Issued During Period, Shares, Acquisitions	83,965
Total consideration transferred	$ 890

PROPERTY AND EQUIPMENT (Narrati

PROPERTY AND EQUIPMENT (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Nov. 30, 2018	Nov. 30, 2017
Depreciation	$ 711	$ 1,096

INTANGIBLE ASSETS AND GOODWIL_2

INTANGIBLE ASSETS AND GOODWILL (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Nov. 30, 2018	Nov. 30, 2017
Amortization of Intangible Assets	$ 1,913	$ 1,631
Approximations [Member]
Amortization of Intangible Assets	$ 1,900	$ 1,800
Terminal Year Growth Rate [Member]
Goodwill measurement input	2.00%
Sensitivity analysis, reduction in fair value	$ 1,126
Discount Rate [Member]
Goodwill measurement input	15.00%
Sensitivity analysis, reduction in fair value	$ 1,961
Decrease in the terminal year growth rate and an increase in the discount rate [Member]
Sensitivity analysis, reduction in fair value	$ 2,899

CONVERTIBLE LOANS (Narrative) (

CONVERTIBLE LOANS (Narrative) (Details) $ / shares in Units, € in Millions, ₪ in Millions	Mar. 07, 2017USD ($)	Nov. 02, 2016USD ($)	Nov. 02, 2016ILS (₪)	Apr. 30, 2018shares	Mar. 31, 2018USD ($)$ / shares	Jan. 31, 2018USD ($)	Mar. 20, 2017shares	Feb. 27, 2017	Jan. 17, 2017USD ($)$ / sharesshares	Jan. 17, 2017EUR (€)shares	Nov. 30, 2018USD ($)$ / sharesshares	Nov. 30, 2017USD ($)$ / sharesshares
Debt Instrument, Convertible, Conversion Price | $ / shares					$ 0.52
Class of Warrant or Right, Grants in Period, Net of Forfeitures | shares											4,488,854	1,144,647
Class of Warrant or Right, Grants in Period, Exercise Price | $ / shares											$ 6.24
Repayments of Convertible Debt	$ 494,000										$ 177,000	$ 4,051,000
Debt Instrument, Interest Rate, Stated Percentage		2.00%	2.00%
Debt Conversion, Converted Instrument and Accrued Interest, Amount					$ 383,000
Proceeds from issuance of convertible loans (net of transaction costs)		$ 280,000	₪ 1								1,912,000	5,899,000
Debt Conversion, Converted Instrument, Amount											$ 8,056,000
Debt Conversion, Converted Instrument, Shares Issued | shares											1,378,737
Debt Conversion, Converted Instrument, Warrants or Options Issued | shares											1,240,972
Financial expenses											$ 3,117,000	2,447,000
Repayments of Convertible Debt, shares issued | shares				107,985
Nine Investments and Admiral Ventures Inc. [Member]
Class of Warrant or Right, Grants in Period, Exercise Price | $ / shares											$ 6.24
Repayments of Convertible Debt						$ 179,000					$ 1,875,000
Units Issued During Period, Units | shares											120,193
Financial expenses											$ 179,000	$ 983,000
Class of Warrant or Right, Grants in Period, Value											$ 434,000
Debt Instrument, Payment Terms								The Company agreed to pay to Admiral, on or before March 1, 2017, between $0.3 million and $1.5 million. Further, beginning April 2017, the Company agreed to make a monthly payment of $125 thousand on account of remaining unpaid balance, and also agreed to remit additional payments under the term of the agreement.
MaSTherCell bondholder [Member]
Class of Warrant or Right, Grants in Period, Net of Forfeitures | shares									8,569	8,569
Class of Warrant or Right, Grants in Period, Exercise Price | $ / shares									$ 6.24
Repayments of Convertible Debt									$ 1,700,000	€ 1.5
Adjustment of Warrants Granted for Services									$ 20,000
Debt Conversion, Converted Instrument, Shares Issued | shares							40,682
Convertible Loans Outstanding 1 [Member]
Incremental Common Shares Attributable to Conversion of Debt Securities | shares											178,570
Debt Instrument, Convertible, Conversion Price | $ / shares											$ 7
Debt Instrument, Interest Rate, Stated Percentage											2.00%
Debt Instrument, Convertible, Beneficial Conversion Feature											$ 114
Convertible Loans Outstanding 1 [Member] | Hemogenyx-Cell [Member]
Pre-money valuation											12,000,000
Convertible Loans Outstanding 1 [Member] | Immugenyx, LLC [Member]
Pre-money valuation											$ 8,000,000
Convertible Loans converted 2 [Member]
Debt Instrument, Convertible, Conversion Price | $ / shares											$ 6.24
Class of Warrant or Right, Grants in Period, Net of Forfeitures | shares											40,064
Class of Warrant or Right, Grants in Period, Exercise Price | $ / shares											$ 6.24
Debt Instrument, Interest Rate, Stated Percentage											6.00%
Debt Instrument, Convertible, Beneficial Conversion Feature											$ 106
Debt Conversion, Converted Instrument, Amount											$ 500,000
Debt Conversion, Converted Instrument, Shares Issued | shares											80,756
Debt Conversion, Converted Instrument, Warrants or Options Issued | shares											80,756
Convertible Loans converted 4 [Member]
Debt Instrument, Convertible, Conversion Price | $ / shares											$ 6.24
Class of Warrant or Right, Grants in Period, Net of Forfeitures | shares												145,509
Class of Warrant or Right, Grants in Period, Exercise Price | $ / shares												$ 6.24
Debt Instrument, Interest Rate, Stated Percentage											6.00%
Debt Instrument, Convertible, Beneficial Conversion Feature											$ 81
Debt Conversion, Converted Instrument, Amount											$ 798,000
Debt Conversion, Converted Instrument, Shares Issued | shares											134,372
Debt Conversion, Converted Instrument, Warrants or Options Issued | shares											34,269
Convertible Loans converted 6 [Member]
Debt Instrument, Convertible, Conversion Price | $ / shares											$ 4.8
Debt Instrument, Convertible, Beneficial Conversion Feature											$ 85
Debt Conversion, Converted Instrument, Amount											$ 100,000
Debt Conversion, Converted Instrument, Shares Issued | shares											37,662
Debt Conversion, Converted Instrument, Warrants or Options Issued | shares											0
Convertible Loans converted 6 [Member] | Default Rate [Member]
Debt Instrument, Interest Rate, Stated Percentage											24.00%

COMMITMENTS (Narrative) (Detail

COMMITMENTS (Narrative) (Details) € in Thousands, $ in Thousands	Oct. 08, 2016USD ($)	Oct. 08, 2016EUR (€)	Sep. 09, 2015USD ($)	Dec. 19, 2016USD ($)	Dec. 19, 2016EUR (€)	May 26, 2016USD ($)	Apr. 30, 2016USD ($)	Apr. 30, 2016EUR (€)	Dec. 31, 2014EUR (€)	Mar. 20, 2012USD ($)	Feb. 08, 2019USD ($)	Nov. 30, 2018USD ($)	Nov. 30, 2018USD ($)	Nov. 30, 2018EUR (€)	Nov. 30, 2017USD ($)	Nov. 30, 2017EUR (€)	Nov. 30, 2018USD ($)	Nov. 30, 2018USD ($)	Nov. 30, 2017USD ($)	Nov. 30, 2018EUR (€)	Jul. 30, 2018USD ($)	Oct. 08, 2016EUR (€)	Apr. 30, 2016EUR (€)	Nov. 17, 2014USD ($)	Nov. 17, 2014EUR (€)	Jun. 30, 2014USD ($)
Revenues													$ 18,655		$ 10,089
CureCell [Member]
Advance payments on account of grant												$ 134	134				$ 134	$ 134
MaSTherCell [Member]
Revenues											$ 4,700		17,300
Revenue from grants [Member]
Revenues													922		$ 848
Maryland Technology Development Corporation [Member]
Grant proceeds utilized																			$ 356
Maryland Technology Development Corporation [Member] | Maximum [Member]
Grants Receivable, Noncurrent																										$ 406
Department De La Gestion Financiere Direction De Lanalyse Financiere [Member]
Grant proceeds, percentage of investment planned										32.00%
Advance payments on account of grant												64	64				64	64
Department De La Gestion Financiere Direction De Lanalyse Financiere [Member] | Revenue from grants [Member]
Revenues										$ 1,200
Department De La Gestion Financiere Direction De Lanalyse Financiere [Member] | Research and development of a potential cure for Type 1 Diabetes [Member]
Grants Receivable, Noncurrent																€ 1,800								$ 2,400	€ 2,000
Repayments of grant advances													34	€ 30
Advance payments on account of grant												152	152				152	152
Department De La Gestion Financiere Direction De Lanalyse Financiere [Member] | Research and development of a potential cure for Type 1 Diabetes [Member] | Revenue from grants [Member]
Revenues | €									€ 1,209							€ 1,200
Department De La Gestion Financiere Direction De Lanalyse Financiere [Member] | Industrial research part of the research program [Member]
Grants Receivable, Noncurrent | €																									€ 1,085
Grants receivable, percentage of budgeted costs																								70.00%	70.00%
Department De La Gestion Financiere Direction De Lanalyse Financiere [Member] | Experimental development part of the research program [Member]
Grants Receivable, Noncurrent | €																									€ 930
Grants receivable, percentage of budgeted costs																								60.00%	60.00%
Department De La Gestion Financiere Direction De Lanalyse Financiere [Member] | Development of a potential cure for Type 1 Diabetes [Member]
Grants Receivable, Noncurrent							$ 1,500																€ 1,300
Grants receivable, percentage of budgeted costs							55.00%																55.00%
Deduction of research and development expenses | €																				€ 303
Department De La Gestion Financiere Direction De Lanalyse Financiere [Member] | Development of a potential cure for Type 1 Diabetes [Member] | Revenue from grants [Member]
Revenues				$ 374	€ 359		$ 800	€ 717
Department De La Gestion Financiere Direction De Lanalyse Financiere [Member] | GMP production of AIP cells for two clinical trials that will be performed in Germany and Belgium [Member]
Grants Receivable, Noncurrent	$ 12,800																					€ 12,300
Deduction of research and development expenses												1,100	1,100				1,100	1,100
Advance payments on account of grant												847	847				847	847
Department De La Gestion Financiere Direction De Lanalyse Financiere [Member] | GMP production of AIP cells for two clinical trials that will be performed in Germany and Belgium [Member] | Revenue from grants [Member]
Revenues	$ 7,000	€ 6,800		$ 1,800	€ 1,700
Grants receivable, percentage of budgeted costs	55.00%																					55.00%
Israel-U.S Binational Industrial Research and Development Foundation [Member]
Grants Receivable, Noncurrent			$ 400
Deduction of research and development expenses												359	359				359	359
Receivable on account of grant.												159	159				159	159
Repayments of grant, percentage of gross sales			5.00%
Israel-U.S Binational Industrial Research and Development Foundation [Member] | Revenue from grants [Member]
Revenues																		200
Korea-Israel Industrial Research and Development Foundation [Member]
Grants Receivable, Noncurrent						$ 400
Repayments of grant, percentage of gross sales						2.50%
Korea-Israel Industrial Research and Development Foundation [Member] | Israeli subsidiary [Member]
Deduction of research and development expenses												279	279				279	279
Receivable on account of grant.												119	119				119	119
Korea-Israel Industrial Research and Development Foundation [Member] | Revenue from grants [Member]
Revenues																	440
BIRD Secant [Member]
Grants Receivable, Noncurrent																					$ 450
Deduction of research and development expenses												275	275				275	275
Receivable on account of grant.												163	$ 163				$ 163	$ 163
BIRD Secant [Member] | Revenue from grants [Member]
Revenues												$ 125

COLLABORATION AND LICENSE AGR_2

COLLABORATION AND LICENSE AGREEMENTS (Narrative) (Details) - USD ($)	Jul. 11, 2018	Jul. 10, 2018	Feb. 02, 2012	Nov. 30, 2018	Nov. 30, 2017	Dec. 31, 2018	Nov. 07, 2018	Jun. 19, 2018	Jan. 31, 2018
Class of Warrant or Right, Grants in Period, Exercise Price				$ 6.24
Research and Development Expense				$ 6,464,000	$ 2,478,000
Adva Biotechnology Ltd. [Member]
Commitment									$ 750
Expenses				$ 361,000
Tel Hashomer Medical Research, Infrastructure and Services Ltd (THM). [Member]
Commitment			$ 15,000
Royalty of net sales, percentage			3.50%
Sublicensing fees, percentage			16.00%
Commitment, shares of common stock			463,651
Commitment, shares of common stock of subsidiary			1,000
Tel Hashomer Medical Research, Infrastructure and Services Ltd (THM). [Member] | On the date of initiation of phase I clinical trials in human subjects [Member]
Commitment			$ 50,000
Tel Hashomer Medical Research, Infrastructure and Services Ltd (THM). [Member] | On the date of initiation of phase II clinical trials in human subject [Member]
Commitment			50,000
Tel Hashomer Medical Research, Infrastructure and Services Ltd (THM). [Member] | On the date of initiation of phase III clinical trials in human subjects [Member]
Commitment			150,000
Tel Hashomer Medical Research, Infrastructure and Services Ltd (THM). [Member] | On the date of initiation of issuance of an approval for marketing of the first product by the FDA [Member]
Commitment			750,000
Tel Hashomer Medical Research, Infrastructure and Services Ltd (THM). [Member] | When worldwide net sales of Products have reached the amount of $150 million for the first time [Member]
Commitment			$ 2,000,000
Mircod Limited [Member]
Collaboration Agreement, royalty percentage								5.00%
Description of completion of Development Project				Subject to completion of the Development Project, Mircod and the Company are to negotiate and enter into a manufacturing and supply agreement under which Mircod is to manufacture and supply products incorporating the Project Results and, at the Company’s request, to provide support and maintenance service for such products. If for whatever reason the parties fail to enter into such manufacturing and supply agreement within 90 days of the completion of the Development Project or if Mircod is unable to perform such services, the Company is entitled to manufacture the products, in which event Mircod will be entitled to a payment of $80,000 and royalties on Net Sales are to increase to 8% of Net Sales.
HekaBio K.K [Member]
Interest in joint venture		49.00%
Noncontrolling interest in joint venture		51.00%
Payments to Acquire Interest in Joint Venture		$ 10,000,000
Option to affect an equity investment		$ 15,000,000
Royalty percentage from joint venture		10.00%
Image Securities Ltd. [Member]
Joint venture, equity investment from other partners	$ 5,000,000
Units Issued During Period, Per Unit Amount	$ 6.24
Class of Warrant or Right, Grants in Period, Exercise Price	$ 6.24
Convertible loan advanced to joint venture				$ 1,000,000
Convertible loan advanced to joint venture, interest rate				6.00%
Proceeds from Divestiture of Interest in joint venture	$ 10,000,000
Monthly consulting services to joint venture				$ 1,000,000
Hemogenyx Pharmaceuticals PLC. [Member]
Royalty of net sales, percentage				12.00%
Loans Receivable, Net				$ 500,000		$ 250,000	$ 1,000,000
Immugenyx, LLC [Member]
Royalty of net sales, percentage				12.00%
Loans Receivable, Net				$ 500,000		$ 250,000	$ 1,000,000
BG Negev Technologies and Applications (BGN) [Member]
Commitment				$ 10,000
BG Negev Technologies and Applications (BGN) [Member] | Minimum [Member]
Royalty of net sales, percentage				2.00%
Sublicensing fees, percentage				15.00%
BG Negev Technologies and Applications (BGN) [Member] | Maximum [Member]
Royalty of net sales, percentage				4.00%
Sublicensing fees, percentage				20.00%
Collaboration agreement [Member]
Research and Development Expense				$ 1,200,000
Service revenue under collaboration agreement				$ 1,000,000

INVESTMENTS IN ASSOCIATE, NET_2

INVESTMENTS IN ASSOCIATE, NET (Narrative) (Details) $ in Millions	12 Months Ended
	Nov. 30, 2018USD ($)
Atvio [Member]
Payments to Acquire Interest in Joint Venture	$ 1
CureCell [Member]
Payments to Acquire Interest in Joint Venture	$ 2.1

EQUITY (Narrative) (Details)

EQUITY (Narrative) (Details) $ / shares in Units, $ in Thousands, € in Millions	Mar. 07, 2017USD ($)	Jul. 31, 2018USD ($)$ / sharesshares	Jan. 31, 2017USD ($)$ / sharesshares	Jan. 31, 2017EUR (€)shares	Feb. 08, 2019USD ($)	Nov. 30, 2018USD ($)$ / sharesshares	Nov. 30, 2017USD ($)shares	Nov. 30, 2015USD ($)	Nov. 30, 2015EUR (€)
Class of Warrant or Right, Grants in Period, Net of Forfeitures | shares						4,488,854	1,144,647
Class of Warrant or Right, Grants in Period, Exercise Price | $ / shares						$ 6.24
Receipts on account of shares to be allotted						$ 2,253	$ 1,483
Class of Warrant or Right, Exercises in Period | shares						136,646	0
Proceeds from Warrant Exercises						$ 853
Repayments of Convertible Debt	$ 494					$ 177	$ 4,051
Warrants subject to exercise price adjustments | shares						769,411	1,066,691
Definitive agreements with an institutional investor [Member]
Units Issued During Period, Units | shares		702,307	2,564,115	2,564,115		1,813,687	721,160
Common Stock Shares Subscriptions			$ 16,000
Units Issued During Period, Exercise Price | $ / shares		$ 6.24	$ 6.24
Proceeds from Issuance of Private Placement		$ 4,600				$ 11,500	$ 4,500
Class of Warrant or Right, Grants in Period, Exercise Price | $ / shares			$ 6.24
Shares which have not been issued | shares						550,481
Receipts on account of shares to be allotted						$ 2,300
Payments of fees for shares not issued						328	225
Stock-based compensation expenses due to issuance of warrants and shares						$ 121	$ 253
Definitive agreements with accredited and other qualified investors [Member]
Units Issued During Period, Units | shares						1,237,642
Units Issued During Period, Exercise Price | $ / shares						$ 6.24
Proceeds from Issuance of Private Placement						$ 7,700
Payments of fees for shares not issued						349
Stock-based compensation expenses due to issuance of warrants and shares						125
MaSTherCell [Member]
Proceeds from Issuance of Private Placement					$ 250	$ 21,500
Convertible Debt								$ 1,800	€ 1.6
Repayments of Convertible Debt			$ 1,700	€ 1.5
Stock Redeemed or Called During Period, Shares | shares			263,148	263,148

LOSS PER SHARE (Narrative) (Det

LOSS PER SHARE (Narrative) (Details)	12 Months Ended
	Nov. 30, 2018shares
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,057,785

STOCK BASED COMPENSATION (Narra

STOCK BASED COMPENSATION (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended			12 Months Ended
	Jul. 31, 2018	Jan. 31, 2018	Dec. 31, 2017	Nov. 30, 2018	Nov. 30, 2017	Nov. 30, 2016
Common Stock, Shares Authorized				145,833,334	145,833,334
Stock-based compensation				$ 4,364	$ 3,364
Class of Warrant or Right, Grants in Period, Net of Forfeitures				4,488,854	1,144,647
Class of Warrant or Right, Grants in Period, Weighted Average Exercise Price				$ 6.27	$ 6.32
Class of Warrant or Right, Exercises in Period				136,646	0
2017 Equity Incentive Plan [Member]
Common Stock, Shares Authorized				1,750,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number				1,040,942
Share-based Compensation Arrangement by Share-based Payment Award, Options, Available for grants				709,058
2017 Equity Incentive Plan [Member] | Maximum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term				10 years
Global share incentive plan (2012) [Member]
Common Stock, Shares Authorized				1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number				699,991
Share-based Compensation Arrangement by Share-based Payment Award, Options, Available for grants				300,009
Global share incentive plan (2012) [Member] | Maximum [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term				10 years
Several consultants [Member]
Class of Warrant or Right, Grants in Period, Net of Forfeitures				78,782	53,148
Class of Warrant or Right, Grants in Period, Fair Value				$ 350	$ 211
Several consultants [Member] | Minimum [Member]
Class of Warrant or Right, Grants in Period, Weighted Average Exercise Price				$ 6.24	$ 6.24
Several consultants [Member] | Maximum [Member]
Class of Warrant or Right, Grants in Period, Weighted Average Exercise Price				$ 15.41	$ 10.20
Success fee [Member]
Class of Warrant or Right, Grants in Period, Net of Forfeitures					38,001
Class of Warrant or Right, Grants in Period, Fair Value					$ 169
Investor relations services, marketing and related services agreement [Member]
Stock Issued During Period, Shares, Issued for Services			195,000
Number of vested shares				140,000
Stock Issued During Period, Value, Issued for Services			$ 1,439
Investor relations services, marketing and related services agreement [Member] | Vest after 30 days [Member]
Stock Issued During Period, Shares, Issued for Services			50,000
Investor relations services, marketing and related services agreement [Member] | Vest monthly over 15 months [Member]
Stock Issued During Period, Shares, Issued for Services			145,000
Consulting agreement with a financial advisor [Member]
Class of Warrant or Right, Grants in Period, Net of Forfeitures	6,629
Class of Warrant or Right, Grants in Period, Weighted Average Exercise Price	$ 6.24	$ 6.24
Class of Warrant or Right, Grants in Period, Fair Value		$ 62
Professional Fees		$ 60
Units Issued During Period, Units	6,629	19,000
Units Issued During Period, Value	$ 88	$ 171
Options Granted to Employees and Directors [Member]
Stock-based compensation				$ 2,426	$ 1,536
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options				$ 3,783
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				3 years 10 months 20 days
Options Granted to Non- Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number				469,974	399,380	441,621
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term				6 years 9 months 29 days
Stock-based compensation				$ 331	$ 322
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options				$ 157
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				3 years 1 month 17 days

TAXES (Narrative) (Details)

TAXES (Narrative) (Details) $ in Thousands, € in Millions, ₩ in Millions	12 Months Ended				24 Months Ended
	Dec. 31, 2020	Dec. 31, 2018	Nov. 30, 2018USD ($)	Dec. 31, 2017	Dec. 31, 2019	Nov. 30, 2018EUR (€)	Nov. 30, 2018KRW (₩)	Nov. 30, 2017USD ($)
United States [Member]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate		21.00%		35.00%
Operating Loss Carryforwards			$ 18,100					$ 12,800
Israel [Member]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate		23.00%		24.00%
Operating Loss Carryforwards			7,230					5,800
Belgium [Member]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate	25.00%			34.00%	29.58%
Operating Loss Carryforwards			5,900			€ 5.2		$ 15,800
Limitation on accumulated tax loss carryforward deductions			1,000
Korea [Member]
Operating Loss Carryforwards			$ 3,200				₩ 3,421
Korea [Member] | The first KRW 200 million of the tax base [Member]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate			10.00%
Korea [Member] | Up to KRW 20 billion [Member]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate			20.00%
Korea [Member] | Up to KRW 300 billion [Member]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate			22.00%
Korea [Member] | Tax base above KRW 300 billion [Member]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate			25.00%

SUBSEQUENT EVENTS (Narrative) (

SUBSEQUENT EVENTS (Narrative) (Details) - Subsequent Event [Member] $ / shares in Units, $ in Thousands	12 Months Ended
	Nov. 30, 2018USD ($)$ / sharesshares
Proceeds from Issuance of Unsecured Debt	$ 250
Debt, Weighted Average Interest Rate	2.00%
Loans Receivable, Net	$ 500
Proceeds from services under joint venture agreement	$ 1,000
Description of Controlled Equity Offering Sales Agreement	In December 2018, the Company entered into a Controlled Equity Offering Sales Agreement (“Sales Agreement”) with Cantor Fitzgerald & Co.(“Cantor”) pursuant to which the Company may offer and sell, from time to time through Cantor, shares of the Company’s common stock having an aggregate offering price of up to $25.0 million. The Company will pay Cantor a commission rate equal to 3.0% of the aggregate gross proceeds from each sale. The Company has not yet sold any shares pursuant to the Sales Agreement.
Budget for gene-therapy research project	$ 1,500
Grants Receivable, Noncurrent	350
Security Deposit	$ 1,600
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures | shares	61,111
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares	$ 13.52
Minimum [Member]
Commitment	$ 726
Maximum [Member]
Commitment	$ 962

Schedule of Annual Depreciation

Schedule of Annual Depreciation Rates, Property and Equipment (Details)	12 Months Ended
	Nov. 30, 2018
Production facility [Member] | Minimum [Member]
Weighted Average Useful Life	5 years
Production facility [Member] | Maximum [Member]
Weighted Average Useful Life	20 years
Laboratory equipment [Member]
Weighted Average Useful Life	5 years
Office equipment and computers [Member] | Minimum [Member]
Weighted Average Useful Life	3 years
Office equipment and computers [Member] | Maximum [Member]
Weighted Average Useful Life	5 years

Schedule of Intangible Assets,

Schedule of Intangible Assets, Useful Lives (Details)	12 Months Ended
	Nov. 30, 2018
Customer Relationships [Member] | Minimum [Member]
Weighted Average Useful Life (Years)	2 years 6 months
Customer Relationships [Member] | Maximum [Member]
Weighted Average Useful Life (Years)	10 years
Brand [Member]
Weighted Average Useful Life (Years)	9 years 9 months
Know-How [Member] | Minimum [Member]
Weighted Average Useful Life (Years)	11 years 9 months
Know-How [Member] | Maximum [Member]
Weighted Average Useful Life (Years)	12 years
Backlog [Member]
Weighted Average Useful Life (Years)	1 year 6 months

Business Combination, Segment A

Business Combination, Segment Allocation (Details) - USD ($) $ in Thousands	12 Months Ended
	Nov. 30, 2018	Nov. 30, 2017	Nov. 30, 2016
Goodwill	$ 15,165	$ 10,684	$ 9,584
CureCell [Member]
Cash and cash equivalents	58
Property and equipment, net	1,104
Inventory	148
Other assets	300
Other intangible assets	3,933
Goodwill	3,950
Total assets	9,493
Deferred income from the company and others	1,945
Deferred taxes	80
Fair value of convertible loan from the company	892
Non-controlling interests	299
Other liabilities	1,487
Total liabilities	4,703
Total consideration transferred	$ 4,790
Percentage of shares issued	36.40%
Fair value according of shares issued	$ 1,853
Acquisition date fair value of previously held equity interest	$ 2,937

Business Acquisition, Pro Forma

Business Acquisition, Pro Forma Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Nov. 30, 2018	Nov. 30, 2017
Revenue	$ 18,794	$ 10,216
Net loss	$ 20,919	$ 14,520

Schedule of Segment Information

Schedule of Segment Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Nov. 30, 2018	Nov. 30, 2017
Revenues	$ 18,655	$ 10,089
Cost of revenues	(10,824)	(6,807)
Gross profit (loss)	7,831	3,282
Research and development expenses, net	(6,464)	(2,478)
Operating profit (loss)	(14,650)	(11,230)
Depreciation and amortization expense	(2,624)	(2,598)
Segment Performance	12,743	8,149
CDMO [Member]
Revenues	22,582	11,484
Cost of revenues	(11,541)	(6,356)
Gross profit (loss)	11,041	5,128
Research and development expenses, net	(39)
Operating expenses	(6,889)	(4,699)
Other expenses	(77)
Operating profit (loss)	4,036	429
Depreciation and amortization expense	(2,613)	(2,720)
Segment Performance	1,423	(2,291)
CTB [Member]
Revenues	0	0
Gross profit (loss)	0	0
Research and development expenses, net	(7,931)	(2,517)
Operating expenses	(6,224)	(3,335)
Other expenses	0
Operating profit (loss)	(14,155)	(5,852)
Depreciation and amortization expense	(11)	(6)
Segment Performance	(14,166)	(5,858)
Corporate and Eliminations [Member]
Revenues	(3,927)	(1,395)
Cost of revenues	1,235	638
Gross profit (loss)	(2,692)	(757)
Research and development expenses, net	2,485	757
Operating expenses	207
Operating profit (loss)	0	0
Consolidated [Member]
Revenues	18,655	10,089
Cost of revenues	(10,306)	(5,718)
Gross profit (loss)	8,349	4,371
Research and development expenses, net	(5,485)	(1,760)
Operating expenses	(12,906)	(8,034)
Other expenses	(77)
Operating profit (loss)	(10,119)	$ (5,423)
Depreciation and amortization expense	(2,624)
Segment Performance	$ (12,743)

Schedule of Reconciliation of S

Schedule of Reconciliation of Segment Performance (Details) - USD ($) $ in Thousands	12 Months Ended
	Nov. 30, 2018	Nov. 30, 2017
Segment Performance	$ (12,743)	$ (8,149)
Stock-based compensation	(4,364)	(3,364)
Financial income (expenses), net	(2,938)	(950)
Net gain on remeasurement of previously equity interest in Atvio and CureCell to acquisition date fair value	4,509	0
Transaction expenses related to GPP agreement	(1,500)
Share in losses of associated companies	(731)	(1,214)
Loss before income tax	$ (17,767)	$ (13,677)

Schedule of Revenues from Major

Schedule of Revenues from Major Customers (Details) - USD ($) $ in Thousands	12 Months Ended
	Nov. 30, 2018	Nov. 30, 2017
Revenues	$ 18,655	$ 10,089
Customer A [Member]
Revenues	2,338	4,115
Customer B [Member]
Revenues	4,374	2,837
Customer C [Member]
Revenues	0	2,055
Customer D [Member]
Revenues	5,236	0
Customer E [Member]
Revenues	$ 2,242	$ 0

Schedule of Property, Plant and

Schedule of Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Nov. 30, 2018	Nov. 30, 2017
Cost	$ 16,580	$ 8,638
Less accumulated depreciation	(4,679)	(3,534)
Total	11,901	5,104
Production facility [Member]
Cost	11,413	6,246
Office furniture and computers [Member]
Cost	1,875	353
Lab equipment [Member]
Cost	$ 3,292	$ 2,039

Schedule of Goodwill (Details)

Schedule of Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Nov. 30, 2018	Nov. 30, 2017
Goodwill, Beginning Balance	$ 10,684	$ 9,584
Goodwill as acquired	4,918
Translation differences	(437)	1,100
Goodwill, Ending Balance	$ 15,165	$ 10,684

Schedule of Intangible Assets (

Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	Nov. 30, 2018	Nov. 30, 2017
Gross Carrying Amount	$ 23,094	$ 19,785
Accumulated amortization	6,394	4,734
Net carrying amount of other intangible assets	16,700	15,051
Know-How [Member]
Gross Carrying Amount	20,344	17,998
Backlog [Member]
Gross Carrying Amount	117	0
Customer Relationships [Member]
Gross Carrying Amount	1,274	369
Brand name [Member]
Gross Carrying Amount	$ 1,359	$ 1,418

Schedule of Intangible Assets_2

Schedule of Intangible Assets, Future Amortization Expense (Details) $ in Thousands	Nov. 30, 2018USD ($)
Amortization expenses, Next Twelve Months	$ 2,086
Amortization expenses, to Year Five	$ 7,929

Schedule of Convertible Debt (D

Schedule of Convertible Debt (Details) - USD ($)	Mar. 07, 2017	Nov. 30, 2018	Nov. 30, 2017	Mar. 31, 2018	Nov. 02, 2016
Convertible Loans Schedule Of Convertible Debt 51		6.00%
Convertible Loans converted		$ 8,056,000
Repayments of Convertible Debt	$ 494,000	177,000	$ 4,051,000
Interest Rate					2.00%
Exercise price				$ 0.52
Accumulated Interest Up to Conversion Date		$ 494,000
Shares Issued Upon Conversion		1,378,737
Warrants Issued Upon Conversion		1,240,972
Convertible Loans Outstanding 1 [Member]
Convertible Loans Outstanding		$ 1,250,000
Interest Rate		2.00%
Maturity period		3 years
Exercise price		$ 7
Beneficial Conversion Feature		$ 114
Convertible Loans converted 1 [Member]
Convertible Loans converted		$ 220,000
Interest Rate		6.00%
Maturity period		2 years
Exercise price		$ 6.24
Beneficial Conversion Feature		$ 87
Accumulated Interest Up to Conversion Date		$ 2,000
Shares Issued Upon Conversion		35,543
Warrants Issued Upon Conversion		35,543
Convertible Loans converted 2 [Member]
Convertible Loans converted		$ 500,000
Interest Rate		6.00%
Maturity period		6 months
Exercise price		$ 6.24
Beneficial Conversion Feature		$ 106
Accumulated Interest Up to Conversion Date		$ 4,000
Shares Issued Upon Conversion		80,756
Warrants Issued Upon Conversion		80,756
Convertible Loans converted 3 [Member]
Convertible Loans converted		$ 5,050,000
Interest Rate		6.00%
Maturity period		2 years
Exercise price		$ 6.24
Beneficial Conversion Feature		$ 2,311
Accumulated Interest Up to Conversion Date		$ 235,000
Shares Issued Upon Conversion		846,961
Warrants Issued Upon Conversion		846,961
Convertible Loans converted 4 [Member]
Convertible Loans converted		$ 798,000
Interest Rate		6.00%
Exercise price		$ 6.24
Beneficial Conversion Feature		$ 81
Accumulated Interest Up to Conversion Date		$ 40,000
Shares Issued Upon Conversion		134,372
Warrants Issued Upon Conversion		34,269
Convertible Loans converted 4 [Member] | Minimum [Member]
Maturity period		6 months
Convertible Loans converted 4 [Member] | Maximum [Member]
Maturity period		1 year 8 months 12 days
Convertible Loans converted 5 [Member]
Convertible Loans converted		$ 1,388,000
Interest Rate		6.00%
Maturity period		2 years
Exercise price		$ 6.24
Beneficial Conversion Feature		$ 251
Accumulated Interest Up to Conversion Date		$ 132,000
Shares Issued Upon Conversion		243,443
Warrants Issued Upon Conversion		243,443
Convertible Loans converted 6 [Member]
Convertible Loans converted		$ 100,000
Maturity period		6 months
Exercise price		$ 4.8
Beneficial Conversion Feature		$ 85
Accumulated Interest Up to Conversion Date		$ 81,000
Shares Issued Upon Conversion		37,662
Warrants Issued Upon Conversion		0
Convertible Loans repaid 1 [Member]
Repayments of Convertible Debt			$ 400,000
Interest Rate			6.00%
Maturity period			3 months
Exercise price			$ 6.24

Schedule of Long-term Debt Inst

Schedule of Long-term Debt Instruments (Details) € in Thousands, $ in Thousands	Nov. 30, 2018USD ($)	Nov. 30, 2018EUR (€)	Nov. 30, 2017USD ($)	Nov. 02, 2016
Debt Instrument, Interest Rate, Stated Percentage				2.00%
Loans payable	$ 2,030		$ 2,496
Current portion of loans payable	(368)		(378)
Noncurrent portion of loans payable	$ 1,662		2,118
Long-term loan a [Member]
Principal Amount | €		€ 1,400
Debt Instrument, Interest Rate, Stated Percentage	4.05%	4.05%
Loans payable	$ 700		899
Current portion of loans payable	(168)		(169)
Long-term loan b [Member]
Principal Amount | €		€ 1,000
Loans payable	869		977
Current portion of loans payable	$ (67)		(70)
Long-term loan b [Member] | Minimum [Member]
Debt Instrument, Interest Rate, Stated Percentage	6.00%	6.00%
Long-term loan b [Member] | Maximum [Member]
Debt Instrument, Interest Rate, Stated Percentage	7.50%	7.50%
Long-term loan c [Member]
Principal Amount | €		€ 790
Loans payable	$ 461		620
Current portion of loans payable	$ (133)		$ (139)
Long-term loan c [Member] | Minimum [Member]
Debt Instrument, Interest Rate, Stated Percentage	5.50%	5.50%
Long-term loan c [Member] | Maximum [Member]
Debt Instrument, Interest Rate, Stated Percentage	6.00%	6.00%

Schedule of Short-term Debt (De

Schedule of Short-term Debt (Details) - USD ($) $ in Thousands	Nov. 30, 2018	Nov. 30, 2017	Nov. 02, 2016
Debt Instrument, Interest Rate, Stated Percentage			2.00%
Current portion of loans payable	$ 368	$ 378
Short-term loans and current maturities of long term loans	$ 647	378
Long-term loan a [Member]
Debt Instrument, Interest Rate, Stated Percentage	4.05%
Current portion of loans payable	$ 168	169
Long-term loan b [Member]
Current portion of loans payable	$ 67	70
Long-term loan b [Member] | Minimum [Member]
Debt Instrument, Interest Rate, Stated Percentage	6.00%
Long-term loan b [Member] | Maximum [Member]
Debt Instrument, Interest Rate, Stated Percentage	7.50%
Long-term loan c [Member]
Current portion of loans payable	$ 133	139
Long-term loan c [Member] | Minimum [Member]
Debt Instrument, Interest Rate, Stated Percentage	5.50%
Long-term loan c [Member] | Maximum [Member]
Debt Instrument, Interest Rate, Stated Percentage	6.00%
Short term-loans [Member]
Current portion of loans payable	$ 279	$ 0
Short term-loans [Member] | Minimum [Member]
Debt Instrument, Interest Rate, Stated Percentage	3.02%
Short term-loans [Member] | Maximum [Member]
Debt Instrument, Interest Rate, Stated Percentage	4.15%

Schedule of Future Minimum Rent

Schedule of Future Minimum Rental Payments for Operating Leases (Details) $ in Thousands	Nov. 30, 2018USD ($)
Operating Leases, Future Minimum Payments Due, Current	$ 783
Operating Leases, Future Minimum Payments, Due in Two Years	626
Operating Leases, Future Minimum Payments, Due Thereafter	3,504
Operating Leases, Future Minimum Payments Due	$ 4,913

Schedule of Investments (Detail

Schedule of Investments (Details) - USD ($) $ in Thousands	12 Months Ended
	Nov. 30, 2018	Nov. 30, 2017
Opening balance	$ 1,321	$ (12)
Reclass from short-term receivables *	(795)	118
Investments	0	2,429
Share in losses of associated companies	(731)	(1,214)
Reductions due to the acquisition of CureCell and Atvio	205	0
Ending balance	$ 0	$ 1,321

Schedule of Stockholders' Equit

Schedule of Stockholders' Equity Note, Warrants or Rights, Activity (Details) - $ / shares	12 Months Ended
	Nov. 30, 2018	Nov. 30, 2017
Class of Warrant or Right, Outstanding, Beginning of Period	2,609,864	1,620,993
Class of Warrant or Right, Outstanding, Weighted Average Exercise Price, Beginning of Period	$ 6.26	$ 6.25
Class of Warrant or Right, Grants in Period, Net of Forfeitures	4,488,854	1,144,647
Class of Warrant or Right, Grants in Period, Weighted Average Exercise Price	$ 6.27	$ 6.32
Class of Warrant or Right, Exercises in Period	(136,646)	0
Class of Warrant or Right, Exercises in Period, Weighted Average Exercise Price	$ 6.24
Class of Warrant or Right, Expirations in Period	(382,414)	(155,776)
Class of Warrant or Right, Expirations in Period, Weighted Average Exercise Price	$ 6.10	$ 6.24
Class of Warrant or Right, Forfeitures in Period	(66,667)	0
Class of Warrant or Right, Forfeitures in Period, Weighted Average Exercise Price	$ 6.24
Class of Warrant or Right, Outstanding, End of Period	6,512,991	2,609,864
Class of Warrant or Right, Outstanding, Weighted Average Exercise Price, End of Period	$ 6.27	$ 6.26

Schedule of Earnings Per Share,

Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Nov. 30, 2018	Nov. 30, 2017
Net loss attributable to Orgenesis Inc	$ 18,291	$ 12,367
Adjustment of redeemable non-controlling interest to redemption amount	884	0
Net loss attributable to Orgenesis Inc. for loss per share	$ 19,175	$ 12,367
Weighted average number of common shares outstanding	13,374,103	9,679,964
Basic loss per common share	$ 1.43	$ 1.28
Net loss attributable to Orgenesis Inc. for loss per share	$ 19,175	$ 12,367
Changes in fair value of embedded derivative and interest expense on convertible loans	0	392
Loss for the year	$ 19,175	$ 12,759
Number of dilutive shares related to convertible note	0	34,288
Weighted average number of common shares outstanding	13,374,103	9,714,252
Diluted loss per common share	$ 1.43	$ 1.31

Employee Stock Ownership Plan (

Employee Stock Ownership Plan (ESOP) Disclosures (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Nov. 30, 2018	Nov. 30, 2017
Options Granted to Employees [Member]
No. of options granted	876,200	691,673
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 7.13	$ 5.28
Employee 1 [Member]
No. of options granted	762,400	525,005
Vesting period	4 years	4 years
Fair value at grant	$ 4,233	$ 1,915
Expiration period	10 years	10 years
Employee 1 [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 4.42	$ 4.8
Employee 1 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 8.91	$ 7.2
Directors [Member]
No. of options granted	113,800	166,668
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 5.99	$ 4.80
Vesting period	1 year	2 years
Fair value at grant	$ 507	$ 558
Expiration period	10 years	10 years

Schedule of Share-based Compens

Schedule of Share-based Compensation, Stock Options Granted to Consultants (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Nov. 30, 2018	Nov. 30, 2017
Options Granted to Non- Employees [Member]
No. of options granted	102,763	16,668
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 4.92	$ 4.80
Non-employee 1 [Member]
No. of options granted		102,763
Vesting period	4 years
Fair value at grant		$ 444
Expiration period		10 years
Non-employee 1 [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price		$ 4.42
Non-employee 1 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price		$ 8.34
Non-employee 2 [Member]
No. of options granted	16,668
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 4.8
Fair value at grant	$ 68
Expiration period	10 years

Schedule of Share-based Payment

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details) - $ / shares	12 Months Ended
	Nov. 30, 2018	Nov. 30, 2017
Options Granted to Employees [Member]
Dividend yield	0.00%	0.00%
Expected term (years)		5 years
Options Granted to Non- Employees [Member]
Dividend yield	0.00%	0.00%
Minimum [Member] | Options Granted to Employees [Member]
Value of one common share	$ 4.42	$ 4.68
Expected stock price volatility	88.00%	93.80%
Risk free interest rate	2.33%	1.89%
Expected term (years)	4 years 1 month 17 days
Minimum [Member] | Options Granted to Non- Employees [Member]
Value of one common share	$ 4.42	$ 3.60
Expected stock price volatility	91.00%	87.00%
Risk free interest rate	2.33%	1.19%
Expected term (years)	9 years 9 months 14 days	4 years
Maximum [Member] | Options Granted to Employees [Member]
Value of one common share	$ 8.7	$ 7.2
Expected stock price volatility	98.00%	95.40%
Risk free interest rate	3.20%	1.76%
Expected term (years)	10 years
Maximum [Member] | Options Granted to Non- Employees [Member]
Value of one common share	$ 8.34	$ 7.44
Expected stock price volatility	95.00%	95.00%
Risk free interest rate	3.20%	1.89%
Expected term (years)	10 years	5 years

Schedule of Share-based Compe_2

Schedule of Share-based Compensation, Stock Options, Activity (Details) - $ / shares	12 Months Ended
	Nov. 30, 2018	Nov. 30, 2017
Options Granted to Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning of Period	1,605,055	978,853
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning of Period	$ 3.11	$ 1.92
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	876,200	691,673
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 7.13	$ 5.28
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period	(61,463)	(38,106)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price	$ 5.26	$ 7.58
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period	(43,365)	(27,365)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price	$ 4.68	$ 4.8
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, End of Period	2,376,427	1,605,055
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, End of Period	$ 4.51	$ 3.11
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number, End of Period	1,504,542	1,135,107
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price, End of Period	$ 2.91	$ 2.57
Options Granted to Non- Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning of Period	399,380	441,621
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning of Period	$ 7.47	$ 6.24
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	102,763	16,668
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 4.92	$ 4.80
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period	0	(58,909)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price	$ 0	$ 8.28
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period	(15,500)	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price	$ 0	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Cancellations in Period	(16,669)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Cancellations in Period, Weighted Average Exercise Price	$ 7.02
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, End of Period	469,974	399,380
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, End of Period	$ 5.75	$ 7.47
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number, End of Period	436,640	379,712
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price, End of Period	$ 5.75	$ 5.76

Disclosure of Share-based Compe

Disclosure of Share-based Compensation Stock Options Exercisable (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Nov. 30, 2018	Nov. 30, 2017	Nov. 30, 2016
Options Granted to Employees [Member]
Exercise Price	$ 4.51	$ 3.11	$ 1.92
Number of Outstanding Options	2,376,427	1,605,055	978,853
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	7 years 1 month 24 days
Aggregate Intrinsic Value	$ 5,167
Number of Exercisable Options	1,504,542	1,135,107
Aggregate Exercisable Options Value	$ 4,598
Options Granted to Non- Employees [Member]
Exercise Price	$ 5.75	$ 7.47	$ 6.24
Number of Outstanding Options	469,974	399,380	441,621
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	6 years 9 months 29 days
Aggregate Intrinsic Value	$ 624
Number of Exercisable Options	436,640	379,712
Aggregate Exercisable Options Value	$ 2,512
Exercise Price 1 [Member] | Options Granted to Employees [Member]
Exercise Price	$ 0.0012
Number of Outstanding Options	462,015
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	4 years 9 months 11 days
Aggregate Intrinsic Value	$ 2,776
Number of Exercisable Options	462,015
Aggregate Exercisable Options Value	$ 1
Exercise Price 1 [Member] | Options Granted to Non- Employees [Member]
Exercise Price	$ 3.36
Number of Outstanding Options	136,775
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	7 years 4 months 28 days
Aggregate Intrinsic Value	$ 362
Number of Exercisable Options	136,775
Aggregate Exercisable Options Value	$ 460
Exercise Price 2 [Member] | Options Granted to Employees [Member]
Exercise Price	$ 0.012
Number of Outstanding Options	278,191
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	3 years 2 months 5 days
Aggregate Intrinsic Value	$ 1,669
Number of Exercisable Options	278,191
Aggregate Exercisable Options Value	$ 3
Exercise Price 2 [Member] | Options Granted to Non- Employees [Member]
Exercise Price	$ 3.60
Number of Outstanding Options	83,334
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	7 years 3 months
Aggregate Intrinsic Value	$ 201
Number of Exercisable Options	83,334
Aggregate Exercisable Options Value	$ 300
Exercise Price 3 [Member] | Options Granted to Employees [Member]
Exercise Price	$ 4.42
Number of Outstanding Options	50,000
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	9 years 7 days
Aggregate Intrinsic Value	$ 79
Number of Exercisable Options	37,500
Aggregate Exercisable Options Value	$ 166
Exercise Price 3 [Member] | Options Granted to Non- Employees [Member]
Exercise Price	$ 4.42
Number of Outstanding Options	10,325
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	9 years 7 days
Aggregate Intrinsic Value	$ 16
Number of Exercisable Options	10,325
Aggregate Exercisable Options Value	$ 46
Exercise Price 4 [Member] | Options Granted to Employees [Member]
Exercise Price	$ 4.8
Number of Outstanding Options	524,999
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	8 years 11 days
Aggregate Intrinsic Value	$ 635
Number of Exercisable Options	440,104
Aggregate Exercisable Options Value	$ 2,112
Exercise Price 4 [Member] | Options Granted to Non- Employees [Member]
Exercise Price	$ 4.80
Number of Outstanding Options	16,667
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	8 years 11 days
Aggregate Intrinsic Value	$ 20
Number of Exercisable Options	16,667
Aggregate Exercisable Options Value	$ 80
Exercise Price 5 [Member] | Options Granted to Employees [Member]
Exercise Price	$ 5.99
Number of Outstanding Options	384,050
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	9 years 4 months 6 days
Aggregate Intrinsic Value	$ 8
Number of Exercisable Options	32,750
Aggregate Exercisable Options Value	$ 196
Exercise Price 5 [Member] | Options Granted to Non- Employees [Member]
Exercise Price	$ 5.30
Number of Outstanding Options	35,000
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	9 years 9 months 14 days
Aggregate Intrinsic Value	$ 25
Number of Exercisable Options	20,000
Aggregate Exercisable Options Value	$ 106
Exercise Price 6 [Member] | Options Granted to Employees [Member]
Exercise Price	$ 6
Number of Outstanding Options	33,334
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	5 years 8 months 1 day
Aggregate Intrinsic Value	$ 0
Number of Exercisable Options	33,334
Aggregate Exercisable Options Value	$ 200
Exercise Price 6 [Member] | Options Granted to Non- Employees [Member]
Exercise Price	$ 5.99
Number of Outstanding Options	25,005
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	9 years 10 months 24 days
Number of Exercisable Options	13,337
Aggregate Exercisable Options Value	$ 80
Exercise Price 7 [Member] | Options Granted to Employees [Member]
Exercise Price	$ 7.2
Number of Outstanding Options	83,334
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	8 years 6 months 4 days
Aggregate Intrinsic Value	$ 0
Number of Exercisable Options	83,334
Aggregate Exercisable Options Value	$ 600
Exercise Price 7 [Member] | Options Granted to Non- Employees [Member]
Exercise Price	$ 6
Number of Outstanding Options	90,000
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	5 years 8 months 1 day
Number of Exercisable Options	90,000
Aggregate Exercisable Options Value	$ 540
Exercise Price 8 [Member] | Options Granted to Employees [Member]
Exercise Price	$ 8.36
Number of Outstanding Options	250,000
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	9 years 6 months 29 days
Aggregate Intrinsic Value	$ 0
Aggregate Exercisable Options Value	$ 0
Exercise Price 8 [Member] | Options Granted to Non- Employees [Member]
Exercise Price	$ 6.40
Number of Outstanding Options	8,333
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	9 years 1 month 17 days
Number of Exercisable Options	1,667
Aggregate Exercisable Options Value	$ 11
Exercise Price 9 [Member] | Options Granted to Employees [Member]
Exercise Price	$ 8.43
Number of Outstanding Options	160,994
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	9 years 5 months 16 days
Aggregate Intrinsic Value	$ 0
Number of Exercisable Options	14,492
Aggregate Exercisable Options Value	$ 156
Exercise Price 9 [Member] | Options Granted to Non- Employees [Member]
Exercise Price	$ 7.32
Number of Outstanding Options	8,334
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	3 years 11 months 23 days
Number of Exercisable Options	8,334
Aggregate Exercisable Options Value	$ 61
Exercise Price 10 [Member] | Options Granted to Employees [Member]
Exercise Price	$ 8.91
Number of Outstanding Options	30,500
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	9 years 6 months 18 days
Aggregate Intrinsic Value	$ 0
Number of Exercisable Options	3,813
Aggregate Exercisable Options Value	$ 34
Exercise Price 10 [Member] | Options Granted to Non- Employees [Member]
Exercise Price	$ 8.34
Number of Outstanding Options	8,600
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	9 years 7 months 10 days
Number of Exercisable Options	8,600
Aggregate Exercisable Options Value	$ 72
Exercise Price 11 [Member] | Options Granted to Employees [Member]
Exercise Price	$ 9
Number of Outstanding Options	20,834
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	4 years 7 months 17 days
Aggregate Intrinsic Value	$ 0
Number of Exercisable Options	20,834
Aggregate Exercisable Options Value	$ 188
Exercise Price 11 [Member] | Options Granted to Non- Employees [Member]
Exercise Price	$ 11.52
Number of Outstanding Options	8,334
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	4 years 4 months 6 days
Number of Exercisable Options	8,334
Aggregate Exercisable Options Value	$ 96
Exercise Price 12 [Member] | Options Granted to Employees [Member]
Exercise Price	$ 9.48
Number of Outstanding Options	58,908
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	3 years 7 months 10 days
Aggregate Intrinsic Value	$ 0
Number of Exercisable Options	58,908
Aggregate Exercisable Options Value	$ 558
Exercise Price 12 [Member] | Options Granted to Non- Employees [Member]
Exercise Price	$ 16.8
Number of Outstanding Options	39,267
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	3 years 4 months 13 days
Number of Exercisable Options	39,267
Aggregate Exercisable Options Value	$ 660
Exercise Price 13 [Member] | Options Granted to Employees [Member]
Exercise Price	$ 10.2
Number of Outstanding Options	39,268
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term	3 years 6 months 4 days
Aggregate Intrinsic Value	$ 0
Number of Exercisable Options	39,267
Aggregate Exercisable Options Value	$ 401

Schedule of Deferred Tax Assets

Schedule of Deferred Tax Assets (Details) - USD ($) $ in Thousands	Nov. 30, 2018	Nov. 30, 2017	Nov. 30, 2016
Net operating loss carry forwards	$ 8,868	$ 11,893
Research and development expenses	2,915	1,065
Employee benefits	181	180
Property and equipment	(47)	(61)
Loans	(125)	0
Deferred income	(117)	(292)
Intangible assets	(4,142)	(5,117)
Less: Valuation allowance	(9,235)	(8,358)	$ (5,151)
Net deferred tax liabilities	$ (1,702)	$ (690)

Schedule of Valuation Allowance

Schedule of Valuation Allowance, Activity (Details) - USD ($) $ in Thousands	12 Months Ended
	Nov. 30, 2018	Nov. 30, 2017
Balance at the beginning of year	$ (8,358)	$ (5,151)
Additions during the year	(877)	(3,207)
Balance at end of year	$ (9,235)	$ (8,358)

Schedule of Assets and Liabilit

Schedule of Assets and Liabilities at Fair Value (Details) - USD ($) $ in Thousands	Nov. 30, 2018	Nov. 30, 2017
Embedded derivatives convertible loans		$ (37)
Call option derivative	$ 0	$ (339)

Schedule of Fair Value, Assumpt

Schedule of Fair Value, Assumptions Used (Details)	Nov. 30, 2017yr
Embedded Derivative [Member] | Share Price [Member]
Derivative Liability, Measurement Input	4.38
Embedded Derivative [Member] | Price Volatility [Member]
Derivative Liability, Measurement Input	77
Embedded Derivative [Member] | Discount on lack of marketability [Member]
Derivative Liability, Measurement Input	0
Embedded Derivative [Member] | Risk Free Interest Rate [Member] | Minimum [Member]
Derivative Liability, Measurement Input	1.21
Embedded Derivative [Member] | Risk Free Interest Rate [Member] | Maximum [Member]
Derivative Liability, Measurement Input	1.39
Embedded Derivative [Member] | Expected Term [Member] | Minimum [Member]
Derivative Liability, Measurement Input	0.17
Embedded Derivative [Member] | Expected Term [Member] | Maximum [Member]
Derivative Liability, Measurement Input	0.42
Embedded Derivative [Member] | Expected Dividend Rate [Member]
Derivative Liability, Measurement Input	0
Put Option Derivative [Member] | Price Volatility [Member]
Derivative Liability, Measurement Input	54
Put Option Derivative [Member] | Discount on lack of marketability [Member]
Derivative Liability, Measurement Input	12
Put Option Derivative [Member] | Risk Free Interest Rate [Member]
Derivative Liability, Measurement Input	1.44
Put Option Derivative [Member] | Expected Term [Member]
Derivative Liability, Measurement Input	0.5

Schedule of Fair Value of Finan

Schedule of Fair Value of Financial Liabilities, Activity (Details) - USD ($) $ in Thousands	12 Months Ended
	Nov. 30, 2018	Nov. 30, 2017
Embedded derivatives, beginning balance	$ (37)
Embedded derivatives, ending balance		$ (37)
Embedded Derivative [Member]
Embedded derivatives, beginning balance	37	240
Repayment	(14)	(876)
Changes in fair value during the period	(23)	662
Option disposal	0
Translation adjustments		11
Embedded derivatives, ending balance	0	37
Convertible Bonds [Member]
Convertible bonds, beginning balance	0	1,818
Repayment		(1,827)
Changes in fair value during the period		22
Translation adjustments		(13)
Convertible bonds, ending balance		0
Put Option Derivative [Member]
Put option derivative, beginning balance	(339)	273
Repayment	0	0
Changes in fair value during the period	49	(612)
Option disposal	290
Translation adjustments		0
Put option derivative, ending balance	$ 0	$ (339)

Schedule of Sensitivity Analysi

Schedule of Sensitivity Analysis of Changes in Fair Value (Details) $ in Thousands	12 Months Ended
	Nov. 30, 2017USD ($)
Base -50% [Member]
Sensitivity analysis due to changes in the assumptions expected volatility	$ 335
Sensitivity analysis due to changes in Atvio's FV	252
Base [Member]
Sensitivity analysis due to changes in the assumptions expected volatility	339
Sensitivity analysis due to changes in Atvio's FV	339
Base plus 50% [Member]
Sensitivity analysis due to changes in the assumptions expected volatility	379
Sensitivity analysis due to changes in Atvio's FV	$ 440

Schedule of Research and Develo

Schedule of Research and Development Expenses (Details) - USD ($) $ in Thousands	12 Months Ended
	Nov. 30, 2018	Nov. 30, 2017
Total expenses	$ 7,386	$ 3,326
Revenues	(18,655)	(10,089)
Research and Development Expense	6,464	2,478
Revenue from grants [Member]
Revenues	$ (922)	$ (848)

Schedule of Financial Expenses

Schedule of Financial Expenses (Details) - USD ($) $ in Thousands	12 Months Ended
	Nov. 30, 2018	Nov. 30, 2017
Decrease in fair value of warrants and financial liabilities measured at fair value	$ 48	$ (902)
Stock-based compensation related to warrants granted due to issuance of credit facility	180	1,497
Interest expense on convertible loans	2,753	1,233
Foreign exchange loss, net	129	562
Other Income	7	57
Total financial expenses	$ 3,117	$ 2,447

Schedule of Related Party Trans

Schedule of Related Party Transactions (Details) - USD ($) $ in Thousands	12 Months Ended
	Nov. 30, 2018	Nov. 30, 2017
Stock Based Compensation	$ 4,364	$ 3,364
Board Members [Member]
Management and consulting fees, compensation	52	25
Stock Based Compensation	304	393
Executive officers [Member]
Management and consulting fees, compensation	1,119	419
Stock Based Compensation	1,479	821
Directors [Member]
Interest Expense, Related Party	$ 13	$ 55

Schedule of Related Parties pre

Schedule of Related Parties presented in the Consolidated Balance Sheets (Details) - USD ($) $ in Thousands	Nov. 30, 2018	Nov. 30, 2017
Loan to related party	$ 1,007	$ 0
Directors [Member]
Due to Related Parties	0	167
Executive officers [Member]
Due to Related Parties	1,164	358
Non-executive directors [Member]
Due to Related Parties	$ 41	$ 316